

09-25-00

A

Box SER



**PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Docket No: 28341/6280NCP

PATENT APPLICATION TRANSMITTAL UNDER 37 C.F.R. 1.53

**Box Patent Application
Commissioner for Patents
Washington, D.C. 20231**



Sir:

Transmitted herewith for filing is the patent application of

Inventor(s): GURNEY, Mark
BIENKOWSKI, Michael Jerome

Title: Alzheimer's Disease Secretase, APP Substrates Therefor, and Uses Therefor

1. Type of Application

- ☐ This is a new application for a
- ☐ utility patent.
- ☐ design patent.
- ☒ This is a continuation-in-part application of prior patent application no.


09/416,901, claiming priority benefit of U.S. provisional patent applications 60,155,493, and 60/169,232. This application also claims benefit as a continuation-in-part of U.S. patent application no. 09/404,133 and PCT/US99/20881, both of which claim priority benefit of U.S. provisional patent application no. 60/101,594.

2. Application Papers Enclosed

- | | |
|-----|--|
| 1 | Title Page |
| 100 | Pages of Specification (excluding Claims, Abstract, Drawings & Sequence Listing) |
| 13 | Page(s) of Claims |
| 1 | Page(s) of Abstract |
| 20 | Sheet(s) of Drawings (Figs. 1 to 12) |
| | <input checked="" type="checkbox"/> Formal |
| | <input type="checkbox"/> Informal |
| 66 | Page(s) of Sequence Listing |

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Patent Application Transmittal and the documents referred to as enclosed therewith are being deposited with the United States Postal Service on **September 22, 2000**, in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service under Mailing Label No. EK 657821557 US.


William K. Merkel

09668314, 092200

3. Declaration or Oath

- ☐ Enclosed
 - ☐ Executed by (check all applicable boxes)
 - ☐ Inventor(s)
 - ☐ Legal representative of inventor(s)
(37 CFR 1.42 or 1.43)
 - ☐ Joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached
 - ☐ The petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 are enclosed. See Item 5D below for fee.
- ☒ Not enclosed - the undersigned attorney or agent is authorized to file this application on behalf of the applicant(s). An executed declaration will follow.

4. Additional Papers Enclosed

- ☐ Preliminary Amendment
- ☐ Information Disclosure Statement
- ☐ Declaration of Biological Deposit
- ☒ Computer readable copy of sequence listing containing nucleotide and/or amino acid sequence
- ☐ Microfiche computer program
- ☐ Verified statement(s) claiming small entity status under 37 CFR 1.9 and 1.27
- ☐ Associate Power of Attorney
- ☐ Verified translation of a non-English patent application
- ☐ An assignment of the invention
- ☒ Return receipt postcard
- ☒ Other Statement of sequence listing under 37 C.F.R. §1.821(f)

5. **Priority Applications Under 35 USC 119**

Certified copies of applications from which priority under 35 USC 119 is claimed are listed below and

- ☐ are attached.
☐ will follow.

COUNTRY	APPLICATION NO.	FILED

6. **Filing Fee Calculation (37 CFR 1.16)**

A. ☒ **Utility Application**

CLAIMS AS FILED - INCLUDING PRELIMINARY AMENDMENT (IF ANY)						
			SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	NO. FILED	NO. EXTRA	RATE	FEE	RATE	FEE
BASIC FEE				\$345.00		\$690.00
TOTAL	78 -20	= 57	X 9 =	\$	X 18 =	\$1,044.00
INDEP.	10 - 3	= 7	X 39 =	\$	X 78 =	\$546.00
<input type="checkbox"/> First Presentation of Multiple Dependent Claim			+ 130 =	\$	+ 260 =	\$
Filing Fee:				\$	OR	\$2,280.00

B. ☐ **Design Application (\$155.00/\$310.00)** Filing Fee: \$ _____

C. ☐ **Plant Application (\$240.00/\$480.00)** Filing Fee: \$ _____

D. **Other Fees**

- ☐ Recording Assignment [Fee -- \$40.00 per assignment] \$ _____
- ☐ Petition fee for filing by other than all the inventors or person on behalf of the inventor where inventor refused to sign or cannot be reached [Fee -- \$130.00] \$ _____
- ☐ Other \$ _____

Total Fees Enclosed \$2,262.00

7. Method of Payment of Fees

- ☒ Enclosed check in the amount of: \$ 2,262.00
- ☒ Charge Deposit Account No. 13-2855 in the amount of: \$ 18.00
A copy of this Transmittal is enclosed.
- ☐ Not enclosed

8. Deposit Account and Refund Authorization

The Commissioner is hereby authorized to charge any deficiency in the amount enclosed or any additional fees which may be required during the pendency of this application under 37 CFR 1.16 or 37 CFR 1.17 or under other applicable rules (except payment of issue fees), to Deposit Account No. 13-2855. A copy of this Transmittal is enclosed.

Please refund any overpayment to Marshall, O'Toole, Gerstein, Murray & Borun at the address below.


9. Correspondence Address

Customer No.: 04743

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300
(312) 474-0448 (Telefacsimile)

By:


William K. Merkel
Reg. No: 40,725


September 22, 2000

JOINT INVENTORS

"EXPRESS MAIL" mailing label No.
EK 657821557 US.

Date of Deposit: September 22, 2000

I hereby certify that this paper (or fee) is being
deposited with the United States Postal
Service "EXPRESS MAIL POST OFFICE TO
ADDRESSEE" service under 37 CFR §1.10 on
the date indicated above and is addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231


William K. Merkel

APPLICATION FOR UNITED STATES LETTERS PATENT

S P E C I F I C A T I O N

TO ALL WHOM IT MAY CONCERN:

Be it known that we, Mark Gurney, a citizen of the United States of America, residing at Lynghals 1, 110 Reykjavik, Iceland, and Michael Jerome Bienkowski, a citizen of the United States of America, residing at 3431 Hollow Wood, Portage, Michigan, 49024, have invented a new and useful Alzheimer's Disease Secretase, App Substrates Therefor, and Uses Therefor, of which the following is a specification.

Alzheimer's Disease Secretase, APP Substrates Therefor, and Uses Therefor

5 The present application is a continuation-in-part of United States Patent Application 09/416,901, filed October 13, 1999 which claims priority benefit of United States Provisional Patent Application No. 60/155,493, filed September 23, 1999 and United States Provisional Patent Application 60/169,232, filed December 6, 1999. The present application also claims priority benefit as a continuation-in-part of United States Patent Application Serial No. 09/404,133 and PCT/US99/20881, both filed September 23, 1999, both of which in turn claim priority benefit of United States
10 Provisional Patent Application No. 60/101,594, filed September 24, 1998. All of these priority applications are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

15 The present invention relates to Alzheimer's Disease, amyloid protein precursor, amyloid beta peptide, and human aspartyl proteases, as well as a method for the identification of agents that modulate the activity of these polypeptides and thereby are candidates to modulate the progression of Alzheimer's disease.

BACKGROUND OF THE INVENTION

20 Alzheimer's disease (AD) causes progressive dementia with consequent formation of amyloid plaques, neurofibrillary tangles, gliosis and neuronal loss. The disease occurs in both genetic and sporadic forms whose clinical course and pathological features are quite similar. Three genes have been discovered to date which, when mutated, cause an autosomal dominant form of Alzheimer's disease.
25 These encode the amyloid protein precursor (APP) and two related proteins, presenilin-1 (PS1) and presenilin-2 (PS2), which, as their names suggest, are structurally and functionally related. Mutations in any of the three proteins have been observed to enhance proteolytic processing of APP via an intracellular pathway that produces amyloid beta peptide (A β peptide, or sometimes here as Abeta), a 40-42
30 amino acid long peptide that is the primary component of amyloid plaque in AD.

002260-47E8960

Dysregulation of intracellular pathways for proteolytic processing may be central to the pathophysiology of AD. In the case of plaque formation, mutations in APP, PS1 or PS2 consistently alter the proteolytic processing of APP so as to enhance formation of A β 1-42, a form of the A β peptide which seems to be particularly amyloidogenic, and thus very important in AD. Different forms of APP range in size from 695-770 amino acids, localize to the cell surface, and have a single C-terminal transmembrane domain. Examples of specific isotypes of APP which are currently known to exist in humans are the 695-amino acid polypeptide described by Kang *et al.* (1987), *Nature* 325: 733-736 which is designated as the "normal" APP; the 751 amino acid polypeptide described by Ponte *et al.* (1988), *Nature* 331: 525-527 (1988) and Tanzi *et al.* (1988), *Nature* 331: 528-530; and the 770 amino acid polypeptide described by Kitaguchi *et al.* (1988), *Nature* 331: 530-532. The A β peptide is derived from a region of APP adjacent to and containing a portion of the transmembrane domain. Normally, processing of APP at the α -secretase site cleaves the midregion of the A β sequence adjacent to the membrane and releases the soluble, extracellular domain of APP from the cell surface. This α -secretase APP processing creates soluble APP- α , (sAPP α) which is normal and not thought to contribute to AD.

Pathological processing of APP at the β - and γ -secretase sites, which are located N-terminal and C-terminal to the α -secretase site, respectively, produces a very different result than processing at the α site. Sequential processing at the β - and γ -secretase sites releases the A β peptide, a peptide possibly very important in AD pathogenesis. Processing at the β - and γ -secretase sites can occur in both the endoplasmic reticulum (in neurons) and in the endosomal/lysosomal pathway after reinternalization of cell surface APP (in all cells). Despite intense efforts, for 10 years or more, to identify the enzymes responsible for processing APP at the β and γ sites, to produce the A β peptide, those proteases remained unknown until this disclosure.

SUMMARY OF THE INVENTION

Here, for the first time, we report the identification and characterization of the β secretase enzyme, termed Aspartyl Protease 2 (Asp2). We disclose some known and some novel human aspartic proteases that can act as β -secretase proteases and, for the first time, we explain the role these proteases have in AD. We describe regions in the proteases critical for their unique function and for the first time characterize their substrate. This is the first description of expressed isolated purified active protein of this type, assays that use the protein, in addition to the identification and creation of useful cell lines and inhibitors. We also identify and characterize both α -secretase and β -secretase activities of a protease, designated as Asp1.

Here we disclose a number of variants of the Asp2 gene and peptide.

In one aspect, the invention provides any isolated or purified nucleic acid polynucleotide that codes for a protease capable of cleaving the beta (β) secretase cleavage site of APP that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic acids that code for the peptide DTG, where the first nucleic acid of the first special set of nucleic acids is the first special nucleic acid, and where the second set of nucleic acids code for either the peptide DSG or DTG, where the last nucleic acid of the second set of nucleic acids is the last special nucleic acid, with the proviso that the nucleic acids disclosed in SEQ ID NO. 1 and SEQ ID NO. 3 are not included. In a preferred embodiment, the two sets of special nucleic acids are separated by nucleic acids that code for about 125 to 222 amino acid positions, which may be any amino acids. In a highly preferred embodiment, the two sets of special nucleic acids are separated by nucleic acids that code for about 150 to 196, or 150-190, or 150 to 172 amino acid positions, which may be any amino acids. In a particular preferred embodiment, the two sets are separated by nucleic acids that code for about 172 amino acid positions, which may be any amino acids. An exemplary nucleic acid polynucleotide comprises the acid nucleotide sequence in SEQ ID NO. 5. In another particular preferred

embodiment, the two sets are separated by nucleic acids that code for about 196 amino acids. An exemplary polynucleotide comprises the nucleotide sequence in SEQ ID NO. 5. In another particular embodiment, the two sets of nucleotides are separated by nucleic acids that code for about 190 amino acids. An exemplary

5 polynucleotide comprises the nucleotide sequence in SEQ ID NO. 1. Preferably, the first nucleic acid of the first special set of amino acids, that is, the first special nucleic acid, is operably linked to any codon where the nucleic acids of that codon codes for any peptide comprising from 1 to 10,000 amino acid (positions). In one variation, the first special nucleic acid is operably linked to nucleic acid polymers that code for any

10 peptide selected from the group consisting of: any reporter proteins or proteins which facilitate purification. For example, the first special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: immunoglobulin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin. In another variation, the last nucleic acid of the

15 second set of special amino acids, that is, the last special nucleic acid, is operably linked to nucleic acid polymers that code for any peptide comprising any amino acids from 1 to 10,000 amino acids. In still another variation, the last special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: any reporter proteins or proteins which facilitate purification. For

20 example, the last special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: immunoglobulin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin.

In a related aspect, the invention provides any isolated or purified nucleic acid

25 polynucleotide that codes for a protease capable of cleaving the beta secretase cleavage site of APP that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic acids that code

30 for DTG, where the first nucleic acid of the first special set of nucleic acids is the first

002260-478966

special nucleic acid, and where the second set of nucleic acids code for either DSG or DTG, where the last nucleic acid of the second set of special nucleic acids is the last special nucleic acid, where the first special nucleic acid is operably linked to nucleic acids that code for any number of amino acids from zero to 81 amino acids and where each of those codons may code for any amino acid. In a preferred embodiment, the first special nucleic acid is operably linked to nucleic acids that code for any number of from 64 to 77 amino acids where each codon may code for any amino acid. In a particular embodiment, the first special nucleic acid is operably linked to nucleic acids that code for 71 amino acids. For example, the first special nucleic acid is operably linked to 71 amino acids and where the first of those 71 amino acids is the amino acid T. In a preferred embodiment, the polynucleotide comprises a sequence that is at least 95% identical to a human Asp1 or Asp2 sequence as taught herein. In another preferred embodiment, the first special nucleic acid is operably linked to nucleic acids that code for any number of from 30 to 54 amino acids, or 35 to 47 amino acids, or 40 to 54 amino acids where each codon may code for any amino acid. In a particular embodiment, the first special nucleic acid is operably linked to nucleic acids that code for 47 amino acids. For example, the first special nucleic acid is operably linked to 47 codons where the first those 47 amino acids is the amino acid E.

In another related aspect, the invention provides for any isolated or purified nucleic acid polynucleotide that codes for a protease capable of cleaving the beta (β) secretase cleavage site of APP and that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic acids that code for the peptide DTG, where the first nucleic acid of the first special set of amino acids is, the first special nucleic acid, and where the second set of special nucleic acids code for either the peptide DSG or DTG, where the last nucleic acid of the second set of special nucleic acids, the last special nucleic acid, is operably linked to nucleic acids that code for any number of codons from 50 to 170 codons. In a preferred embodiment, the last special nucleic acid is operably linked to nucleic acids

comprising from 100 to 170 codons. In a highly preferred embodiment, the last special nucleic acid is operably linked to nucleic acids comprising from 142 to 163 codons. In a particular embodiment, the last special nucleic acid is operably linked to nucleic acids comprising about 142 codons, or about 163 codons, or about 170
5 codons. In a highly preferred embodiment, the polynucleotide comprises a sequence that is at least 95% identical to aspartyl-protease encoding sequences taught herein. In one variation, the second set of special nucleic acids code for the peptide DSG. In another variation, the first set of nucleic acid polynucleotide is operably linked to a peptide purification tag. For example, the nucleic acid polynucleotide is operably
10 linked to a peptide purification tag which is six histidine. In still another variation, the first set of special nucleic acids are on one polynucleotide and the second set of special nucleic acids are on a second polynucleotide, where both first and second polynucleotides have at least 50 codons. In one embodiment of this type, both of the polynucleotides are in the same solution. In a related aspect, the invention provides a
15 vector which contains a polynucleotide as described above, or a cell or cell line which is transformed or transfected with a polynucleotide as described above or with a vector containing such a polynucleotide.

In still another aspect, the invention provides an isolated or purified peptide or protein comprising an amino acid polymer that is a protease capable of cleaving the
20 beta (β) secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid position can be any amino acid, where the first set of special amino acids consists of the peptide DTG, where the first amino acid of the first special set of amino acids is, the first special amino acid, where the second set of
25 amino acids is selected from the peptide comprising either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, with the proviso that the proteases disclosed in SEQ ID NO. 2 and SEQ ID NO. 4 are not included. In preferred embodiments, the two sets of amino acids are separated by
30 about 125 to 222 amino acid positions or about 150 to 196 amino acids, or about 150-190 amino acids, or about 150 to 172 amino acids, where in each position it may be

any amino acid. In a particular embodiment, the two sets of amino acids are separated by about 172 amino acids. For example, the protease has the amino acid sequence described in SEQ ID NO 6. In another particular embodiment, the two sets of amino acids are separated by about 196 amino acids. For example, the two sets of amino acids are separated by the same amino acid sequences that separate the same set of special amino acids in SEQ ID NO 4. In another particular embodiment, the two sets of nucleotides are separated by about 190 amino acids. For example, the two sets of nucleotides are separated by the same amino acid sequences that separate the same set of special amino acids in SEQ ID NO 2. In one embodiment, the first amino acid of the first special set of amino acids, that is, the first special amino acid, is operably linked to any peptide comprising from 1 to 10,000 amino acids. In another embodiment, the first special amino acid is operably linked to any peptide selected from the group consisting of: any reporter proteins or proteins which facilitate purification. In particular embodiments, the first special amino acid is operably linked to any peptide selected from the group consisting of: immunoglobulin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin. In still another variation, the last amino acid of the second set of special amino acids, that is, the last special amino acid, is operably linked to any peptide comprising any amino acids from 1 to 10,000 amino acids. By way of nonlimiting example, the last special amino acid is operably linked any peptide selected from the group consisting of any reporter proteins or proteins which facilitate purification. In particular embodiments, the last special amino acid is operably linked to any peptide selected from the group consisting of: immunoglobulin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin.

In a related aspect, the invention provides any isolated or purified peptide or protein comprising an amino acid polypeptide that codes for a protease capable of cleaving the beta secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid in each position can be any amino acid, where the first set of special amino acids consists of the amino acids DTG, where the

first amino acid of the first special set of amino acids is, the first special amino acid, D, and where the second set of amino acids is either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, G, where the first special amino acid is operably linked to amino acids that code for any number of amino acids from zero to 81 amino acid positions where in each position it may be any amino acid. In a preferred embodiment, the first special amino acid is operably linked to a peptide from about 30-77 or about 64 to 77 amino acids positions where each amino acid position may be any amino acid. In a particular embodiment, the first special amino acid is operably linked to a peptide 35, 47, 71, or 77 amino acids. In a very particular embodiment, the first special amino acid is operably linked to 71 amino acids and the first of those 71 amino acids is the amino acid T. For example, the polypeptide comprises a sequence that is at least 95% identical to an aspartyl protease sequence as described herein. In another embodiment, the first special amino acid is operably linked to any number of from 40 to 54 amino acids (positions) where each amino acid position may be any amino acid. In a particular embodiment, the first special amino acid is operably linked to amino acids that code for a peptide of 47 amino acids. In a very particular embodiment, the first special amino acid is operably linked to a 47 amino acid peptide where the first those 47 amino acids is the amino acid E. In another particular embodiment, the first special amino acid is operably linked to the same corresponding peptides from SEQ ID NO. 3 that are 35, 47, 71, or 77 peptides in length, beginning counting with the amino acids on the first special sequence, DTG, towards the N-terminal of SEQ ID NO. 3. In another particular embodiment, the polypeptide comprises a sequence that is at least 95% identical to the same corresponding amino acids in SEQ ID NO. 4, that is, identical to that portion of the sequences in SEQ ID NO. 4, including all the sequences from both the first and or the second special nucleic acids, toward the – terminal, through and including 71, 47, 35 amino acids before the first special amino acids. For example, the complete polypeptide comprises the peptide of 71 amino acids, where the first of the amino acid is T and the second is Q.

5

30

002260-TE9990095344-092000

group consisting of DSG and DTG; and (c) about 100 to 300 amino acids separating the first and second tripeptide sequences, wherein the polypeptide cleaves the beta secretase cleavage site of amyloid protein precursor. In one embodiment, the polypeptide comprises an amino acid sequence depicted in SEQ ID NO: 2 or 4, whereas in another embodiment, the polypeptide comprises an amino acid sequence other than the amino acid sequences set forth in SEQ ID NOs: 2 and 4. Similarly, the invention provides a purified polynucleotide comprising a nucleotide sequence that encodes a polypeptide that cleaves the beta secretase cleavage site of amyloid protein precursor; wherein the polynucleotide includes a strand that hybridizes to one or more of SEQ ID NOs: 3, 5, and 7 under the following hybridization conditions: hybridization overnight at 42°C for 2.5 hours in 6 X SSC/0.1% SDS, followed by washing in 1.0 X SSC at 65°C, 0.1% SDS. In one embodiment, the polypeptide comprises an amino acid sequence depicted in SEQ ID NO: 2 or 4, whereas in another embodiment, the polypeptide comprises an amino acid sequence other than the amino acid sequences set forth in SEQ ID NOs: 2 and 4. Likewise, the invention provides a purified polypeptide having aspartyl protease activity, wherein the polypeptide is encoded by polynucleotides as described in the preceding sentences. The invention also provides a vector or host cell comprising such polynucleotides, and a method of making the polypeptides using the vectors or host cells to recombinantly express the polypeptide.

The invention also provides for a purified polypeptide that comprises a fragment of a human Asp1 protein (hu-Asp1), wherein said polypeptide lacks at least one portion of (a) the transmembrane domain of said hu-Asp1 protein; and (b) the amino-terminal propeptide of said hu-Asp1 protein; and wherein the polypeptide retains amyloid precursor protein (APP) proteolytic activity characteristic of said human Asp1 protein. With respect to Asp1, "APP proteolytic activity" means hu-Asp1 α -secretase activity and/or hu-Asp1 β -secretase activity, as described below in detail.

For example, the invention provides polypeptides that comprise a fragment of hu-Asp1 having the amino acid sequence set forth as SEQ ID NO: 2, wherein the

polypeptide lacks transmembrane domain amino acids 469-492 of SEQ ID NO: 2. Determination of transmembrane domain amino acids of hu-Asp1 having sequence that is not identical with SEQ ID NO: 2 is performed through techniques such as sequence alignment with SEQ ID NO: 2 and/or by conventional techniques (e.g.,
5 hydropathy analysis) for identifying transmembrane spanning domains of proteins. Polypeptides of the invention that lack transmembrane domain amino acids optionally also lack cytoplasmic domain amino acids, e.g., hu-Asp1 that comprise a fragment of SEQ ID NO: 2 and that lack cytoplasmic domain amino acids 493-518 of SEQ ID NO: 2.

10 In one specific embodiment, the invention provides for a polypeptide that comprises a fragment of hu-Asp1 and wherein the polypeptide lacks the amino terminal amino propeptide of hu-Asp1 protein and/or the signal peptide of hu-Asp1. By "amino-terminal propeptide of hu-Asp1" is meant that portion of hu-Asp1
15 following the signal peptide that is cleaved (apparently autocatalytically under appropriate acid conditions as described below). Referring to hu-Asp1 comprising the amino acid sequence of SEQ ID NO: 2, the signal peptide and propeptide comprise amino acids 1-62 of SEQ ID NO: 2. The invention also encompasses a polypeptide that comprise a fragment of hu-Asp1 having the amino acid sequence set forth as SEQ ID NO: 2, wherein the polypeptide lacks the signal peptide and amino terminal
20 propeptide amino acids 1-62 of SEQ ID NO: 2. The portions of hu-Asp1 allelic variants are readily identified by sequence alignment with SEQ ID NO: 2 and/or by analysis of hu-Asp1 processing as described in detail below.

In still another, related embodiment, the invention provides a polypeptide comprising an amino acid sequence that is 95% identical to a fragment of the hu-Asp1
25 protein having the amino acid sequence of SEQ ID NO: 2, wherein said polypeptide lacks at least a transmembrane domain or an amino terminal propeptide characteristic of a hu-Asp1 protein; and wherein the polypeptide has amyloid precursor protein (APP) proteolytic activity.

In yet another aspect, the invention provides an isolated nucleic acid molecule
30 comprising a polynucleotide, said polynucleotide encoding a Hu-Asp polypeptide and

having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a nucleotide sequence encoding a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), wherein said Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) polypeptides have the complete amino acid sequence of SEQ ID NO. 2, SEQ ID NO. 4, and SEQ ID NO. 6, respectively; and

(b) a nucleotide sequence complementary to the nucleotide sequence of (a).

Several species are particularly contemplated. For example, the invention provides a nucleic acid and molecule wherein said Hu-Asp polypeptide is Hu-Asp1, and said polynucleotide molecule of 1(a) comprises the nucleotide sequence of SEQ ID NO. 1; and a nucleic acid molecule wherein said Hu-Asp polypeptide is Hu-Asp2(a), and said polynucleotide molecule of 1(a) comprises the nucleotide sequence of SEQ ID NO. 4; and a nucleic acid molecule wherein said Hu-Asp polypeptide is Hu-Asp2(b), and said polynucleotide molecule of 1(a) comprises the nucleotide sequence of SEQ ID NO. 5. In addition to the foregoing, the invention provides an isolated nucleic acid molecule comprising polynucleotide which hybridizes under stringent conditions to a polynucleotide having the nucleotide sequence in (a) or (b) as described above.

Additionally, the invention provides a vector comprising a nucleic acid molecule as described in the preceding paragraph. In a preferred embodiment, the nucleic acid molecule is operably linked to a promoter for the expression of a Hu-Asp polypeptide. Individual vectors which encode Hu-Asp1, and Hu-Asp2(a), and Hu-Asp2(b) are all contemplated. Likewise, the invention contemplates a host cell comprising any of the foregoing vectors, as well as a method of obtaining a Hu-Asp polypeptide comprising culturing such a host cell and isolating the Hu-Asp polypeptide. Host cells of the invention include bacterial cells, such as *E. coli*, and eukaryotic cells. Among the eukaryotic cells that are contemplated are insect cells, such as sf9 or High 5 cells; and mammalian cells, such as human, rodent, lagomorph, and primate. Preferred human cells include HEK293, and IMR-32 cells. Other

preferred mammalian cells include COS-7, CHO-K1, Neuro-2A, and 3T3 cells. Also among the eukaryotic cells that are contemplated are a yeast cell and an avian cell.

In a related aspect, the invention provides an isolated Hu-Asp1 polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO. 2. The invention also provides an isolated Hu-Asp2(a) polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO. 4. The invention also provides an isolated Hu-Asp2(a) polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO. 8.

The invention also provides for a purified polynucleotide comprising a nucleotide sequence encoding a polypeptide that comprises a fragment of a human Asp1 protein (hu-Asp1), wherein the polynucleotide lacks nucleotide sequence encoding at least one portion of the hu-Asp1 protein, selected from the group consisting of (a) the transmembrane domain of the hu-Asp1 protein; and (b) the amino-terminal propeptide of said hu-Asp1 protein, and wherein the polypeptide encoded by said polynucleotide retains amyloid precursor protein (APP) proteolytic activity characteristic of said human Asp1 protein. Characteristic APP proteolytic activity includes hu-Asp1 α -secretase activity and/or hu-Asp1 β -secretase activity, as characterized in detail below.

Additionally, the invention provides a vector comprising polynucleotides of the preceding paragraph, and host cells transfected or transformed with the above-mentioned polynucleotides or vectors.

In a preferred embodiment, the invention provides polynucleotides that comprise a nucleotide sequence encoding a fragment of hu-Asp1 having the amino acid sequence set forth as SEQ ID NO: 2, and wherein the polynucleotide lacks sequences encoding the transmembrane amino acids 469-492 of SEQ ID NO: 2. These polynucleotide of the invention also include those that further lack the nucleotide sequence encoding the cytoplasmic domain amino acids 493-518 of SEQ

ID NO: 2 and/or the nucleotide sequence encoding amino acids 1-62 of SEQ ID NO: 2, which represent the codons for the signal peptide and amino-terminal propeptide.

In another preferred embodiment, the invention provides polynucleotides that comprise a nucleotide sequence encoding a fragment of hu-Asp1 having the amino acid sequence set forth as SEQ ID NO: 2, and wherein the polynucleotide lacks sequence encoding the signal peptide and amino terminal propeptide amino acids 1-62 of SEQ ID NO: 2.

In another, related aspect, the invention provides a nucleotide sequence that hybridizes under stringent conditions to a nucleic acid comprising the complement of the nucleotide sequence set forth as SEQ ID NO: 1, wherein the polynucleotide encodes a polypeptide having amyloid precursor protein (APP) processing activity, and wherein said polynucleotide lacks nucleotide sequence encoding a transmembrane domain and/or the polynucleotide lacks nucleotides sequence encoding an amino terminal propeptide characteristic of hu-Asp1.

In still another aspect, the invention provides an isolated antibody that binds specifically to any Hu-Asp polypeptide described herein, especially the polypeptide described in the preceding paragraphs.

The invention also provides several assays involving aspartyl protease enzymes of the invention. For example, the invention provides

a method to identify a cell that can be used to screen for inhibitors of β secretase activity comprising:

(a) identifying a cell that expresses a protease capable of cleaving APP at the β secretase site, comprising:

- i) collect the cells or the supernatant from the cells to be identified
- ii) measure the production of a critical peptide, where the critical peptide is selected from the group consisting of either the APP C-terminal peptide or soluble APP,
- iii) select the cells which produce the critical peptide.

In one variation, the cells are collected and the critical peptide is the APP C-terminal peptide created as a result of the β secretase cleavage. In another variation, the supernatant is collected and the critical peptide is soluble APP, where the soluble APP has a C-terminus created by β secretase cleavage. In preferred
5 embodiments, the cells contain any of the nucleic acids or polypeptides described above and the cells are shown to cleave the β -secretase site of any peptide having the following peptide structure, P2, P1, P1', P2', where P2 is K or N, where P1 is M or L, where P1' is D, where P2' is A. The method where P2 is K and P1 is M. The method where P2 is N and P1 is L.

10 In still another aspect, the invention provides novel isoforms of amyloid protein precursor (APP) where the last two carboxy terminus amino acids of that isoform are both lysine residues. In this context, the term "isoform" is defined as any APP polypeptide, including APP variants (including mutations), and APP fragments that exists in humans, such as those described in US 5,766,846, col 7, lines 45-67,
15 incorporated into this document by reference, modified as described herein by the inclusion of two C-terminal lysine residues. For example, the invention provides a polypeptide comprising the isoform known as APP695, modified to include two lysine residues as its last two carboxy terminus amino acids. An exemplary polypeptide comprises the amino acid sequence set forth in SEQ ID NO. 16. The
20 invention further includes APP isoform variants as set forth in SEQ ID NOs. 18 and 20. The invention further includes all polynucleotides that encode an APP protein that has been modified to include two C-terminal lysines; as well has any eukaryotic cell line comprising such nucleic acids or polypeptides. Preferred cell lines include a mammalian cell line (*e.g.*, HEK293, Neuro2a).

25 Thus, in one embodiment, the invention provides a polypeptide comprising the amino acid sequence of a mammalian amyloid protein precursor (APP) or fragment thereof containing an APP cleavage site recognizable by a mammalian β -secretase, and further comprising two lysine residues at the carboxyl terminus of the amino acid sequence of the mammalian APP or APP fragment. As taught herein in detail, the
30 addition of two additional lysine residues to APP sequences has been found to greatly

increase A β processing of the APP in APP processing assays. Thus, the di-lysine modified APP reagents of the invention are particularly useful in assays to identify modulators of A β production, for use in designing therapeutics for the treatment or prevention of Alzheimer's disease. In one embodiment, the polypeptide comprises the complete amino acid sequence of a mammalian amyloid protein precursor (APP), and further comprises the two lysine residues at the carboxyl terminus of the amino acid sequence of the mammalian amyloid protein precursor. In an alternative embodiment, the polypeptide comprises only a fragment of the APP, the fragment containing at least that portion of APP that is cleaved by a mammalian β -secretase (or α -secretase or γ -secretase) in the formation of A β peptides.

The practice of assays that monitor cleavage of APP can be facilitated by attaching a marker to a portion of the APP. Measurement of retained or liberated marker can be used to quantitate the amount of APP cleavage that occurs in the assay, e.g., in the presence or absence of a putative modulator of cleavage activity. Thus, in one preferred embodiment, the polypeptide of the invention further includes a marker. For example, the marker comprises a reporter protein amino acid sequence attached to the APP amino acid sequence. Exemplary reporter proteins include a fluorescing protein (e.g., green fluorescing proteins, luciferase) or an enzyme that is used to cleave a substrate to produce a colorimetric cleavage product. Also contemplated are tag sequences which are commonly used as epitopes for quantitative immunoassays.

In a preferred embodiment, the di-lysine-modified APP of the invention is a human APP. For example, human APP isoforms such as APP695, APP751, and APP770, modified to include the two lysines, are contemplated. In a preferred embodiment, the APP isoform comprises at least one variation selected from the group consisting of a Swedish KM-NL mutation and a London V717-F mutation, or any other mutation that has been observed in a subpopulation that is particularly prone to development of Alzheimer's disease. These mutations are recognized as mutations that influence APP processing into A β . In a highly preferred embodiment, the APP protein or fragment thereof comprises the APP-Sw β -secretase peptide sequence NLDA, which is associated with increased levels of A β processing and therefore is

particularly useful in assays relating to Alzheimer's research. More particularly, the APP protein or fragment thereof preferably comprises the APP-Sw β -secretase peptide sequence SEVNLDAEFR (SEQ ID NO: 63).

5 In one preferred embodiment, the APP protein or fragment thereof further includes an APP transmembrane domain carboxy-terminal to the APP-Sw β -secretase peptide sequence. Polypeptides that include the TM domain are particularly useful in cell-based APP processing assays. In contrast, embodiments lacking the TM domain are useful in cell-free assays of APP processing.

10 In addition to working with APP from humans and various animal models, researchers in the field of Alzheimer's also have construct chimeric APP polypeptides which include stretches of amino acids from APP of one species (e.g., humans) fused to stretches of APP from one or more other species (e.g., rodent). Thus, in another embodiment of the polypeptide of the invention, the APP protein or fragment thereof comprises a chimeric APP, the chimeric APP including partial APP amino acid
15 sequences from at least two species. A chimeric APP that includes amino acid sequence of a human APP and a rodent APP is particularly contemplated.

20 In a related aspect, the invention provides a polynucleotide comprising a nucleotide sequence that encodes a polypeptide as described in the preceding paragraphs. Such a polynucleotide is useful for recombinant expression of the polypeptide of the invention for use in APP processing assays. In addition, the polynucleotide is useful for transforming into cells to produce recombinant cells that express the polypeptide of the invention, which cells are useful in cell-based assays to identify modulators of APP processing. Thus, in addition to polynucleotides, the invention provides a vector comprising such polynucleotides, especially expression
25 vectors where the polynucleotide is operably linked to a promoter to promote expression of the polypeptide encoded by the polynucleotide in a host cell. The invention further provides a host cell transformed or transfected with such a polynucleotide or a vector. Among the preferred host cells are mammalian cells, especially human cells.

0966314-09200

In another, related embodiment, the invention provides a polypeptide useful for assaying for modulators of β -secretase activity, said polypeptide comprising an amino acid sequence of the formula $\text{NH}_2\text{-X-Y-Z-KK-COOH}$; wherein X, Y, and Z each comprise an amino acid sequence of at least one amino acid; wherein $\text{NH}_2\text{-X}$ comprises an amino-terminal amino acid sequence having at least one amino acid residue; wherein Y comprises an amino acid sequence of a β -secretase recognition site of a mammalian amyloid protein precursor (APP); and wherein Z-KK-COOH comprises a carboxy-terminal amino acid sequence ending in two lysine (K) residues. In one preferred variation, the carboxyl-terminal amino acid sequence Z includes a hydrophobic domain that is a transmembrane domain in host cells that express the polypeptide. Host cells that express such a polypeptide are particularly useful in assays described herein for identifying modulators of APP processing. In another preferred variation, the amino-terminal amino acid sequence X includes an amino acid sequence of a reporter or marker protein, as described above. In still another preferred variation, the β -secretase recognition site Y comprises the human APP-Sw β -secretase peptide sequence NLDA. It will be apparent that these preferred variations are not mutually exclusive of each other -- they may be combined in a single polypeptide. The invention further provides a polynucleotide comprising a nucleotide sequence that encodes such polypeptides, vectors which comprise such polynucleotides, and host cells which comprises such vectors, polynucleotides, and/or polypeptides.

In yet another aspect, the invention provides a method for identifying inhibitors of an enzyme that cleaves the beta secretase cleavable site of APP comprising:

- a) culturing cells in a culture medium under conditions in which the enzyme causes processing of APP and release of amyloid beta-peptide into the medium and causes the accumulation of CTF99 fragments of APP in cell lysates,
- b) exposing the cultured cells to a test compound; and specifically determining whether the test compound inhibits the function of the enzyme by measuring the amount of amyloid beta-peptide released into the medium and/or the amount of CTF99 fragments of APP in cell lysates;

002260 " 44E89960

5 c) identifying test compounds diminishing the amount of soluble amyloid beta peptide present in the culture medium and diminution of CTF99 fragments of APP in cell lysates as Asp2 inhibitors. In preferred embodiments, the cultured cells are a human, rodent or insect cell line. It is also preferred that the human or rodent cell line exhibits β secretase activity in which processing of APP occurs with release of amyloid beta-peptide into the culture medium and accumulation of CTF99 in cell lysates. Among the contemplated test compounds are antisense oligomers directed against the enzyme that exhibits β secretase activity, which oligomers reduce release of soluble amyloid beta-peptide into the culture medium and accumulation of CTF99 in cell lysates.

In yet another aspect, the invention provides a method for the identification of an agent that decreases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising:

15 a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and

b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent; whereby a lower level of activity in the presence of said test agent than in the absence of said test agent indicates that said test agent has decreased the activity of said Hu-Asp polypeptide.

20 In a related aspect, the invention provides a method for assaying for modulators of β -secretase activity, comprising the steps of:

(a) contacting a first composition with a second composition both in the presence and in the absence of a putative modulator compound, wherein the first composition comprises a mammalian β -secretase polypeptide or biologically active fragment thereof, and wherein the second composition comprises a substrate polypeptide having an amino acid sequence comprising a β -secretase cleavage site;

25 (b) measuring cleavage of the substrate polypeptide in the presence and in the absence of the putative modulator compound; and (c) identifying modulators of β -secretase activity from a difference in cleavage in the presence versus in the absence of the

30

putative modulator compound. A modulator that is a β -secretase antagonist (inhibitor) reduces such cleavage, whereas a modulator that is a β -secretase agonist increases such cleavage. Since such assays are relevant to development of Alzheimer's disease therapeutics for humans, it will be readily apparent that, in one preferred embodiment, the first composition comprises a purified human Asp2 polypeptide. In one variation, the first composition comprises a soluble fragment of a human Asp2 polypeptide that retains Asp2 β -secretase activity. Several such fragments (including Δ TM fragments) are described herein in detail. Thus, in a particular embodiment, the soluble fragment is a fragment lacking an Asp2 transmembrane domain. Assaying to identify inhibitors of Asp1 β -secretase activity also is contemplated.

The β -secretase cleavage site in APP is known, and it will be appreciated that the assays of the invention can be performed with either intact APP or fragments or analogs of APP that retain the β -secretase recognition and cleavage site. Thus, in one variation, the substrate polypeptide of the second composition comprises the amino acid sequence SEVNLDAEFR, which includes the β -secretase recognition site of human APP that contains the "Swiss" mutation. In another variation, the substrate polypeptide of the second composition comprises the amino acid sequence EVKMDAEF. In another variation, the second composition comprises a polypeptide having an amino acid sequence of a human amyloid precursor protein (APP). For example, the human amyloid precursor protein is selected from the group consisting of: APP695, APP751, and APP770. Preferably, the human amyloid precursor protein (irrespective of isoform selected) includes at least one mutation selected from a KM-NL Swiss mutation and a V-F London mutation. As explained elsewhere, one preferred embodiment involves a variation wherein the polypeptide having an amino acid sequence of a human APP further comprises an amino acid sequence comprising a marker sequence attached amino-terminal to the amino acid sequence of the human amyloid precursor protein. Preferably, the polypeptide having an amino acid sequence of a human APP further comprises two lysine residues attached to the carboxyl terminus of the amino acid sequence of the human APP. The assays can be

performed in a cell free setting, using cell-free enzyme and cell-free substrate, or can be performed in a cell-based assay wherein the second composition comprises a eukaryotic cell that expresses amyloid precursor protein (APP) or a fragment thereof containing a β -secretase cleavage site. Preferably, the APP expressed by the host cell is an APP variant that includes two carboxyl-terminal lysine residues. It will also be appreciated that the β -secretase enzyme can be an enzyme that is expressed on the surface of the same cells.

The present invention provides isolated nucleic acid molecules comprising a polynucleotide that codes for a polypeptide selected from the group consisting of human aspartyl proteases. In particular, human aspartyl protease 1 (Hu-Asp1) and two alternative splice variants of human aspartyl protease-2 (Hu-Asp2), a "long" (L) form designated herein as Hu-Asp2(a) and a "short" (S) form designated Hu-Asp2(b). As used herein, all references to "Hu-Asp" should be understood to refer to all of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b). In addition, as used herein, all references to "Hu-Asp2" should be understood to refer to both Hu-Asp2(a) and Hu-Asp2(b). Hu-Asp1 is expressed most abundantly in pancreas and prostate tissues, while Hu-Asp2(a) and Hu-Asp2(b) are expressed most abundantly in pancreas and brain tissues. The invention also provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof which exhibit aspartyl protease activity.

In a preferred embodiment, the nucleic acid molecules comprise a polynucleotide having a nucleotide sequence selected from the group consisting of residues 1-1554 of SEQ ID NO. 1, encoding Hu-Asp1, residues 1-1503 of SEQ ID NO. 3, encoding Hu-Asp2(a), and residues 1-1428 of SEQ ID NO.5, encoding Hu-Asp2(b). In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a polynucleotide encoding Hu-Asp1, Hu-Asp2(a), Hu-Asp-2(b), or fragments thereof.

European patent application EP 0 848 062 discloses a polypeptide referred to as "Asp 1," that bears substantial homology to Hu-Asp1, while international application WO 98/22597 discloses a polypeptide referred to as "Asp 2," that bears substantial homology to Hu-Asp2(a).

The present invention also provides vectors comprising the isolated nucleic acid molecules of the invention, host cells into which such vectors have been introduced, and recombinant methods of obtaining a Hu-Asp1, Hu-Asp2(a), or Hu-Asp2(b) polypeptide comprising culturing the above-described host cell and isolating the relevant polypeptide.

In another aspect, the invention provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof. In a preferred embodiment, the Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides have the amino acid sequence given in SEQ ID NO. 2, SEQ ID NO. 4, or SEQ ID NO.6, respectively. The present invention also describes active forms of Hu-Asp2, methods for preparing such active forms, methods for preparing soluble forms, methods for measuring Hu-Asp2 activity, and substrates for Hu-Asp2 cleavage. The invention also describes antisense oligomers targeting the Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) mRNA transcripts and the use of such antisense reagents to decrease such mRNA and consequently the production of the corresponding polypeptide. Isolated antibodies, both polyclonal and monoclonal, that binds specifically to any of the Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides of the invention are also provided.

The invention also provides a method for the identification of an agent that modulates the activity of any of Hu-Asp-1, Hu-Asp2(a), and Hu-Asp2(b). The inventions describes methods to test such agents in cell-free assays to which Hu-Asp2 polypeptide is added, as well as methods to test such agents in human or other mammalian cells in which Hu-Asp2 is present.

For example, it will be evident from the Examples in the detailed description that the invention provides a method of identifying agents that modulate amyloid precursor protein (APP) processing activity of hu-Asp1, comprising the steps of: contacting amyloid precursor protein (APP) and purified and isolated hu-Asp1 in the presence and absence of a test agent; determining APP processing activity of the hu-Asp1 in the presence and absence of the test agent; and identifying agents that modulate APP processing activity of the hu-Asp1 in the presence and absence of the test agent, wherein reduced activity in the presence of the test agent identifies an agent

that inhibits hu-Asp1 activity and increased activity in the presence of the test agent identifies an agent that enhances hu-Asp1 activity. An embodiment of this method comprises a polypeptide purified and isolated from a cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes hu-Asp1. It will be appreciated that variations of this method can be performed using Asp1 fragments and variants described herein, or using unpurified Asp1 that is being recombinantly over-expressed in host cells, or using suitable APP peptide substrates described herein or APP-KK variants described herein, instead of native APP.

In specific embodiments, the method employs a polypeptide purified and isolated from a cell transformed or transfected with a polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding the hu-Asp1 amino acid sequence set forth in SEQ ID NO: 2, (b) a nucleotide sequence encoding a fragment of hu-Asp1 (SEQ ID NO: 2), wherein said fragment exhibits aspartyl protease activity characteristic of hu-Asp1, or (c) a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to a hu-Asp1-encoding polynucleotide (SEQ ID NO: 1). These nucleotide sequences include those which encode a hu-Asp1 amino acid sequence lacking the transmembrane amino acids 469-492 of SEQ ID NO: 2, those that encode a hu-Asp1 amino acid sequence that further lacks the cytoplasmic domain amino acids 493-518 of SEQ ID NO: 2, and those that encode a hu-Asp1 amino acid sequence that further lacks amino terminal amino acids 1-62 of SEQ ID NO: 2.

In some variations of this method, the determining step comprises determining α -secretase APP processing activity of the hu-Asp1 protein or measuring the production of amyloid alpha peptide by the cell in the presence and absence of the test agent. The invention also provides for the method of identifying agents that modulate APP processing activity wherein the determining step comprises either determining a β -secretase APP processing activity of the hu-Asp1 protein or measuring the production of amyloid beta peptide by the cell in the presence and absence of the test agent. The invention also provides for methods of treating Alzheimer's disease with

an agent identified as a modulator of APP processing activity of hu-Asp1 according to the methods described in the preceding paragraphs.

5 The invention also provides for methods of identifying agents that modulate the amyloid precursor protein (APP) processing activity of hu-Asp1, comprising the steps of contacting hu-Asp1 and APP in the presence and absence of a test agent; determining APP processing activity of hu-Asp1 in the presence and absence of the test agent, wherein the contacting step comprises growing a host cell transformed or transfected with a polynucleotide comprising a nucleotide sequence encoding the hu-Asp1 in the presence and absence of the test agent; and identifying agents that
10 modulate APP processing activity of the hu-Asp1 expressed by the cell in the presence and absence of the test agent, wherein reduced activity in the presence of the test agent identifies an agent that inhibits hu-Asp1 APP processing activity and increased activity in the presence of the test agent identifies an agent that enhances hu-Asp1 activity. In a preferred variation, the host cells which express the hu-Asp1
15 also express APP. In a highly preferred variation, the cells express APP having an amino acid sequence that includes a carboxy-terminal di-lysine, or express APP comprising the Swedish mutation (K→N, M→L) adjacent to the β-secretase processing site.

20 In one embodiment of this method, the determining step comprises assaying for cleavage of APP at the α-secretase processing site including methods wherein the determining step comprises measuring the production of amyloid alpha peptide by the cell in the presence and absence of the test agent.

25 In another embodiment of this method, the determining step comprises assaying for cleavage of APP at the β-secretase processing site including methods wherein the determining step comprises measuring the production of amyloid beta peptide by the cell in the presence and absence of the test agent.

30 In particular embodiments of this method, the host cell is transformed or transfected with a polynucleotide having the nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding the hu-Asp1 amino acid sequence set forth in SEQ ID NO: 2, (b) a nucleotide sequence encoding a fragment of

hu-Asp1 (SEQ ID NO: 2), wherein said fragment exhibits aspartyl protease activity characteristic of hu-Asp1, or (c) a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to a hu-Asp1-encoding polynucleotide (SEQ ID NO: 1). These methods encompass those wherein the host cell comprises a vector that comprise the polynucleotide. The invention also provides for methods of treating Alzheimer's disease with an agent identified as a modulator of APP processing activity of hu-Asp1 according to the methods described in the preceding paragraphs.

The invention also provides for methods of identifying agents that modulate the amyloid precursor protein (APP) processing activity of hu-Asp1, comprising the steps of contacting hu-Asp1 and APP in the presence and absence of a test agent; wherein the hu-Asp1 aspartyl protease is encoded by a nucleic acid that hybridizes under stringent hybridization conditions to a hu-Asp1 encoding polynucleotide set out as SEQ ID NO: 1, determining APP processing activity of hu-Asp1 in the presence and absence of the test agent, and comparing the APP processing activity of the hu-Asp1 aspartyl protease in the presence of the test agent to the activity in the absence of the agent to identify agents that modulate the activity of the hu-Asp1 aspartyl protease, wherein a modulator that is an hu-Asp1 inhibitor reduces APP processing and a modulator that is an hu-Asp1 agonist increases such processing.

In one embodiment of this method, the hu-Asp1 aspartyl protease is purified and isolated. In another embodiment, the determined APP processing activity of hu-Asp1 is cleavage of APP peptide within the α -secretase processing site. In still another embodiment, the determined APP processing activity of hu-Asp1 is cleavage of APP peptide within the β -secretase processing site. The invention also provides for methods of treating Alzheimer's disease with an agent identified as a modulator of APP processing activity of hu-Asp1 according to the methods described in the preceding paragraphs.

The invention provides for methods for assaying for human Asp1(hu-Asp1) α -secretase activity comprising contacting the hu-Asp1 protein with an amyloid precursor protein (APP) substrate, wherein the substrate contains an α -secretase

cleavage site; and measuring cleavage of the APP substrate at the α -secretase cleavage site, thereby assaying hu-Asp1 α -secretase activity. An example of α -secretase activity is APP processing wherein the APP substrate is cleaved at a site adjacent to the cell membrane (at residues Phe²⁰Ala²¹ in relation to the A β peptide). This
5 cleavage results in the release of a soluble, extracellular domain of APP, known as amyloid alpha peptide (sAPP α), from the cell surface into the cytoplasm. The sAPP α within the cytoplasm can be detected and quantitated thereby measuring α -secretase activity.

The hu-Asp1 enzyme used in the methods of the invention can be purified and
10 isolated from a cell which is transfected or transformed with a polynucleotide that encodes hu-Asp1, such as SEQ ID NO: 1, or a polynucleotide sequence that encodes the the amino acid sequence of SEQ ID NO: 2. Further, the hu-Asp1 protein used in the methods may be a fragment of the amino acid sequence of SEQ ID NO: 2 which retains α -secretase activity. Possible fragments that may be of use for the methods
15 include those lacking the transmembrane domain amino acids 469-492 of SEQ ID NO: 2, those fragments that lack the cytoplasmic amino acids 493-492 of SEQ ID NO: 2, those fragments that lack the amino terminal amino acids 1-62 of SEQ ID NO: 2 or combinations thereof.

The invention also encompasses methods of assaying for α -secretase activity
20 where hu-Asp1 protein and its substrate are brought into contact by a growing cell transfected or transformed with a polynucleotide encoding the hu-Asp1 protein or a fragment thereof that retains α -secretase activity under conditions where the cell expresses hu-Asp1 protein in the presence of the APP substrate. The APP substrate in such circumstances can be exogenously introduced, or more preferably, is expressed
25 by the cell that expresses Asp1. These methods also encompass contacting hu-Asp1 protein with a cell that expresses a polynucleotide that encodes an APP substrate containing an α -secretase cleavage site. For example, the cell may express a polynucleotide that encodes a polypeptide having an α -secretase cleavage site comprising the amino acid sequence LVFFAEDF or KLVFFAED. In addition, the
30 APP substrate may comprise any human isoform of APP, such as "normal" APP

(APP695), APP 751, or APP770. These APP substrates can be further modified to comprise a carboxy-terminal di-lysine motif.

To measure the cleavage of the substrates for the methods of assaying for α -secretase activity of the invention, the substrates of the method can be further modified to comprise detectable labels such as radioactive, enzymatic, chemiluminescent or fluorescent labels. In particular, shorter peptide substrates preferably comprise internally quenched labels that result in increased detectability after cleavage of the peptide substrates. The peptide substrates may be modified to have attached a paired fluorophore and quencher including but not limited to 7-amino-4-methyl coumarin and dinitrophenol, respectively, such that cleavage of the peptide by the hu-Asp1 results in increased fluorescence due to physical separation of the fluorophore and quencher. Other paired fluorophores and quenchers include bodipy-tetramethylrhodamine and QSY-5 (Molecular Probes, Inc.) In a variant of this assay, biotin or another suitable tag may be placed on one end of the peptide to anchor the peptide to a substrate assay plate and a fluorophore may be placed at the other end of the peptide. Useful fluorophores include those listed above as well as Europium labels such as W8044 (EG&G Wallac, Inc.). A preferred label is oregon green that may be attached to a Cys residue. Cleavage of the peptide by Asp1 will release the fluorophore or other tag from the plate, allowing compounds to be assayed for inhibition of Asp1 proteolytic cleavage as shown by an increase in retained fluorescence. Preferred colorimetric assays of hu-Asp1 proteolytic activity utilize other suitable substrates that include the P₂ and P₁ amino acids comprising the recognition site for cleavage linked to o-nitrophenol through an amide linkage, such that cleavage by the hu-Asp1 results in an increase in optical density after altering the assay buffer to alkaline pH.

The present invention also provides for methods of assaying for α -secretase activity comprising contacting hu-Asp1 protein with an APP substrate, determining the level of hu-Asp1 α -secretase activity in the presence and absence of a modulator of hu-Asp1 α -secretase activity and comparing the hu-Asp1 secretase activity in the presence and absence of the modulator. The modulators determined to increase hu-

Asp1 α -secretase activity will be identified as candidate Alzheimer's disease therapeutics. The invention also encompasses methods which comprise a step for treating Alzheimer's disease with identified candidate Alzheimer disease therapeutics. The invention also provides for compositions comprising a candidate Alzheimer's disease therapeutic identified by the α -secretase assaying methods of the invention. Asp1 modulators that reduce Asp1 β -secretase activity and increase Asp1 α -secretase activity are highly preferred. Assays for Asp1 β -secretase activity are preferred essentially as described in detail herein for Asp2.

The invention provides for Asp1 protease substrate peptides or fragments thereof, wherein said peptides comprise an amino acid sequence consisting of fifty or fewer amino acids which comprise the Asp1 cleavage site having the amino acid sequence GLALALEP. This peptide was derived from the Asp1 amino acid sequence and the discovery of an apparent Asp1 autocatalytic cleavage in acidic conditions. The Asp1 substrate of the invention may also comprise a detectable label, such as a radioactive label, chemiluminescent label, enzymatic label or a fluorescent label. The fluorescently labeled substrate can consist of internally quenched labels as described above.

The invention also encompasses methods comprising the steps of contacting hu-Asp1 protein with an Asp1 substrate under acidic conditions and determining the level of Asp1 proteolytic activity. An example of Asp1 proteolytic activity is the auto-catalytic processing hu-Asp undergoes in acidic environments, wherein cleavage occurs at an amino acid site surrounding Ala⁶³ and cleaves the amino terminal amino acids of the hu-Asp1 pro-peptide. The hu-Asp1 pro-peptide refers to a secreted form of Asp1 that has completed intercellular processing which resulted in cleavage of its signal sequence.

For the methods of assaying Asp1 proteolytic activity, the hu-Asp1 may be produced in a cell transformed or transfected with a polynucleotide that encodes hu-Asp1. The hu-Asp1 protein may be isolated and purified from these cells or the method may utilize a cell growing under conditions that it expresses hu-Asp1. The method may also be carried out with a fragment of hu-Asp1 that retains its proteolytic

activity. The fragments provided for by the invention include hu-Asp1 polypeptide sequences which lack the amino acids that encode a transmembrane domain such as amino acids 469-492 of SEQ ID NO: 2 or fragments that lacks the cytoplasmic domain such as amino acids 493-518 of SEQ ID NO: 2.

5 Additional features and variations of the invention will be apparent to those skilled in the art from the entirety of this application, including the drawing and detailed description, and all such features are intended as aspects of the invention. Likewise, features of the invention described herein can be re-combined into additional embodiments that are also intended as aspects of the invention, irrespective
10 of whether the combination of features is specifically mentioned above as an aspect or embodiment of the invention. Also, only such limitations which are described herein as critical to the invention should be viewed as such; variations of the invention lacking limitations which have not been described herein as critical are intended as aspects of the invention.

15 In addition to the foregoing, the invention includes, as an additional aspect, all embodiments of the invention narrower in scope in any way than the variations specifically mentioned above. Although the applicant(s) invented the full scope of the claims appended hereto, the claims appended hereto are not intended to encompass within their scope the prior art work of others. Therefore, in the event that
20 statutory prior art within the scope of a claim is brought to the attention of the applicants by a Patent Office or other entity or individual, the applicant(s) reserve the right to exercise amendment rights under applicable patent laws to redefine the subject matter of such a claim to specifically exclude such statutory prior art or obvious variations of statutory prior art from the scope of such a claim. Variations of
25 the invention defined by such amended claims also are intended as aspects of the invention.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

Sequence ID No. 1: Human Asp-1, nucleotide sequence.

30 Sequence ID No. 2: Human Asp-1, predicted amino acid sequence.

Sequence ID No. 3: Human Asp-2(a), nucleotide sequence.

Sequence ID No. 4: Human Asp-2(a), predicted amino acid sequence. The Asp2(a) amino acid sequence includes a putative signal peptide comprising residues 1 to 21; and a putative pre-propeptide after the signal peptide that extends through residue 45 (as assessed by processing observed of recombinant Asp2(a) in CHO cells), and a putative propeptide that may extend to at least about residue 57, based on the observation of an observed GRR↓GS sequence which has characteristics of a protease recognition sequence. The Asp2(a) further includes a transmembrane domain comprising residues 455-477, a cytoplasmic domain comprising residues 478-501, and a putative alpha-helical spacer region, comprising residues 420-454, believed to be unnecessary for proteolytic activity, between the protease catalytic domain and the transmembrane domain.

Sequence ID No. 5: Human Asp-2(b), nucleotide sequence.

Sequence ID No. 6: Human Asp-2(b), predicted amino acid sequence. The Asp2(b) amino acid sequence includes a putative signal peptide, pre-propeptide, and propeptide as described above for Asp2(a). The Asp2(b) further includes a transmembrane domain comprising residues 430-452, a cytoplasmic domain comprising residues 453-476, and a putative alpha-helical spacer region, comprising residues 395-429, believed to be unnecessary for proteolytic activity, between the protease catalytic domain and the transmembrane domain.

Sequence ID No. 7: Murine Asp-2(a), nucleotide sequence.

Sequence ID No. 8: Murine Asp-2(a), predicted amino acid sequence. The proteolytic processing of murine Asp2(a) is believed to be analogous to the processing described above for human Asp2(a). In addition, a variant lacking amino acid residues 190-214 of SEQ ID NO: 8 is specifically contemplated as a murine Asp2(b) polypeptide.

Sequence ID No. 9: Human APP695, nucleotide sequence.

Sequence ID No.10: Human APP695, predicted amino acid sequence.

Sequence ID No.11: Human APP695-Sw, nucleotide sequence.

Sequence ID No.12: Human APP695-Sw. predicted amino acid sequence. In the APP695 isoform, the Sw mutation is characterized by a KM→NL alteration at positions 595-596 (compared to normal APP695).

Sequence ID No.13: Human APP695-VF, nucleotide sequence.

5 Sequence ID No.14: Human APP695-VF, predicted amino acid sequence. In the APP 695 isoform, the VF mutation is characterized by a V→F alteration at position 642 (compared to normal APP 695).

Sequence ID No.15: Human APP695-KK, nucleotide sequence.

10 Sequence ID No.16: Human APP695-KK, predicted amino acid sequence.
(APP695 with two carboxy-terminal lysine residues.)

Sequence ID No.17: Human APP695-Sw-KK, nucleotide sequence.

Sequence ID No.18: Human APP695-Sw-KK, predicted amino acid sequence

Sequence ID No.19: Human APP695-VF-KK, nucleotide sequence

15 Sequence ID No.20: Human APP695-VF-KK, predicted amino acid sequence

Sequence ID No.21: T7-Human-pro-Asp-2(a)ΔTM, nucleotide sequence

Sequence ID No.22: T7-Human-pro-Asp-2(a)ΔTM, amino acid sequence

Sequence ID No.23: T7-Caspase-Human-pro-Asp-2(a)ΔTM, nucleotide
sequence

20 Sequence ID No.24: T7-Caspase-Human-pro-Asp-2(a)ΔTM, amino acid
sequence

Sequence ID No.25: Human-pro-Asp-2(a)ΔTM (low GC), nucleotide
sequence

Sequence ID No.26: Human-pro-Asp-2(a)ΔTM, (low GC), amino acid
sequence

25 Sequence ID No.27: T7-Caspase-Caspase 8
cleavage-Human-pro-Asp-2(a)ΔTM, nucleotide sequence

Sequence ID No.28: T7-Caspase-Caspase 8
cleavage-Human-pro-Asp-2(a)ΔTM, amino acid sequence

Sequence ID No.29: Human Asp-2(a)ΔTM, nucleotide sequence

30 Sequence ID No.30: Human Asp-2(a)ΔTM, amino acid sequence

Sequence ID No.31: Human Asp-2(a) Δ TM(His)₆, nucleotide sequence

Sequence ID No. 32: Human Asp-2(a) Δ TM(His)₆, amino acid sequence

Sequence ID Nos. 33-49 are short synthetic peptide and oligonucleotide sequences that are described below in the Detailed Description of the Invention.

5 Sequence ID No. 50: Human Asp2(b) Δ TM polynucleotide sequence.

Sequence ID No. 51: Human Asp2(b) Δ TM polypeptide sequence (exemplary variant of Human Asp2(b) lacking transmembrane and intracellular domains of Hu-Asp2(b) set forth in SEQ ID NO: 6.

Sequence ID No. 52: Human Asp2(b) Δ TM(His)₆ polynucleotide sequence.

10 Sequence ID No. 53: Human Asp2(b) Δ TM(His)₆ polypeptide sequence (Human Asp2(b) Δ TM with six histidine tag attached to C-terminus).

Sequence ID No. 54: Human APP770-encoding polynucleotide sequence.

Sequence ID No. 55: Human APP770 polypeptide sequence. To introduce the KM-NL Swedish mutation, residues KM at positions 670-71 are changed to NL. To introduce the V-F London mutation, the V residue at position 717 is changed to F.

Sequence ID No. 56: Human APP751 encoding polynucleotide sequence.

Sequence ID No. 57: Human APP751 polypeptide sequence (Human APP751 isoform).

Sequence ID No. 58: Human APP770-KK encoding polynucleotide sequence.

20 Sequence ID No. 59: Human APP770-KK polypeptide sequence. (Human APP770 isoform to which two C-terminal lysines have been added).

Sequence ID No. 60: Human APP751-KK encoding polynucleotide sequence.

Sequence ID No. 61: Human APP751-KK polypeptide sequence (Human APP751 isoform to which two C-terminal lysines have been added).

25 Sequence ID Nos. 62-65: Various short peptide sequences described in detail in detailed description.

Sequence ID No. 66: Predicted amino acid sequence of human Asp-1 Δ TM(His)₆ as described in Example 14.

30 Sequence ID No. 67: Amino acid sequence of secreted recombinant Asp-1 Δ TM(His)₆ as described in Example 14.

5

10

15

20

25

30

Figure 8: Figure 8 shows the nucleotide (SEQ ID No. 25) and predicted amino acid sequence (SEQ ID No. 26) of Human-pro-Asp-2(a) Δ TM (low GC)

Figure 9: Western blot showing reduction of CTF99 production by HEK125.3 cells transfected with antisense oligomers targeting the Hu-Asp2 mRNA.

5 Figure 10: Western blot showing increase in CTF99 production in mouse Neuro-2a cells cotransfected with APP-KK with and without Hu-Asp2 only in those cells cotransfected with Hu-Asp2. A further increase in CTF99 production is seen in cells cotransfected with APP-Sw-KK with and without Hu-Asp2 only in those cells cotransfected with Hu-Asp2

10 Figure 11: Figure 11 shows the predicted amino acid sequence (SEQ ID No. 30) of Human-Asp2(a) Δ TM

Figure 12: Figure 11 shows the predicted amino acid sequence (SEQ ID No. 30) of Human-Asp2(a) Δ TM(His)₆

15 DETAILED DESCRIPTION OF THE INVENTION

A few definitions used in this invention follow, most definitions to be used are those that would be used by one ordinarily skilled in the art.

The term " β amyloid peptide" means any peptide resulting from beta secretase cleavage of APP. This includes peptides of 39, 40, 41, 42 and 43 amino acids, extending
20 from the β -secretase cleavage site to 39, 40, 41, 42 and 43 amino acids C-terminal to the β -secretase cleavage site. β amyloid peptide also includes sequences 1-6, SEQ ID NOs. 1-6 of US 5,750,349, issued 12 May 1998 (incorporated into this document by reference).

A β -secretase cleavage fragment disclosed here is called CTF-99, which extends from β -secretase cleavage site to the carboxy terminus of APP.

25 When an isoform of APP is discussed then what is meant is any APP polypeptide, including APP variants (including mutations), and APP fragments that exists in humans such as those described in US 5,766,846, col 7, lines 45-67, incorporated into this document by reference.

30 The term " β -amyloid precursor protein" (APP) as used herein is defined as a polypeptide that is encoded by a gene of the same name localized in humans on the

long arm of chromosome 21 and that includes “ β AP – here “ β -amyloid protein” see above, within its carboxyl third. APP is a glycosylated, single-membrane spanning protein expressed in a wide variety of cells in many mammalian tissues. Examples of specific isotypes of APP which are currently known to exist in humans are the 695 amino acid polypeptide described by Kang et. al. (1987) Nature 325:733-736 which is designated as the “normal” APP (SEQ ID NOs: 9-10); the 751 amino acid polypeptide described by Ponte et al. (1988) Nature 331:525-527 (1988) and Tanzi et al. (1988) Nature 331:528-530 (SEQ ID NOs: 56-57); and the 770-amino acid polypeptide described by Kitaguchi et. al. (1988) Nature 331:530-532 (SEQ ID NOs: 54-55). Examples of specific variants of APP include point mutation which can differ in both position and phenotype (for review of known variant mutation see Hardy (1992) Nature Genet. 1:233-234). All references cited here incorporated by reference. The term “APP fragments” as used herein refers to fragments of APP other than those which consist solely of β AP or β AP fragments. That is, APP fragments will include amino acid sequences of APP in addition to those which form intact β AP or a fragment of β AP.

When the term “any amino acid” is used, the amino acids referred to are to be selected from the following, three letter and single letter abbreviations - which may also be used, are provided as follows:

Alanine, Ala, A; Arginine, Arg, R; Asparagine, Asn, N; Aspartic acid, Asp, D; Cysteine, Cys, C; Glutamine, Gln, Q; Glutamic Acid, Glu, E; Glycine, Gly, G; Histidine, His, H; Isoleucine, Ile, I; Leucine, Leu, L; Lysine, Lys, K; Methionine, Met, M; Phenylalanine, Phe, F; Proline, Pro, P; Serine, Ser, S; Threonine, Thr, T; Tryptophan, Trp, W; Tyrosine, Tyr, Y; Valine, Val, V; Aspartic acid or Asparagine, Asx, B; Glutamic acid or Glutamine, Glx, Z; Any amino acid, Xaa, X.

The present invention describes a method to scan gene databases for the simple active site motif characteristic of aspartyl proteases. Eukaryotic aspartyl proteases such as pepsin and renin possess a two-domain structure which folds to bring two aspartyl residues into proximity within the active site. These are embedded in the short tripeptide motif DTG, or more rarely, DSG. Most aspartyl proteases

0968344-09200
002260-4789360

occur as proenzyme whose N-terminus must be cleaved for activation. The DTG or DSG active site motif appears at about residue 65-70 in the proenzyme (prorenin, pepsinogen), but at about residue 25-30 in the active enzyme after cleavage of the N-terminal prodomain. The limited length of the active site motif makes it difficult to search collections of short, expressed sequence tags (EST) for novel aspartyl proteases. EST sequences typically average 250 nucleotides or less, and so would encode 80-90 amino acid residues or less. That would be too short a sequence to span the two active site motifs. The preferred method is to scan databases of hypothetical or assembled protein coding sequences. The present invention describes a computer method to identify candidate aspartyl proteases in protein sequence databases. The method was used to identify seven candidate aspartyl protease sequences in the *Caenorhabditis elegans* genome. These sequences were then used to identify by homology search Hu-Asp1 and two alternative splice variants of Hu-Asp2, designated herein as Hu-Asp2(a) and Hu-Asp2(b).

In a major aspect of the invention disclosed here we provide new information about APP processing. Pathogenic processing of the amyloid precursor protein (APP) via the A β pathway requires the sequential action of two proteases referred to as β -secretase and γ -secretase. Cleavage of APP by the β -secretase and γ -secretase generates the N-terminus and C-terminus of the A β peptide, respectively. Because over production of the A β peptide, particularly the A β_{1-42} , has been implicated in the initiation of Alzheimer's disease, inhibitors of either the β -secretase and/or the γ -secretase have potential in the treatment of Alzheimer's disease. Despite the importance of the β -secretase and γ -secretase in the pathogenic processing of APP, molecular definition of these enzymes has not been accomplished to date. That is, it was not known what enzymes were required for cleavage at either the β -secretase or the γ -secretase cleavage site. The sites themselves were known because APP was known and the A β_{1-42} peptide was known, see US 5,766,846 and US 5,837,672, (incorporated by reference, with the exception to reference to "soluble" peptides). But what enzyme was involved in producing the A β_{1-42} peptide was unknown.

Alignment of the amino acid sequences of Hu-Asp2 with other known aspartyl proteases reveals a similar domain organization. All of the sequences contain a signal sequence followed by a pro-segment and the catalytic domain containing 2 copies of the aspartyl protease active site motif (DTG/DSG) separated by approximately 180 amino acid residues. Comparison of the processing site for proteolytic removal of the pro-segment in the mature forms of pepsin A, pepsin C, cathepsin D, cathepsin E and renin reveals that the mature forms of these enzymes contain between 31-35 amino acid residues upstream of the first DTG motif. Inspection of this region in the Hu-Asp-2 amino acid sequence indicates a preferred processing site within the sequence GRR↓GS as proteolytic processing of pro-protein precursors commonly occurs at site following dibasic amino acid pairs (eg. RR). Also, processing at this site would yield a mature enzyme with 35 amino acid residues upstream of the first DTG, consistent with the processing sites for other aspartyl proteases. In the absence of self-activation of Hu-Asp2 or a knowledge of the endogenous protease that processes Hu-Asp2 at this site, a recombinant form was engineered by introducing a recognition site for the PreSission protease (LEVLFQ↓GP) into the expression plasmids for bacterial, insect cell, and mammalian cell expression of pro-Hu-Asp2. In each case, the Gly residue in P1' position corresponds to the Gly residue 35 amino acids upstream of the first DTG motif in Hu-Asp2.

The present invention involves the molecular definition of several novel human aspartyl proteases and one of these, referred to as Hu-Asp-2(a) and Hu-Asp2(b), has been characterized in detail. Previous forms of asp1 and asp 2 have been disclosed, see EP 0848062 A2 and EP 0855444A2, inventors David Powel et al., assigned to Smith Kline Beecham Corp. (incorporated by reference). Herein are disclosed old and new forms of Hu-Asp 2. For the first time they are expressed in active form, their substrates are disclosed, and their specificity is disclosed. Prior to this disclosure cell or cell extracts were required to cleave the β -secretase site, now purified protein can be used in assays, also described here. Based on the results of (1) antisense knock out experiments, (2) transient transfection knock in experiments, and (3) biochemical experiments using purified recombinant Hu-Asp-2, we demonstrate

that Hu-Asp-2 is the β -secretase involved in the processing of APP. Although the nucleotide and predicted amino acid sequence of Hu-Asp-2(a) has been reported, see above, see EP 0848062 A2 and EP 0855444A2, no functional characterization of the enzyme was disclosed. Here the authors characterize the Hu-Asp-2 enzyme and are able to explain why it is a critical and essential enzyme required in the formation of $A\beta_{1-42}$, peptide and possible a critical step in the development of AD.

In another embodiment the present invention also describes a novel splice variant of Hu-Asp2, referred to as Hu-Asp-2(b), that has never before been disclosed.

In another embodiment, the invention provides isolated nucleic acid molecules comprising a polynucleotide encoding a polypeptide selected from the group consisting of human aspartyl protease 1 (Hu-Asp1) and two alternative splice variants of human aspartyl protease-2 (Hu-Asp2), designated herein as Hu-Asp2(a) and Hu-Asp2(b). As used herein, all references to "Hu-Asp2" should be understood to refer to both Hu-Asp2(a) and Hu-Asp2(b). Hu-Asp1 is expressed most abundantly in pancreas and prostate tissues, while Hu-Asp2(a) and Hu-Asp2(b) are expressed most abundantly in pancreas and brain tissues. The invention also provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof which exhibit aspartyl protease activity.

The predicted amino acid sequences of Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) share significant homology with previously identified mammalian aspartyl proteases such as pepsinogen A, pepsinogen B, cathepsin D, cathepsin E, and renin. P.B.Szecs, *Scand. J. Clin. Lab. Invest.* 52:(Suppl. 210 5-22 (1992)). These enzymes are characterized by the presence of a duplicated DTG/DSG sequence motif. The Hu-Asp1 and HuAsp2 polypeptides disclosed herein also exhibit extremely high homology with the ProSite consensus motif for aspartyl proteases extracted from the SwissProt database.

The nucleotide sequence given as residues 1-1554 of SEQ ID NO:1 corresponds to the nucleotide sequence encoding Hu-Asp1, the nucleotide sequence given as residues 1-1503 of SEQ ID NO:3 corresponds to the nucleotide sequence encoding Hu-Asp2(a), and the nucleotide sequence given as residues 1-1428 of SEQ

ID NO:5 corresponds to the nucleotide sequence encoding Hu-Asp2(b). The isolation and sequencing of DNA encoding Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) is described below in Examples 1 and 2.

As is described in Examples 1 and 2, automated sequencing methods were used to obtain the nucleotide sequence of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b). The Hu-Asp nucleotide sequences of the present invention were obtained for both DNA strands, and are believed to be 100% accurate. However, as is known in the art, nucleotide sequence obtained by such automated methods may contain some errors. Nucleotide sequences determined by automation are typically at least about 90%, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of a given nucleic acid molecule. The actual sequence may be more precisely determined using manual sequencing methods, which are well known in the art. An error in sequence which results in an insertion or deletion of one or more nucleotides may result in a frame shift in translation such that the predicted amino acid sequence will differ from that which would be predicted from the actual nucleotide sequence of the nucleic acid molecule, starting at the point of the mutation. The Hu-Asp DNA of the present invention includes cDNA, chemically synthesized DNA, DNA isolated by PCR, genomic DNA, and combinations thereof. Genomic Hu-Asp DNA may be obtained by screening a genomic library with the Hu-Asp2 cDNA described herein, using methods that are well known in the art, or with oligonucleotides chosen from the Hu-Asp2 sequence that will prime the polymerase chain reaction (PCR). RNA transcribed from Hu-Asp DNA is also encompassed by the present invention.

Due to the degeneracy of the genetic code, two DNA sequences may differ and yet encode identical amino acid sequences. The present invention thus provides isolated nucleic acid molecules having a polynucleotide sequence encoding any of the Hu-Asp polypeptides of the invention, wherein said polynucleotide sequence encodes a Hu-Asp polypeptide having the complete amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or fragments thereof.

Also provided herein are purified Hu-Asp polypeptides, both recombinant and non-recombinant. Most importantly, methods to produce Hu-Asp2 polypeptides in active form are provided. These include production of Hu-Asp2 polypeptides and variants thereof in bacterial cells, insect cells, and mammalian cells, also in forms that allow secretion of the Hu-Asp2 polypeptide from bacterial, insect or mammalian cells into the culture medium, also methods to produce variants of Hu-Asp2 polypeptide incorporating amino acid tags that facilitate subsequent purification. In a preferred embodiment of the invention the Hu-Asp2 polypeptide is converted to a proteolytically active form either in transformed cells or after purification and cleavage by a second protease in a cell-free system, such active forms of the Hu-Asp2 polypeptide beginning with the N-terminal sequence TQHGIR or ETDEEP. The sequence TQHGIR represents the amino-terminus of Asp2(a) or Asp2(b) beginning with residue 22 of SEQ ID NO: 4 or 6, after cleavage of a putative 21 residue signal peptide. Recombinant Asp2(a) expressed in and purified from insect cells was observed to have this amino terminus, presumably as a result of cleavage by a signal peptidase. The sequence ETDEEP represents the amino-terminus of Asp2(a) or Asp2(b) beginning with residue 46 of SEQ ID NO: 4 or 6, as observed when Asp2(a) has been recombinantly produced in CHO cells (presumably after cleavage by both a rodent signal peptidase and another rodent peptidase that removes a propeptide sequence). The Asp2(a) produced in the CHO cells possesses β -secretase activity, as described in greater detail in Examples 11 and 12. Variants and derivatives, including fragments, of Hu-Asp proteins having the native amino acid sequences given in SEQ ID Nos: 2, 4, and 6 that retain any of the biological activities of Hu-Asp are also within the scope of the present invention. Of course, one of ordinary skill in the art will readily be able to determine whether a variant, derivative, or fragment of a Hu-Asp protein displays Hu-Asp activity by subjecting the variant, derivative, or fragment to a standard aspartyl protease assay. Fragments of Hu-Asp within the scope of this invention include those that contain the active site domain containing the amino acid sequence DTG, fragments that contain the active site domain amino acid sequence DSG, fragments containing both the DTG and DSG active site sequences,

fragments in which the spacing of the DTG and DSG active site sequences has been lengthened, fragments in which the spacing has been shortened. Also within the scope of the invention are fragments of Hu-Asp in which the transmembrane domain has been removed to allow production of Hu-Asp2 in a soluble form. In another embodiment of the invention, the two halves of Hu-Asp2, each containing a single active site DTG or DSG sequence can be produced independently as recombinant polypeptides, then combined in solution where they reconstitute an active protease.

Thus, the invention provides a purified polypeptide comprising a fragment of a mammalian Asp2 protein, wherein said fragment lacks the Asp2 transmembrane domain of said Asp2 protein, and wherein the polypeptide and the fragment retain the β -secretase activity of said mammalian Asp2 protein. In a preferred embodiment, the purified polypeptide comprises a fragment of a human Asp2 protein that retains the β -secretase activity of the human Asp2 protein from which it was derived. Examples include:

a purified polypeptide that comprises a fragment of Asp2(a) having the amino acid sequence set forth in SEQ ID NO: 4, wherein the polypeptide lacks transmembrane domain amino acids 455 to 477 of SEQ ID NO: 4;

a purified polypeptide as described in the preceding paragraph that further lacks cytoplasmic domain amino acids 478 to 501 of SEQ ID NO: 4;

a purified polypeptide as described in either of the preceding paragraphs that further lacks amino acids 420-454 of SEQ ID NO: 4, which constitute a putative alpha helical region between the catalytic domain and the transmembrane domain that is believed to be unnecessary for β -secretase activity;

a purified polypeptide that comprises an amino acid sequence that includes amino acids 58 to 419 of SEQ ID NO: 4, and that lacks amino acids 22 to 57 of SEQ ID NO: 4;

a purified polypeptide that comprises an amino acid sequence that includes amino acids 46 to 419 of SEQ ID NO: 4, and that lacks amino acids 22 to 45 of SEQ ID NO: 4;

a purified polypeptide that comprises an amino acid sequence that includes amino acids 22 to 454 of SEQ ID NO: 4.

a purified polypeptide that comprises a fragment of Asp2(b) having the amino acid sequence set forth in SEQ ID NO: 6, and wherein said polypeptide lacks transmembrane domain amino acids 430 to 452 of SEQ ID NO: 6;

a purified polypeptide as described in the preceding paragraph that further lacks cytoplasmic domain amino acids 453 to 476 of SEQ ID NO: 6;

a purified polypeptide as described in either of the preceding two paragraphs that further lacks amino acids 395-429 of SEQ ID NO: 4, which constitute a putative alpha helical region between the catalytic domain and the transmembrane domain that is believed to be unnecessary for β -secretase activity;

a purified polypeptide comprising an amino acid sequence that includes amino acids 58 to 394 of SEQ ID NO: 4, and that lacks amino acids 22 to 57 of SEQ ID NO: 4;

a purified polypeptide comprising an amino acid sequence that includes amino acids 46 to 394 of SEQ ID NO: 4, and that lacks amino acids 22 to 45 of SEQ ID NO: 4; and

a purified polypeptide comprising an amino acid sequence that includes amino acids 22 to 429 of SEQ ID NO: 4.

Also included as part of the invention is a purified polynucleotide comprising a nucleotide sequence that encodes such polypeptides; a vector comprising a polynucleotide that encodes such polypeptides; and a host cell transformed or transfected with such a polynucleotide or vector.

Hu-Asp variants may be obtained by mutation of native Hu-Asp-encoding nucleotide sequences, for example. A Hu-Asp variant, as referred to herein, is a polypeptide substantially homologous to a native Hu-Asp polypeptide but which has an amino acid sequence different from that of native Hu-Asp because of one or more deletions, insertions, or substitutions in the amino acid sequence. The variant amino acid or nucleotide sequence is preferably at least about 80% identical, more

preferably at least about 90% identical, and most preferably at least about 95% identical, to a native Hu-Asp sequence. Thus, a variant nucleotide sequence which contains, for example, 5 point mutations for every one hundred nucleotides, as compared to a native Hu-Asp gene, will be 95% identical to the native protein. The percentage of sequence identity, also termed homology, between a native and a variant Hu-Asp sequence may also be determined, for example, by comparing the two sequences using any of the computer programs commonly employed for this purpose, such as the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wisconsin), which uses the algorithm of Smith and Waterman (*Adv. Appl. Math.* 2: 482-489 (1981)).

Alterations of the native amino acid sequence may be accomplished by any of a number of known techniques. For example, mutations may be introduced at particular locations by procedures well known to the skilled artisan, such as oligonucleotide-directed mutagenesis, which is described by Walder *et al.* (*Gene* 42:133 (1986)); Bauer *et al.* (*Gene* 37:73 (1985)); Craik (*BioTechniques*, January 1985, pp. 12-19); Smith *et al.* (*Genetic Engineering: Principles and Methods*, Plenum Press (1981)); and U.S. Patent Nos. 4,518,584 and 4,737,462.

Hu-Asp variants within the scope of the invention may comprise conservatively substituted sequences, meaning that one or more amino acid residues of a Hu-Asp polypeptide are replaced by different residues that do not alter the secondary and/or tertiary structure of the Hu-Asp polypeptide. Such substitutions may include the replacement of an amino acid by a residue having similar physicochemical properties, such as substituting one aliphatic residue (Ile, Val, Leu or Ala) for another, or substitution between basic residues Lys and Arg, acidic residues Glu and Asp, amide residues Gln and Asn, hydroxyl residues Ser and Tyr, or aromatic residues Phe and Tyr. Further information regarding making phenotypically silent amino acid exchanges may be found in Bowie *et al.*, *Science* 247:1306-1310 (1990). Other Hu-Asp variants which might retain substantially the biological activities of Hu-Asp are those where amino acid substitutions have been made in areas outside functional regions of the protein.

09663344-092200

In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a portion of the nucleic acid molecules described above, *e.g.*, to at least about 15 nucleotides, preferably to at least about 20 nucleotides, more preferably to at least about 30 nucleotides, and still more preferably to at least about from 30 to at least about 100 nucleotides, of one of the previously described nucleic acid molecules. Such portions of nucleic acid molecules having the described lengths refer to, *e.g.*, at least about 15 contiguous nucleotides of the reference nucleic acid molecule. By stringent hybridization conditions is intended overnight incubation at about 42°C for about 2.5 hours in 6 X SSC/0.1% SDS, followed by washing of the filters four times for 15 minutes in 1.0 X SSC at 65°C, 0.1% SDS.

Fragments of the Hu-Asp encoding nucleic acid molecules described herein, as well as polynucleotides capable of hybridizing to such nucleic acid molecules may be used as a probe or as primers in a polymerase chain reaction (PCR). Such probes may be used, *e.g.*, to detect the presence of Hu-Asp nucleic acids in *in vitro* assays, as well as in Southern and northern blots. Cell types expressing Hu-Asp may also be identified by the use of such probes. Such procedures are well known, and the skilled artisan will be able to choose a probe of a length suitable to the particular application. For PCR, 5' and 3' primers corresponding to the termini of a desired Hu-Asp nucleic acid molecule are employed to isolate and amplify that sequence using conventional techniques.

Other useful fragments of the Hu-Asp nucleic acid molecules are antisense or sense oligonucleotides comprising a single stranded nucleic acid sequence capable of binding to a target Hu-Asp mRNA (using a sense strand), or Hu-Asp DNA (using an antisense strand) sequence. In a preferred embodiment of the invention these Hu-Asp antisense oligonucleotides reduce Hu-Asp mRNA and consequent production of Hu-Asp polypeptides.

In another aspect, the invention includes Hu-Asp polypeptides with or without associated native pattern glycosylation. Both Hu-Asp1 and Hu-Asp2 have canonical acceptor sites for Asn-linked sugars, with Hu-Asp1 having two of such sites, and

Hu-Asp2 having four. Hu-Asp expressed in yeast or mammalian expression systems (discussed below) may be similar to or significantly different from a native Hu-Asp polypeptide in molecular weight and glycosylation pattern. Expression of Hu-Asp in bacterial expression systems will provide non-glycosylated Hu-Asp.

5 The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. Hu-Asp polypeptides may be recovered and purified from tissues, cultured cells, or recombinant cell cultures by well-known methods, including ammonium sulfate or ethanol precipitation, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic
10 interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, and high performance liquid chromatography (HPLC). In a preferred embodiment, an amino acid tag is added to the Hu-Asp polypeptide using genetic engineering techniques that are well known to practitioners of the art which include addition of six histidine amino acid residues to allow
15 purification by binding to nickel immobilized on a suitable support, epitopes for polyclonal or monoclonal antibodies including but not limited to the T7 epitope, the myc epitope, and the V5a epitope, and fusion of Hu-Asp2 to suitable protein partners including but not limited to glutathione-S-transferase or maltose binding protein. In a preferred embodiment these additional amino acid sequences are added to the
20 C-terminus of Hu-Asp but may be added to the N-terminus or at intervening positions within the Hu-Asp2 polypeptide.

 The present invention also relates to vectors comprising the polynucleotide molecules of the invention, as well as host cell transformed with such vectors. Any of the polynucleotide molecules of the invention may be joined to a vector, which
25 generally includes a selectable marker and an origin of replication, for propagation in a host. Because the invention also provides Hu-Asp polypeptides expressed from the polynucleotide molecules described above, vectors for the expression of Hu-Asp are preferred. The vectors include DNA encoding any of the Hu-Asp polypeptides described above or below, operably linked to suitable transcriptional or translational
30 regulatory sequences, such as those derived from a mammalian, microbial, viral, or

insect gene. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, mRNA ribosomal binding sites, and appropriate sequences which control transcription and translation. Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA encoding Hu-Asp.

5 Thus, a promoter nucleotide sequence is operably linked to a Hu-Asp DNA sequence if the promoter nucleotide sequence directs the transcription of the Hu-Asp sequence.

Selection of suitable vectors to be used for the cloning of polynucleotide molecules encoding Hu-Asp, or for the expression of Hu-Asp polypeptides, will of course depend upon the host cell in which the vector will be transformed, and, where
10 applicable, the host cell from which the Hu-Asp polypeptide is to be expressed. Suitable host cells for expression of Hu-Asp polypeptides include prokaryotes, yeast, and higher eukaryotic cells, each of which is discussed below.

The Hu-Asp polypeptides to be expressed in such host cells may also be fusion proteins which include regions from heterologous proteins. Such regions may be
15 included to allow, *e.g.*, secretion, improved stability, or facilitated purification of the polypeptide. For example, a sequence encoding an appropriate signal peptide can be incorporated into expression vectors. A DNA sequence for a signal peptide (secretory leader) may be fused inframe to the Hu-Asp sequence so that Hu-Asp is translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in
20 the intended host cell promotes extracellular secretion of the Hu-Asp polypeptide. Preferably, the signal sequence will be cleaved from the Hu-Asp polypeptide upon secretion of Hu-Asp from the cell. Nonlimiting examples of signal sequences that can be used in practicing the invention include the yeast Ifactor and the honeybee melatin leader in sf9 insect cells.

25 In a preferred embodiment, the Hu-Asp polypeptide will be a fusion protein which includes a heterologous region used to facilitate purification of the polypeptide. Many of the available peptides used for such a function allow selective binding of the fusion protein to a binding partner. For example, the Hu-Asp polypeptide may be modified to comprise a peptide to form a fusion protein which specifically binds to a
30 binding partner, or peptide tag. Nonlimiting examples of such peptide tags include the

6-His tag, thioredoxin tag, hemagglutinin tag, GST tag, and OmpA signal sequence tag. As will be understood by one of skill in the art, the binding partner which recognizes and binds to the peptide may be any molecule or compound including metal ions (*e.g.*, metal affinity columns), antibodies, or fragments thereof, and any protein or peptide which binds the peptide, such as the FLAG tag.

Suitable host cells for expression of Hu-Asp polypeptides includes prokaryotes, yeast, and higher eukaryotic cells. Suitable prokaryotic hosts to be used for the expression of Hu-Asp include bacteria of the genera *Escherichia*, *Bacillus*, and *Salmonella*, as well as members of the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*. For expression in, *e.g.*, *E. coli*, a Hu-Asp polypeptide may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in a prokaryotic host. The N-terminal Met may optionally then be cleaved from the expressed Hu-Asp polypeptide. Other N-terminal amino acid residues can be added to the Hu-Asp polypeptide to facilitate expression in *Escherichia coli* including but not limited to the T7 leader sequence, the T7-caspase 8 leader sequence, as well as others leaders including tags for purification such as the 6-His tag (Example 9). Hu-Asp polypeptides expressed in *E. coli* may be shortened by removal of the cytoplasmic tail, the transmembrane domain, or the membrane proximal region. Hu-Asp polypeptides expressed in *E. coli* may be obtained in either a soluble form or as an insoluble form which may or may not be present as an inclusion body. The insoluble polypeptide may be rendered soluble by guanidine HCl, urea or other protein denaturants, then refolded into a soluble form before or after purification by dilution or dialysis into a suitable aqueous buffer. If the inactive proform of the Hu-Asp was produced using recombinant methods, it may be rendered active by cleaving off the prosegment with a second suitable protease such as human immunodeficiency virus protease.

Expression vectors for use in prokaryotic hosts generally comprises one or more phenotypic selectable marker genes. Such genes generally encode, *e.g.*, a protein that confers antibiotic resistance or that supplies an auxotrophic requirement. A wide variety of such vectors are readily available from commercial sources.

Examples include pSPORT vectors, pGEM vectors (Promega), pPROEX vectors (LTI, Bethesda, MD), Bluescript vectors (Stratagene), pET vectors (Novagen) and pQE vectors (Qiagen).

5 Hu-Asp may also be expressed in yeast host cells from genera including *Saccharomyces*, *Pichia*, and *Kluveromyces*. Preferred yeast hosts are *S. cerevisiae* and *P. pastoris*. Yeast vectors will often contain an origin of replication sequence from a 2T yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Vectors replicable in both yeast and *E. coli* (termed shuttle
10 vectors) may also be used. In addition to the above-mentioned features of yeast vectors, a shuttle vector will also include sequences for replication and selection in *E. coli*. Direct secretion of Hu-Asp polypeptides expressed in yeast hosts may be accomplished by the inclusion of nucleotide sequence encoding the yeast I-factor leader sequence at the 5' end of the Hu-Asp-encoding nucleotide sequence.

15 Insect host cell culture systems may also be used for the expression of Hu-Asp polypeptides. In a preferred embodiment, the Hu-Asp polypeptides of the invention are expressed using an insect cell expression system (*see* Example 10). Additionally, a baculovirus expression system can be used for expression in insect cells as reviewed by Luckow and Summers, *Bio/Technology* 6:47 (1988).

20 In another preferred embodiment, the Hu-Asp polypeptide is expressed in mammalian host cells. Nonlimiting examples of suitable mammalian cell lines include the COS7 line of monkey kidney cells (Gluzman *et al.*, *Cell* 23:175 (1981)), human embryonic kidney cell line 293, and Chinese hamster ovary (CHO) cells. Preferably, Chinese hamster ovary (CHO) cells are used for expression of Hu-Asp
25 proteins (Example 11).

The choice of a suitable expression vector for expression of the Hu-Asp polypeptides of the invention will of course depend upon the specific mammalian host cell to be used, and is within the skill of the ordinary artisan. Examples of suitable expression vectors include pcDNA3 (Invitrogen) and pSVL (Pharmacia Biotech). A
30 preferred vector for expression of Hu-Asp polypeptides is pcDNA3.1-Hygro

(Invitrogen). Expression vectors for use in mammalian host cells may include transcriptional and translational control sequences derived from viral genomes. Commonly used promoter sequences and enhancer sequences which may be used in the present invention include, but are not limited to, those derived from human cytomegalovirus (CMV), Adenovirus 2, Polyoma virus, and Simian virus 40 (SV40). Methods for the construction of mammalian expression vectors are disclosed, for example, in Okayama and Berg (*Mol. Cell. Biol.* 3:280 (1983)); Cosman *et al.* (*Mol. Immunol.* 23:935 (1986)); Cosman *et al.* (*Nature* 312:768 (1984)); EP-A-0367566; and WO 91/18982.

The polypeptides of the present invention may also be used to raise polyclonal and monoclonal antibodies, which are useful in diagnostic assays for detecting Hu-Asp polypeptide expression. Such antibodies may be prepared by conventional techniques. See, for example, *Antibodies: A Laboratory Manual*, Harlow and Land (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1988); *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Kennet *et al.* (eds.), Plenum Press, New York (1980). Synthetic peptides comprising portions of Hu-Asp containing 5 to 20 amino acids may also be used for the production of polyclonal or monoclonal antibodies after linkage to a suitable carrier protein including but not limited to keyhole limpet hemacyanin (KLH), chicken ovalbumin, or bovine serum albumin using various cross-linking reagents including carbodimides, glutaraldehyde, or if the peptide contains a cysteine, N-methylmaleimide. A preferred peptide for immunization when conjugated to KLH contains the C-terminus of Hu-Asp1 or Hu-Asp2 comprising QRRPRDPEVVNDESSLVRHRWK (SEQ ID NO: 2, residues 497-518) or LRQQHDDFADDISLLK (SEQ ID NO:4, residues 486-501), respectively. See SEQ ID Nos. 33-34.

The Hu-Asp nucleic acid molecules of the present invention are also valuable for chromosome identification, as they can hybridize with a specific location on a human chromosome. Hu-Asp1 has been localized to chromosome 21, while Hu-Asp2 has been localized to chromosome 11q23.3-24.1. There is a current need for

identifying particular sites on the chromosome, as few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. The relationship between genes and diseases that have been mapped to the same chromosomal region can then be identified through linkage analysis, wherein the coinheritance of physically adjacent genes is determined. Whether a gene appearing to be related to a particular disease is in fact the cause of the disease can then be determined by comparing the nucleic acid sequence between affected and unaffected individuals.

In another embodiment, the invention relates to a method of assaying Hu-Asp function, specifically Hu-Asp2 function which involves incubating in solution the Hu-Asp polypeptide with a suitable substrate including but not limited to a synthetic peptide containing the β -secretase cleavage site of APP, preferably one containing the mutation found in a Swedish kindred with inherited AD in which KM is changed to NL, such peptide comprising the sequence SEVNLDAEFR in an acidic buffering solution, preferably an acidic buffering solution of pH5.5 (see Example 12) using cleavage of the peptide monitored by high performance liquid chromatography as a measure of Hu-Asp proteolytic activity. Preferred assays for proteolytic activity utilize internally quenched peptide assay substrates. Such suitable substrates include peptides which have attached a paired fluorphore and quencher including but not limited to 7-amino-4-methyl coumarin and dinitrophenol, respectively, such that cleavage of the peptide by the Hu-Asp results in increased fluorescence due to physical separation of the fluorphore and quencher. Other paired fluorphores and quenchers include bodipy-tetramethylrhodamine and QSY-5 (Molecular Probes, Inc.). In a variant of this assay, biotin or another suitable tag may be placed on one end of the peptide to anchor the peptide to a substrate assay plate and a fluorphore may be placed at the other end of the peptide. Useful fluorphores include those listed above as well as Europium labels such as W8044 (EG&g Wallac, Inc.). Cleavage of the peptide by Asp2 will release the fluorphore or other tag from the plate, allowing

compounds to be assayed for inhibition of Asp2 proteolytic cleavage as shown by an increase in retained fluorescence. Preferred colorimetric assays of Hu-Asp proteolytic activity utilize other suitable substrates that include the P2 and P1 amino acids comprising the recognition site for cleavage linked to o-nitrophenol through an amide linkage, such that cleavage by the Hu-Asp results in an increase in optical density after altering the assay buffer to alkaline pH.

In another embodiment, the invention relates to a method for the identification of an agent that increases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising

(a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and

(b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent;

whereby a higher level of activity in the presence of said test agent than in the absence of said test agent indicates that said test agent has increased the activity of said Hu-Asp polypeptide. Such tests can be performed with Hu-Asp polypeptide in a cell free system and with cultured cells that express Hu-Asp as well as variants or isoforms thereof.

In another embodiment, the invention relates to a method for the identification of an agent that decreases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising

(a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and

(b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent; whereby a lower level of activity in the presence of said test agent than in the absence of said test agent indicates that said test agent has decreased the activity of said Hu-Asp polypeptide. Such tests can be performed with

Hu-Asp polypeptide in a cell free system and with cultured cells that express Hu-Asp as well as variants or isoforms thereof.

In another embodiment, the invention relates to a novel cell line (HEK125.3 cells) for measuring processing of amyloid β peptide ($A\beta$) from the amyloid protein precursor (APP). The cells are stable transformants of human embryonic kidney 293 cells (HEK293) with a bicistronic vector derived from pIRES-EGFP (Clontech) containing a modified human APP cDNA, an internal ribosome entry site and an enhanced green fluorescent protein (EGFP) cDNA in the second cistron. The APP cDNA was modified by adding two lysine codons to the carboxyl terminus of the APP coding sequence. This increases processing of $A\beta$ peptide from human APP by 2-4 fold. This level of $A\beta$ peptide processing is 60 fold higher than is seen in nontransformed HEK293 cells. HEK125.3 cells will be useful for assays of compounds that inhibit $A\beta$ peptide processing. This invention also includes addition of two lysine residues to the C-terminus of other APP isoforms including the 751 and 770 amino acid isoforms, to isoforms of APP having mutations found in human AD including the Swedish KM \rightarrow NL and V717 \rightarrow F mutations, to C-terminal fragments of APP, such as those beginning with the β -secretase cleavage site, to C-terminal fragments of APP containing the β -secretase cleavage site which have been operably linked to an N-terminal signal peptide for membrane insertion and secretion, and to C-terminal fragments of APP which have been operably linked to an N-terminal signal peptide for membrane insertion and secretion and a reporter sequence including but not limited to green fluorescent protein or alkaline phosphatase, such that β -secretase cleavage releases the reporter protein from the surface of cells expressing the polypeptide.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Example 1

Development of a Search Algorithm Useful for the Identification of Aspartyl Proteases, and Identification of *C. elegans* Aspartyl Protease Genes in Wormpep 12

5 *Materials and Methods:*

Classical aspartyl proteases such as pepsin and renin possess a two-domain structure which folds to bring two aspartyl residues into proximity within the active site. These are embedded in the short tripeptide motif DTG, or more rarely, DSG. The DTG or DSG active site motif appears at about residue 25-30 in the enzyme, but
 10 at about 65-70 in the proenzyme (prorenin, pepsinogen). This motif appears again about 150-200 residues downstream. The proenzyme is activated by cleavage of the N-terminal prodomain. This pattern exemplifies the double domain structure of the modern day aspartyl enzymes which apparently arose by gene duplication and divergence. Thus;

15 $\text{NH}_2\text{-----X-----D}^{25}\text{TG-----Y-----D}^{Y+25}\text{TG-----C}$

where X denotes the beginning of the enzyme, following the N-terminal prodomain, and Y denotes the center of the molecule where the gene repeat begins again.

In the case of the retroviral enzymes such as the HIV protease, they represent only a half of the two-domain structures of well-known enzymes like pepsin,
 20 cathepsin D, renin, etc. They have no prosegment, but are carved out of a polyprotein precursor containing the *gag* and *pol* proteins of the virus. They can be represented by:

$\text{NH}_2\text{-----D}^{25}\text{TG-----C100}$

This "monomer" only has about 100 aa, so is extremely parsimonious as compared to
 25 the other aspartyl protease "dimers" which have of the order of 330 or so aa, not counting the N-terminal prodomain.

The limited length of the eukaryotic aspartyl protease active site motif makes it difficult to search EST collections for novel sequences. EST sequences typically average 250 nucleotides, and so in this case would be unlikely to span both aspartyl
 30 protease active site motifs. Instead, we turned to the *C. elegans* genome. The *C. elegans* genome is estimated to contain around 13,000 genes. Of these, roughly

12,000 have been sequenced and the corresponding hypothetical open reading frame (ORF) has been placed in the database Wormpep12. We used this database as the basis for a whole genome scan of a higher eukaryote for novel aspartyl proteases, using an algorithm that we developed specifically for this purpose. The following

5 AWK script for locating proteins containing two DTG or DSG motifs was used for the search, which was repeated four times to recover all pairwise combinations of the aspartyl motif.

```

BEGIN{RS=">"}          /* defines ">" as record separator for FASTA format */
{
10 pos = index($0,"DTG")    /* finds "DTG" in record*/
if (pos>0) {
    rest = substr($0,pos+3)    /*get rest of record after first DTG*/
    pos2 = index(rest,"DTG")    /*find second DTG*/
    if (pos2>0) printf ("%s%s\n", ">", $0)}    /*report hits*/
15 }
}
```

The AWK script shown above was used to search Wormpep12, which was downloaded from <ftp.sanger.ac.uk/pub/databases/wormpep>, for sequence entries containing at least two DTG or DSG motifs. Using AWK limited each record to 3000

20 characters or less. Thus, 35 or so larger records were eliminated manually from Wormpep12 as in any case these were unlikely to encode aspartyl proteases.

Results and Discussion:

The Wormpep 12 database contains 12,178 entries, although some of these (<10%) represent alternatively spliced transcripts from the same gene. Estimates of

25 the number of genes encoded in the *C. elegans* genome is on the order of 13,000 genes, so Wormpep12 may be estimated to cover greater than 90% of the *C. elegans* genome.

Eukaryotic aspartyl proteases contain a two-domain structure, probably arising from ancestral gene duplication. Each domain contains the active site motif D(S/T)G

30 located from 20-25 amino acid residues into each domain. The retroviral (e.g., HIV protease) or retrotransposon proteases are homodimers of subunits which are homologous to a single eukaryotic aspartyl protease domain. An AWK script was used to search the Wormpep12 database for proteins in which the D(S/T)G motif

occurred at least twice. This identified >60 proteins with two DTG or DSG motifs. Visual inspection was used to select proteins in which the position of the aspartyl domains was suggestive of a two-domain structure meeting the criteria described above.

5 In addition, the PROSITE eukaryotic and viral aspartyl protease active site pattern PS00141 was used to search Wormpep12 for candidate aspartyl proteases. (Bairoch A., Bucher P., Hofmann K., The PROSITE database: its status in 1997, *Nucleic Acids Res.* 24:217-221(1997)). This generated an overlapping set of Wormpep12 sequences. Of these, seven sequences contained two DTG or DSG
10 motifs and the PROSITE aspartyl protease active site pattern. Of these seven, three were found in the same cosmid clone (F21F8.3, F21F8.4, and F21F8.7) suggesting that they represent a family of proteins that arose by ancestral gene duplication. Two other ORFs with extensive homology to F21F8.3, F21F8.4 and F21F8.7 are present in the same gene cluster (F21F8.2 and F21F8.6), however, these contain only a single
15 DTG motif. Exhaustive BLAST searches with these seven sequences against Wormpep12 failed to reveal additional candidate aspartyl proteases in the *C. elegans* genome containing two repeats of the DTG or DSG motif.

BLASTX search with each *C. elegans* sequence against SWISS-PROT, GenPep and TREMBL revealed that R12H7.2 was the closest worm homologue to the
20 known mammalian aspartyl proteases, and that T18H9.2 was somewhat more distantly related, while CEASP1, F21F8.3, F21F8.4, and F21F8.7 formed a subcluster which had the least sequence homology to the mammalian sequences.

Discussion:

APP, the presenilins, and p35, the activator of cdk5, all undergo intracellular
25 proteolytic processing at sites which conform to the substrate specificity of the HIV protease. Dysregulation of a cellular aspartyl protease with the same substrate specificity, might therefore provide a unifying mechanism for causation of the plaque and tangle pathologies in AD. Therefore, we sought to identify novel human aspartyl proteases. A whole genome scan in *C. elegans* identified seven open reading frames
30 that adhere to the aspartyl protease profile that we had identified. These seven

aspartyl proteases probably comprise the complete complement of such proteases in a simple, multicellular eukaryote. These include four closely related aspartyl proteases unique to *C. elegans* which probably arose by duplication of an ancestral gene. The other three candidate aspartyl proteases (T18H9.2, R12H7.2 and C11D2.2) were found to have homology to mammalian gene sequences.

Example 2

Identification of Novel Human Aspartyl Proteases Using Database Mining by Genome Bridging

Materials and Methods:

Computer-assisted analysis of EST databases, cDNA , and predicted polypeptide sequences:

Exhaustive homology searches of EST databases with the CEASP1, F21F8.3, F21F8.4, and F21F8.7 sequences failed to reveal any novel mammalian homologues. TBLASTN searches with R12H7.2 showed homology to cathepsin D, cathepsin E, pepsinogen A, pepsinogen C and renin, particularly around the DTG motif within the active site, but also failed to identify any additional novel mammalian aspartyl proteases. This indicates that the *C. elegans* genome probably contains only a single lysosomal aspartyl protease which in mammals is represented by a gene family that arose through duplication and consequent modification of an ancestral gene.

TBLASTN searches with T18H9.2, the remaining *C. elegans* sequence, identified several ESTs which assembled into a contig encoding a novel human aspartyl protease (Hu-ASP1). As is described above in Example 1, BLASTX search with the Hu-ASP1 contig against SWISS-PROT revealed that the active site motifs in the sequence aligned with the active sites of other aspartyl proteases. Exhaustive, repetitive rounds of BLASTN searches against LifeSeq, LifeSeqFL, and the public EST collections identified 102 EST from multiple cDNA libraries that assembled into a single contig. The 51 sequences in this contig found in public EST collections also have been assembled into a single contig (THC213329) by The Institute for Genome Research (TIGR). The TIGR annotation indicates that they failed to find any hits in

the database for the contig. Note that the TIGR contig is the reverse complement of the LifeSeq contig that we assembled. BLASTN search of Hu-ASP1 against the rat and mouse EST sequences in ZooSeq revealed one homologous EST in each database (Incyte clone 700311523 and IMAGE clone 313341, GenBank accession number W10530, respectively).

TBLASTN searches with the assembled DNA sequence for Hu-ASP1 against both LifeSeqFL and the public EST databases identified a second, related human sequence (Hu-Asp2) represented by a single EST (2696295). Translation of this partial cDNA sequence reveals a single DTG motif which has homology to the active site motif of a bovine aspartyl protease, NM1.

BLAST searches, contig assemblies and multiple sequence alignments were performed using the bioinformatics tools provided with the LifeSeq, LifeSeqFL and LifeSeq Assembled databases from Incyte. Predicted protein motifs were identified using either the ProSite dictionary (Motifs in GCG 9) or the Pfam database.

Full-length cDNA cloning of Hu-Asp1

The open reading frame of *C. elegans* gene T18H9.2CE was used to query Incyte LifeSeq and LifeSeq-FL databases and a single electronic assembly referred to as 1863920CE1 was detected. The 5' most cDNA clone in this contig, 1863920, was obtained from Incyte and completely sequenced on both strands. Translation of the open reading frame contained within clone 1863920 revealed the presence of the duplicated aspartyl protease active site motif (DTG/DSG) but the 5' end was incomplete. The remainder of the Hu-Asp1 coding sequence was determined by 5' Marathon RACE analysis using a human placenta Marathon ready cDNA template (Clontech). A 3'-antisense oligonucleotide primer specific for the 5' end of clone 1863920 was paired with the 5'-sense primer specific for the Marathon ready cDNA synthetic adaptor in the PCR. Specific PCR products were directly sequenced by cycle sequencing and the resulting sequence assembled with the sequence of clone 1863920 to yield the complete coding sequence of Hu-Asp-1 (SEQ ID No. 1).

Several interesting features are present in the primary amino acid sequence of Hu-Asp1 (Figure 1, SEQ ID No. 2). The sequence contains a signal peptide (residues

1-20 in SEQ ID No. 2), a pro-segment, and a catalytic domain containing two copies of the aspartyl protease active site motif (DTG/DSG). The spacing between the first and second active site motifs is about 200 residues which should correspond to the expected size of a single, eukaryotic aspartyl protease domain. More interestingly, the sequence contains a predicted transmembrane domain (residues 469-492 in SEQ ID No.2) near its C-terminus which suggests that the protease is anchored in the membrane. This feature is not found in any other aspartyl protease.

Cloning of a full-length Hu-Asp-2 cDNAs:

As is described above in Example 1, genome wide scan of the *Caenorhabditis elegans* database WormPep12 for putative aspartyl proteases and subsequent mining of human EST databases revealed a human ortholog to the *C. elegans* gene T18H9.2 referred to as Hu-Asp1. The assembled contig for Hu-Asp1 was used to query for human paralogs using the BLAST search tool in human EST databases and a single significant match (2696295CE1) with approximately 60% shared identity was found in the LifeSeq FL database. Similar queries of either gb105PubEST or the family of human databases available from TIGR did not identify similar EST clones. cDNA clone 2696295, identified by single pass sequence analysis from a human uterus cDNA library, was obtained from Incyte and completely sequence on both strands. This clone contained an incomplete 1266 bp open-reading frame that encoded a 422 amino acid polypeptide but lacked an initiator ATG on the 5' end. Inspection of the predicted sequence revealed the presence of the duplicated aspartyl protease active site motif DTG/DSG, separated by 194 amino acid residues. Subsequent queries of later releases of the LifeSeq EST database identified an additional ESTs, sequenced from a human astrocyte cDNA library (4386993), that appeared to contain additional 5' sequence relative to clone 2696295. Clone 4386993 was obtained from Incyte and completely sequenced on both strands. Comparative analysis of clone 4386993 and clone 2696295 confirmed that clone 4386993 extended the open-reading frame by 31 amino acid residues including two in-frame translation initiation codons. Despite the presence of the two in-frame ATGs, no in-frame stop codon was observed upstream

of the ATG indicating that the 4386993 may not be full-length. Furthermore, alignment of the sequences of clones 2696295 and 4386993 revealed a 75 base pair insertion in clone 2696295 relative to clone 4386993 that results in the insertion of 25 additional amino acid residues in 2696295. The remainder of the Hu-Asp2 coding sequence was determined by 5' Marathon RACE analysis using a human hippocampus Marathon ready cDNA template (Clontech). A 3'-antisense oligonucleotide primer specific for the shared 5'-region of clones 2696295 and 4386993 was paired with the 5'-sense primer specific for the Marathon ready cDNA synthetic adaptor in the PCR. Specific PCR products were directly sequenced by cycle sequencing and the resulting sequence assembled with the sequence of clones 2696295 and 4386993 to yield the complete coding sequence of Hu-Asp2(a) (SEQ ID No. 3) and Hu-Asp2(b) (SEQ ID No. 5), respectively.

Several interesting features are present in the primary amino acid sequence of Hu-Asp2(a) (Figure 2 and SEQ ID No. 4) and Hu-Asp-2(b) (Figure 3, SEQ ID No. 6). Both sequences contain a signal peptide (residues 1-21 in SEQ ID No. 4 and SEQ ID No. 6), a pro-segment, and a catalytic domain containing two copies of the aspartyl protease active site motif (DTG/DSG). The spacing between the first and second active site motifs is variable due to the 25 amino acid residue deletion in Hu-Asp-2(b) and consists of 168-*versus*-194 amino acid residues, for Hu-Asp2(b) and Hu-Asp-2(a), respectively. More interestingly, both sequences contains a predicted transmembrane domain (residues 455-477 in SEQ ID No.4 and 430-452 in SEQ ID No. 6) near their C-termini which indicates that the protease is anchored in the membrane. This feature is not found in any other aspartyl protease except Hu-Asp1.

Example 3

Molecular cloning of mouse Asp2 cDNA and genomic DNA.

Cloning and characterization of murine Asp2 cDNA.

The murine ortholog of Hu-Asp2 was cloned using a combination of cDNA library screening, PCR, and genomic cloning. Approximately 500,000 independent clones from a mouse brain cDNA library were screened using a ³²P-labeled coding

sequence probe prepared from Hu-Asp2. Replicate positives were subjected to DNA sequence analysis and the longest cDNA contained the entire 3' untranslated region and 47 amino acids in the coding region. PCR amplification of the same mouse brain cDNA library with an antisense oligonucleotide primer specific for the 5'-most
5 cDNA sequence determined above and a sense primer specific for the 5' region of human Asp2 sequence followed by DNA sequence analysis gave an additional 980 bp of the coding sequence. The remainder of the 5' sequence of murine Asp-2 was derived from genomic sequence (see below).

10 *Isolation and sequence analysis of the murine Asp-2 gene.*

A murine EST sequence encoding a portion of the murine Asp2 cDNA was identified in the GenBank EST database using the BLAST search tool and the Hu-Asp2 coding sequence as the query. Clone g3160898 displayed 88% shared identity to the human sequence over 352 bp. Oligonucleotide primer pairs specific for
15 this region of murine Asp2 were then synthesized and used to amplify regions of the murine gene. Murine genomic DNA, derived from strain 129/SvJ, was amplified in the PCR (25 cycles) using various primer sets specific for murine Asp2 and the products analyzed by agarose gel electrophoresis. The primer set Zoo-1 and Zoo-4 amplified a 750 bp fragment that contained approximately 600 bp of intron sequence
20 based on comparison to the known cDNA sequence. This primer set was then used to screen a murine BAC library by PCR, a single genomic clone was isolated and this cloned was confirmed contain the murine Asp2 gene by DNA sequence analysis. Shotgun DNA sequencing of this Asp2 genomic clone and comparison to the cDNA sequences of both Hu-Asp2 and the partial murine cDNA sequences defined the
25 full-length sequence of murine Asp2 (SEQ ID No. 7). The predicted amino acid sequence of murine Asp2 (SEQ ID No. 8) showed 96.4% shared identity (GCG BestFit algorithm) with 18/501 amino acid residue substitutions compared to the human sequence (Figure 4). The proteolytic processing of murine Asp2(a) is believed to be analogous to the processing described above for human Asp2(a). In addition, a
30 variant lacking amino acid residues 190-214 of SEQ ID NO: 8 is specifically

contemplated as a murine Asp2(b) polypeptide. All forms of murine Asp2(b) gene and protein are intended as aspects of the invention.

Example 4

5 **Tissue Distribution of Expression of Hu-Asp2 Transcripts**

Materials and Methods:

10 The tissue distribution of expression of Hu-Asp-2 was determined using multiple tissue Northern blots obtained from Clontech (Palo Alto, CA). Incyte clone 2696295 in the vector pINCY was digested to completion with *EcoRI/NotI* and the 1.8 kb cDNA insert purified by preparative agarose gel electrophoresis. This fragment was radiolabeled to a specific activity $> 1 \times 10^9$ dpm/ μ g by random priming in the presence of [α -³²P-dATP] (>3000 Ci/mmol, Amersham, Arlington Heights, IL) and Klenow fragment of DNA polymerase I. Nylon filters containing denatured, size fractionated poly A⁺ RNAs isolated from different human tissues were hybridized with 2 x 10⁶ dpm/ml probe in ExpressHyb buffer (Clontech, Palo Alto, CA) for 1 hour at 68 °C and washed as recommended by the manufacture. Hybridization signals were visualized by autoradiography using BioMax XR film (Kodak, Rochester, NY) with intensifying screens at -80 °C.

20 *Results and Discussion:*

25 Limited information on the tissue distribution of expression of Hu-Asp-2 transcripts was obtained from database analysis due to the relatively small number of ESTs detected using the methods described above (< 5). In an effort to gain further information on the expression of the Hu-Asp2 gene, Northern analysis was employed to determine both the size(s) and abundance of Hu-Asp2 transcripts. PolyA⁺ RNAs isolated from a series of peripheral tissues and brain regions were displayed on a solid support following separation under denaturing conditions and Hu-Asp2 transcripts were visualized by high stringency hybridization to radiolabeled insert from clone 2696295. The 2696295 cDNA probe visualized a constellation of transcripts that

migrated with apparent sizes of 3.0kb, 4.4 kb and 8.0 kb with the latter two transcript being the most abundant.

Across the tissues surveyed, Hu-Asp2 transcripts were most abundant in pancreas and brain with lower but detectable levels observed in all other tissues examined except thymus and PBLs. Given the relative abundance of Hu-Asp2 transcripts in brain, the regional expression in brain regions was also established. A similar constellation of transcript sizes were detected in all brain regions examined [cerebellum, cerebral cortex, occipital pole, frontal lobe, temporal lobe and putamen] with the highest abundance in the medulla and spinal cord.

Example 5

Northern Blot Detection of HuAsp-1 and HuAsp-2 Transcripts in Human Cell Lines

A variety of human cell lines were tested for their ability to produce Hu-Asp1 and Asp2 mRNA. Human embryonic kidney (HEK-293) cells, African green monkey (Cos-7) cells, Chinese hamster ovary (CHO) cells, HELA cells, and the neuroblastoma cell line IMR-32 were all obtained from the ATCC. Cells were cultured in DME containing 10% FCS except CHO cells which were maintained in α -MEM/10% FCS at 37 °C in 5% CO₂ until they were near confluence. Washed monolayers of cells (3 X 10⁷) were lysed on the dishes and poly A⁺ RNA extracted using the Qiagen Oligotex Direct mRNA kit. Samples containing 2 µg of poly A⁺ RNA from each cell line were fractionated under denaturing conditions (glyoxal-treated), transferred to a solid nylon membrane support by capillary action, and transcripts visualized by hybridization with random-primed labeled (³²P) coding sequence probes derived from either Hu-Asp1 or Hu-Asp2. Radioactive signals were detected by exposure to X-ray film and by image analysis with a PhosphorImager.

The Hu-Asp1 cDNA probe visualized a similar constellation of transcripts (2.6 kb and 3.5 kb) that were previously detected in human tissues. The relative abundance determined by quantification of the radioactive signal was Cos-7 > HEK 292 = HELA > IMR32.

The Hu-Asp2 cDNA probe also visualized a similar constellation of transcripts compared to tissue (3.0 kb, 4.4 kb, and 8.0 kb) with the following relative abundance; HEK 293 > Cos 7 > IMR32 > HELA.

5

Example 6

Modification of APP to increase A β processing for in vitro screening

Human cell lines that process A β peptide from APP provide a means to screen in cellular assays for inhibitors of β - and γ -secretase. Production and release of A β peptide into the culture supernatant is monitored by an enzyme-linked immunosorbent
10 assay (EIA). Although expression of APP is widespread and both neural and non-neuronal cell lines process and release A β peptide, levels of endogenous APP processing are low and difficult to detect by EIA. A β processing can be increased by expressing in transformed cell lines mutations of APP that enhance A β processing. We made the serendipitous observation that addition of two lysine residues to the
15 carboxyl terminus of APP695 increases A β processing still further. This allowed us to create a transformed cell line that releases A β peptide into the culture medium at the remarkable level of 20,000 pg/ml.

Materials And Methods

20 *Materials:*

Human embryonic kidney cell line 293 (HEK293 cells) were obtained internally. The vector pIRES-EGFP was purchased from Clontech. Oligonucleotides for mutation using the polymerase chain reaction (PCR) were purchased from Genosys. A plasmid containing human APP695 (SEQ ID No. 9 [nucleotide] and SEQ
25 ID No. 10 [amino acid]) was obtained from Northwestern University Medical School. This was subcloned into pSK (Stratagene) at the *Not1* site creating the plasmid pAPP695.

Mutagenesis protocol:

The Swedish mutation (K670N, M671L) was introduced into pAPP695 using
30 the Stratagene Quick Change Mutagenesis Kit to create the plasmid pAPP695NL

(SEQ ID No. 11 [nucleotide] and SEQ ID No. 12 [amino acid]). To introduce a di-lysine motif at the C-terminus of APP695, the forward primer #276 5' GACTGACCACTCGACCAGGTTC (SEQ ID No. 47) was used with the "patch" primer #274 5'

5 CGAATTAAATTCCAGCACACTGGCTACTTCTTGTTCTGCATCTCAAAGAAC (SEQ ID No. 48) and the flanking primer #275

CGAATTAAATTCCAGCACACTGGCTA (SEQ ID No. 49) to modify the 3' end of the APP695 cDNA (SEQ ID No. 15 [nucleotide] and SEQ ID No. 16 [amino acid]).

This also added a BstX1 restriction site that will be compatible with the BstX1 site in
10 the multiple cloning site of pIRES-EGFP. PCR amplification was performed with a Clontech HF Advantage cDNA PCR kit using the polymerase mix and buffers supplied by the manufacturer. For "patch" PCR, the patch primer was used at 1/20th the molar concentration of the flanking primers. PCR amplification products were purified using a QIAquick PCR purification kit (Qiagen). After digestion with
15 restriction enzymes, products were separated on 0.8% agarose gels and then excised DNA fragments were purified using a QIAquick gel extraction kit (Qiagen).

To reassemble a modified APP695-Sw cDNA, the 5' Not1-Bgl2 fragment of the APP695-Sw cDNA and the 3' Bgl2-BstX1 APP695 cDNA fragment obtained by PCR were ligated into pIRES-EGFP plasmid DNA opened at the Not1 and BstX1
20 sites. Ligations were performed for 5 minutes at room temperature using a Rapid DNA Ligation kit (Boehringer Mannheim) and transformed into Library Efficiency DH5a Competent Cells (GibcoBRL Life Technologies). Bacterial colonies were screened for inserts by PCR amplification using primers #276 and #275. Plasmid DNA was purified for mammalian cell transfection using a QIAprep Spin Miniprep
25 kit (Qiagen). The construct obtained was designated pMG125.3 (APPSW-KK, SEQ ID No. 17 [nucleotide] and SEQ ID No. 18 [amino acid]).

Mammalian Cell Transfection:

HEK293 cells for transfection were grown to 80% confluence in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum. Cotransfections
30 were performed using LipofectAmine (Gibco-BRL) with 3 µg pMG125.3 DNA and 9

µg pcDNA3.1 DNA per 10×10^6 cells. Three days posttransfection, cells were passaged into medium containing G418 at a concentration of 400 µg/ml. After three days growth in selective medium, cells were sorted by their fluorescence.

Clonal Selection of 125.3 cells by FACS:

5 Cell samples were analyzed on an EPICS Elite ESP flow cytometer (Coulter, Hialeah, FL) equipped with a 488 nm excitation line supplied by an air-cooled argon laser. EGFP emission was measured through a 525 nm band-pass filter and fluorescence intensity was displayed on a 4-decade log scale after gating on viable cells as determined by forward and right angle light scatter. Single green cells were
10 separated into each well of one 96 well plate containing growth medium without G418. After a four day recovery period, G418 was added to the medium to a final concentration of 400 µg/ml. After selection, 32% of the wells contained expanding clones. Wells with clones were expanded from the 96 well plate to a 24 well plate and then a 6 well plate with the fastest growing colonies chosen for expansion at each
15 passage. The final cell line selected was the fastest growing of the final six passaged. This clone, designated 125.3, has been maintained in G418 at 400 ug/ml with passage every four days into fresh medium. No loss of Aβ production or EGFP fluorescence has been seen over 23 passages.

20 *Aβ EIA Analysis (Double Antibody Sandwich ELISA for hAβ 1-40/42):*

Cell culture supernatants harvested 48 hours after transfection were analyzed in a standard Aβ EIA as follows. Human Aβ 1-40 or 1-42 was measured using monoclonal antibody (mAb) 6E10 (Senetek, St. Louis, MO) and biotinylated rabbit antiserum 162 or 164 (New York State Institute for Basic Research, Staten Island,
25 NY) in a double antibody sandwich ELISA. The capture antibody 6E10 is specific to an epitope present on the N-terminal amino acid residues 1-16 of hAβ. The conjugated detecting antibodies 162 and 164 are specific for hAβ 1-40 and 1-42, respectively. Briefly, a Nunc Maxisorp 96 well immunoplate was coated with 100 µl/well of mAb 6E10 (5µg/ml) diluted in 0.1M carbonate-bicarbonate buffer, pH 9.6
30 and incubated at 4°C overnight. After washing the plate 3x with 0.01M DPBS

(Modified Dulbecco's Phosphate Buffered Saline (0.008M sodium phosphate, 0.002M potassium phosphate, 0.14M sodium chloride, 0.01 M potassium chloride, pH 7.4) from Pierce, Rockford, IL) containing 0.05% of Tween-20 (DPBST), the plate was blocked for 60 minutes with 200 μ l of 10% normal sheep serum (Sigma) in 5 0.01M DPBS to avoid non-specific binding. Human A β 1-40 or 1-42 standards 100 μ l/well (Bachem, Torrance, CA) diluted, from a 1mg/ml stock solution in DMSO, in culture medium was added after washing the plate, as well as 100 μ l/well of sample, e.g., conditioned medium of transfected cells.

The plate was incubated for 2 hours at room temperature and 4°C overnight. 10 The next day, after washing the plate, 100 μ l/well biotinylated rabbit antiserum 162 1:400 or 164 1:50 diluted in DPBST + 0.5% BSA was added and incubated at room temperature for 1 hour, 15 minutes. Following washes, 100 μ l/well neutravidin-horseradish peroxidase (Pierce, Rockford, IL) diluted 1:10,000 in DPBST was applied and incubated for 1 hour at room temperature. After the last washes 15 μ l/well of o-phenylenediamine dihydrochloride (Sigma Chemicals, St. Louis, MO) in 50mM citric acid/100mM sodium phosphate buffer (Sigma Chemicals, St. Louis, MO), pH 5.0, was added as substrate and the color development was monitored at 450nm in a kinetic microplate reader for 20 minutes using Soft max Pro software. All standards and samples were run in triplicates. The samples with absorbance values 20 falling within the standard curve were extrapolated from the standard curves using Soft max Pro software and expressed in pg/ml culture medium.

Results:

Addition of two lysine residues to the carboxyl terminus of APP695 greatly increases A β processing in HEK293 cells as shown by transient expression (Table 1). 25 Addition of the di-lysine motif to APP695 increases A β processing to that seen with the APP695 containing the Swedish mutation. Combining the di-lysine motif with the Swedish mutation further increases processing by an additional 2.8 fold.

Cotransformation of HEK293 cells with pMG125.3 and pcDNA3.1 allowed dual selection of transformed cells for G418 resistance and high level expression of 30 EGFP. After clonal selection by FACS, the cell line obtained, produces a remarkable

20,000 pg A β peptide per ml of culture medium after growth for 36 hours in 24 well plates. Production of A β peptide under various growth conditions is summarized in Table 2.

5

TABLE 1

Release of A β peptide into the culture medium 48 hours after transient transfection of HEK293 cells with the indicated vectors containing wildtype or modified APP. Values tabulated are mean + SD and P-value for pairwise comparison using Student's t-test assuming unequal variances.

10

APP Construct	A β 1-40 peptide (pg/ml)	Fold Increase	P-value
pIRES-EGFP vector	147 + 28	1.0	
wt APP695 (142.3)	194 + 15	1.3	0.051
wt APP695-KK (124.1)	424 + 34	2.8	3 x 10 ⁻⁵
APP695-Sw (143.3)	457 + 65	3.1	2 x 10 ⁻³
APP695-SwKK (125.3)	1308 + 98	8.9	3 x 10 ⁻⁴

20

25

Release of A β peptide from HEK125.3 cells under various growth conditions.

5

10

15

20

25

30

continual presence of the oligofectin G/antisense oligomer. To monitor A β peptide release, 400 μ l of conditioned medium was removed periodically from the culture well and replaced with fresh medium beginning 24 hours after transfection. A β peptides in the conditioned medium were assayed via immunoprecipitation and Western blotting. Data reported are from culture supernatants harvested 48 hours after transfection.

The 16 different antisense oligomers obtained from Sequitur Inc. were transfected separately into HEK125.3 cells to determine their affect on A β peptide processing. Only antisense oligomers targeted against Asp2 significantly reduced Abeta processing by HEK125.3 cells. Both A β (1-40) and A β (1-42) were inhibited by the same degree. In Table 3, percent inhibition is calculated with respect to untransfected cells. Antisense oligomer reagents giving greater than 50% inhibition are marked with an asterisk. Of the reagents tested, 3 or 4 antisense oligomers targeted against Asp1 gave an average 52% inhibition of A β (1-40) processing and 47% inhibition of A β (1-42) processing. For Asp2, 4 of 4 antisense oligomers gave greater than 50% inhibition with an average inhibition of 62% of A β (1-40) processing and 60% for A β (1-42) processing.

TABLE 3

Inhibition of A β peptide release from HEK125.3 cells treated with antisense oligomers.

	Gene Targeted	Antisense Oligomer	Abeta (1-40)	Abeta (1-42)
5	Asp1-1	S644	62%*	56%*
	Asp1-2	S645	41%*	38%*
	Asp1-3	S646	52%*	46%*
	Asp1-4	S647	6%	25%*
10	Asp2-1	S648	71%*	67%*
	Asp2-2	S649	83%*	76%*
	Asp2-3	S650	46%*	50%*
	Asp2-4	S651	47%*	46%*
	Con1-1	S652	13%	18%
15	Con1-2	S653	35%	30%
	Con1-3	S655	9%	18%
	Con1-4	S674	29%	18%
	Con2-1	S656	12%	18%
	Con2-2	S657	16%	19%
20	Con2-3	S658	8%	35%
	Con2-4	S659	3%	18%

Since HEK293 cells derive from kidney, the experiment was extended to human IMR-32 neuroblastoma cells which express all three APP isoforms and which release A β peptides into conditioned medium at measurable levels. [See Neill *et al.*, *J. NeuroSci. Res.*, (1994) 39: 482-93; and Asami-Odaka *et al.*, *Biochem.*, (1995) 34:10272-8.] Essentially identical results were obtained in the neuroblastoma cells as the HEK293 cells. As shown in Table 3B, the pair of Asp2 antisense oligomers

reduced Asp2 mRNA by roughly one-half, while the pair of reverse control oligomers lacked this effect (Table 3B).

Table 3B

Reduction of A β 40 and A β 42 in human neuroblastoma IMR-32 cells and mouse neuroblastoma Neuro-2A cells treated with Asp2 antisense and control oligomers as indicated. Oligomers were transfected in quadruplicate cultures. Values tabulated are normalized against cultures treated with oligofectin-GTM only (mean + SD, ** p<0.001 compared to reverse control oligomer).

		IMR-32 cells		Neuro-2A cells	
	Asp2 mRNA	A β 40	A β 42	A β 40	A β 42
Asp2-1A	-75%	-49 + 2%**	-42 + 14%**	-70 + 7%**	-67 + 2%**
Asp2-1R	0.16	-0 + 3%	21.26	-9 + 15%	1.05
Asp2-2A	-39%	-43 + 3%**	-44 + 18%**	-61 + 12%**	-61 + 12%**
Asp2-2R	0.47	12.2	19.22	6.15	-8 + 10%

Together with the reduction in Asp2 mRNA there was a concomitant reduction in the release of A β 40 and A β 42 peptides into the conditioned medium. Thus, Asp2 functions directly or indirectly in a human kidney and a human neuroblastoma cell line to facilitate the processing of APP into A β peptides. Molecular cloning of the mouse Asp2 cDNA revealed a high degree of homology to human (>96% amino acid identity, see Example 3), and indeed, complete nucleotide identity at the sites targeted by the Asp2-1A and Asp2-2A antisense oligomers. Similar results were obtained in mouse Neuro-2a cells engineered to express APP-Sw-KK. The Asp2 antisense oligomers reduced release of A β peptides into the medium while the reverse control oligomers did not (Table 3B). Thus, the three antisense experiments with HEK293,

IMR-32 and Neuro-2a cells indicate that Asp2 acts directly or indirectly to facilitate A β processing in both somatic and neural cell lines.

Example 8

5 **Demonstration of Hu-Asp2 β -Secretase Activity in Cultured Cells**

Several mutations in APP associated with early onset Alzheimer's disease have been shown to alter A β peptide processing. These flank the – and C-terminal cleavage sites that release A β from APP. These cleavage sites are referred to as the β -secretase and γ -secretase cleavage sites, respectively. Cleavage of APP at the

10 β -secretase site creates a C-terminal fragment of APP containing 99 amino acids of 11,145 daltons molecular weight. The Swedish KM–NL mutation immediately upstream of the β -secretase cleavage site causes a general increase in production of both the 1-40 and 1-42 amino acid forms of A β peptide. The London VF mutation (V717–F in the APP770 isoform) has little effect on total A β peptide production, but

15 appears to preferentially increase the percentage of the longer 1-42 amino acid form of A β peptide by affecting the choice of β -secretase cleavage site used during APP processing. Thus, we sought to determine if these mutations altered the amount and type of A β peptide produced by cultured cells cotransfected with a construct directing expression of Hu-Asp2.

20 Two experiments were performed which demonstrate Hu-Asp2 β -secretase activity in cultured cells. In the first experiment, treatment of HEK125.3 cells with antisense oligomers directed against Hu-Asp2 transcripts as described in Example 7 was found to decrease the amount of the C-terminal fragment of APP created by β -secretase cleavage (CTF99) (Figure 9). This shows that Hu-Asp2 acts directly or

25 indirectly to facilitate β -secretase cleavage. In the second experiment, increased expression of Hu-Asp2 in transfected mouse Neuro2A cells is shown to increase accumulation of the CTF99 β -secretase cleavage fragment (Figure 10). This increase is seen most easily when a mutant APP-KK clone containing a C-terminal di-lysine motif is used for transfection. A further increase is seen when Hu-Asp2 is

cotransfected with APP-Sw-KK containing the Swedish mutation KM →NL. The Swedish mutation is known to increase cleavage of APP by the β-secretase.

A second set of experiments demonstrate Hu-Asp2 facilitates γ-secretase activity in cotransfection experiments with human embryonic kidney HEK293 cells.

5 Cotransfection of Hu-Asp2 with an APP-KK clone greatly increases production and release of soluble Aβ1-40 and Aβ1-42 peptides from HEK293 cells. There is a proportionately greater increase in the release of Aβ1-42. A further increase in production of Aβ1-42 is seen when Hu-Asp2 is cotransfected with APP-VF (SEQ ID No. 13 [nucleotide] and SEQ ID No. 14 [amino acid]) or APP-VF-KK SEQ ID No. 19
10 [nucleotide] and SEQ ID No. 20 [amino acid]) clones containing the London mutation V717→F. The V717→F mutation is known to alter cleavage specificity of the APP γ-secretase such that the preference for cleavage at the Aβ42 site is increased. Thus, Asp2 acts directly or indirectly to facilitate γ-secretase processing of APP at the β42 cleavage site.

15 *Materials*

Antibodies 6E10 and 4G8 were purchased from Senetek (St. Louis, MO). Antibody 369 was obtained from the laboratory of Paul Greengard at the Rockefeller University. Antibody C8 was obtained from the laboratory of Dennis Selkoe at the Harvard Medical School and Brigham and Women's Hospital.

20 *APP Constructs used*

The APP constructs used for transfection experiments comprised the following APP: wild-type APP695 (SEQ ID No. 9 and No. 10)

APP-Sw: APP695 containing the Swedish KM→NL mutation (SEQ ID No. 11 and No. 12), wherein the lysine (K) at residue 595 of APP695 is changed to
25 asparagine (N) and the methionine (M) at residue 596 of APP695 is changed to leucine (L).),

APP-VF: APP695 containing the London V→F mutation (SEQ ID Nos. 13 & 14) (Affected residue 717 of the APP770 isoform corresponds with residue 642 of the APP695 isoform. Thus, APP-VF as set in SEQ ID NO: 14 comprises the APP695
30 sequence, wherein the valine (V) at residue 642 is changed to phenylalanine (F).)

APP-KK: APP695 containing a C-terminal KK motif (SEQ ID Nos. 15 & 16),

APP-Sw-KK: APP695-Sw containing a C-terminal KK motif (SEQ ID No. 17 & 18),

APP-VF-KK: APP695-VF containing a C-terminal KK motif (SEQ ID Nos. 19 & 20).

These were inserted into the vector pIRES-EGFP (Clontech, Palo Alto CA) between the *NotI* and *BstXI* sites using appropriate linker sequences introduced by PCR.

Transfection of antisense oligomers or plasmid DNA constructs in HEK293 cells, HEK125.3 cells and Neuro-2A cells,

Human embryonic kidney HEK293 cells and mouse Neuro-2a cells were transfected with expression constructs using the Lipofectamine Plus reagent from Gibco/BRL. Cells were seeded in 24 well tissue culture plates to a density of 70-80% confluence. Four wells per plate were transfected with 2 µg DNA (3:1, APP:cotransfectant), 8 µl Plus reagent, and 4 µl Lipofectamine in OptiMEM. OptiMEM was added to a total volume of 1 ml, distributed 200 µl per well and incubated 3 hours. Care was taken to hold constant the ratios of the two plasmids used for cotransfection as well as the total amount of DNA used in the transfection. The transfection media was replaced with DMEM, 10%FBS, NaPyruvate, with antibiotic/antimycotic and the cells were incubated under normal conditions (37°C, 5% CO₂) for 48 hours. The conditioned media were removed to polypropylene tubes and stored at -80°C until assayed for the content of Aβ1-40 and Aβ1-42 by EIA as described in the preceding examples. Transfection of antisense oligomers into HEK125.3 cells was as described in Example 7.

Preparation of cell extracts, Western blot protocol

Cells were harvested after being transfected with plasmid DNA for about 60 hours. First, cells were transferred to 15-ml conical tube from the plate and centrifuged at 1,500 rpm for 5 minutes to remove the medium. The cell pellets were washed once with PBS. We then lysed the cells with lysis buffer (10 mM HEPES, pH

7.9, 150 mM NaCl, 10% glycerol, 1 mM EGTA, 1 mM EDTA, 0.1 mM sodium vanadate and 1% NP-40). The lysed cell mixtures were centrifuged at 5000 rpm and the supernatant was stored at -20°C as the cell extracts. Equal amounts of extracts from HEK125.3 cells transfected with the Asp2 antisense oligomers and controls were precipitated with antibody 369 that recognizes the C-terminus of APP and then CTF99 was detected in the immunoprecipitate with antibody 6E10. The experiment was repeated using C8, a second precipitating antibody that also recognizes the C-terminus of APP. For Western blot of extracts from mouse Neuro-2a cells cotransfected with Hu-Asp2 and APP-KK, APP-Sw-KK, APP-VF-KK or APP-VF, equal amounts of cell extracts were electrophoresed through 4-10% or 10-20% Tricine gradient gels (NOVEX, San Diego, CA). Full length APP and the CTF99 β -secretase product were detected with antibody 6E10.

Results

Transfection of HEK125.3 cells with Asp2-1 or Asp2-2 antisense oligomers reduces production of the CTF β -secretase product in comparison to cells similarly transfected with control oligomers having the reverse sequence (Asp2-1 reverse & Asp2-2 reverse), see Figure 9. Correspondingly, cotransfection of Hu-Asp2 into mouse Neuro-2a cells with the APP-KK construct increased the formation of CTF99. (See Fig. 10.) This was further increased if Hu-Asp2 was coexpressed with APP-Sw-KK, a mutant form of APP containing the Swedish KM-NL mutation that increases β -secretase processing.

Effects of Asp2 on the production of Ab peptides from endogenously expressed APP isoforms were assessed in HEK293 cells transfected with a construct expressing Asp2 or with the empty vector after selection of transformants with the antibiotic G418. A β 40 production was increased in cells transformed with the Asp2 construct in comparison to those transformed with the empty vector DNA. A β 40 levels in conditioned medium collected from the Asp2 transformed and control cultures was 424 ± 45 pg/ml and 113 ± 58 pg/ml, respectively ($p < 0.001$). A β 42 release was below the limit of detection by the EIA, while the release of sAPP α was unaffected, 112 ± 8 ng/ml versus 111 ± 40 ng/ml. This further indicates that Asp2

acts directly or indirectly to facilitate the processing and release of A β from endogenously expressed APP.

Co-transfection of Hu-Asp2 with APP has little effect on A β 40 production but increases A β 42 production above background (Table 4). Addition of the di-lysine motif to the C-terminus of APP increases A β peptide processing about two fold, although A β 40 and A β 42 production remain quite low (352 pg/ml and 21 pg/ml, respectively). Cotransfection of Asp2 with APP-KK further increases both A β 40 and A β 42 production.

The APP V717→F mutation has been shown to increase γ -secretase processing at the A β 42 cleavage site. Cotransfection of Hu-Asp2 with the APP-VF or APP-VF-KK constructs increased A β 42 production (a two fold increase with APP-VF and a four-fold increase with APP-VF-KK, Table 4), but had mixed effects on A β 40 production (a slight decrease with APP-VF, and a two fold increase with APP-VF-KK in comparison to the pcDNA cotransfection control. Thus, the effect of Asp2 on A β 42 production was proportionately greater leading to an increase in the ratio of A β 42/total A β . Indeed, the ratio of A β 42/total A β reaches a very high value of 42% in HEK293 cells cotransfected with Hu-Asp2 and APP-VF-KK.

Table 4

Results of cotransfecting Hu-Asp2 or pcDNA plasmid DNA with various APP constructs containing the V717-F mutation that modifies γ -secretase processing.

- 5 Cotransfection with Asp2 consistently increases the ratio of A β 42/total A β . Values tabulated are A β peptide pg/ml.

	pcDNA Cotransfection			Asp2 Cotransfection		
	A β 40	A β 42	A β 42/Tot al	A β 40	A β 42	A β 42/Tot al
10						
	APP	192 \pm 1 8	<4	<2%	188 \pm 40	8 \pm 10 3.9%
	APP-VF	118 \pm 1 5	15 \pm 19	11.5%	85 \pm 7	24 \pm 12 22.4%
15	APP-KK	352 \pm 2 4	21 \pm 6	5.5%	1062 \pm 101	226 \pm 4 17.5%
	APP-VF-K K	230 \pm 3 1	88 \pm 24	27.7%	491 \pm 35	355 \pm 3 42%
20						

Example 9

Bacterial expression of human Asp2(a)

5 *Expression of recombinant Hu-Asp2(a) in E. coli.*

Hu-Asp2(a) can be expressed in *E. coli* after addition of N-terminal sequences such as a T7 tag (SEQ ID No. 21 and No. 22) or a T7 tag followed by a caspase 8 leader sequence (SEQ ID No. 23 and No. 24). Alternatively, reduction of the GC content of the 5' sequence by site directed mutagenesis can be used to increase the yield of Hu-Asp2 (SEQ ID No. 25 and No. 26). In addition, Asp2(a) can be engineered with a proteolytic cleavage site (SEQ ID No. 27 and No. 28). To produce a soluble protein after expression and refolding, deletion of the transmembrane domain and cytoplasmic tail, or deletion of the membrane proximal region, transmembrane domain, and cytoplasmic tail is preferred. Any materials (vectors, host cells, etc.) and methods described herein to express Hu-Asp2(a) should in principle be equally effective for expression of Hu-Asp2(b).

15 *Methods*

PCR with primers containing appropriate linker sequences was used to assemble fusions of Asp2(a) coding sequence with N-terminal sequence modifications including a T7 tag (SEQ ID Nos. 21 and 22) or a T7-caspase 8 leader (SEQ ID Nos. 23 and 24). These constructs were cloned into the expression vector pet23a(+) [Novagen] in which a T7 promoter directs expression of a T7 tag preceding a sequence of multiple cloning sites. To clone Hu-Asp2 sequences behind the T7 leader of pet23a⁺, the following oligonucleotides were used for amplification of the selected Hu-Asp2(a) sequence: #553=GTGGATCCACCCAGCACGGCATCCGGCTG (SEQ ID No. 35), #554=GAAAGCTTTCATGACTCATCTGTCTGTGGAATGTTG (SEQ ID No. 36) which placed BamHI and HindIII sites flanking the 5' and 3' ends of the insert, respectively. The Asp2(a) sequence was amplified from the full length Asp2(a) cDNA cloned into pcDNA3.1 using the Advantage-GC cDNA PCR [Clontech] following the manufacturer's supplied protocol using annealing & extension at 68°C in

a two-step PCR cycle for 25 cycles. The insert and vector were cut with BamHI and HindIII, purified by electrophoresis through an agarose gel, then ligated using the Rapid DNA Ligation kit [Boehringer Mannheim]. The ligation reaction was used to transform the *E. coli* strain JM109 (Promega) and colonies were picked for the purification of plasmid (Qiagen, Qiaprep minispin) and DNA sequence analysis. For inducible expression using induction with isopropyl b-D-thiogalactopyranoside (IPTG), the expression vector was transferred into *E. coli* strain BL21 (Statagene). Bacterial cultures were grown in LB broth in the presence of ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 1 mM IPTG for 4 hour at 37°C. The cell pellet was harvested by centrifugation.

To clone Hu-Asp2 sequences behind the T7 tag and caspase leader (SEQ ID Nos. 23 and 24), the construct created above containing the T7-Hu-Asp2 sequence (SEQ ID Nos. 21 and 22) was opened at the BamHI site, and then the phosphorylated caspase 8 leader oligonucleotides #559=GATCGATGACTATCTCTGACTCTCCGCGTGAACAGGACG (SEQ ID No. 37), #560=GATCCGTCCTGTTCACGCGGAGAGTCAGAGATAGTCATC (SEQ ID No. 38) were annealed and ligated to the vector DNA. The 5' overhang for each set of oligonucleotides was designed such that it allowed ligation into the BamHI site but not subsequent digestion with BamHI. The ligation reaction was transformed into JM109 as above for analysis of protein expression after transfer to *E. coli* strain BL21.

In order to reduce the GC content of the 5' terminus of asp2(a), a pair of antiparallel oligos were designed to change degenerate codon bases in 15 amino acid positions from G/C to A/T (SEQ ID Nos. 25 and 26). The new nucleotide sequence at the 5' end of asp2 did not change the encoded amino acid and was chosen to optimize *E. Coli* expression. The sequence of the sense linker is 5' CGGCATCCGGCTGCCCCCTGCGTAGCGGTCTGGGTGGTGCTCCACTGGGTCT GCGTCTGCCCCGGGAGACCGACGAA G 3' (SEQ ID No. 39). The sequence of the antisense linker is : 5' CTTCTGTCGGTCTCCCGGGGAGACGACGACCCAGTGGAGCACCACCCAGACCGCTACGCAGGGGAGCCGGATGCCG 3' (SEQ ID No. 40). After annealing

the phosphorylated linkers together in 0.1 M NaCl-10 mM Tris, pH 7.4 they were ligated into unique Cla I and Sma I sites in Hu-Asp2 in the vector pTAC. For inducible expression using induction with isopropyl b-D-thiogalactopyranoside (IPTG), bacterial cultures were grown in LB broth in the presence of ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 1 mM IPTG for 4 hour at 37°C. The cell pellet was harvested by centrifugation.

To create a vector in which the leader sequences can be removed by limited proteolysis with caspase 8 such that this liberates a Hu-Asp2 polypeptide beginning with the N-terminal sequence GSFV (SEQ ID Nos. 27 and 28), the following procedure was followed. Two phosphorylated oligonucleotides containing the caspase 8 cleavage site IETD, #571=5' GATCGATGACTATCTCTGACTCTCCGCTGGACTCTGGTATCGAAACCGACG (SEQ ID No. 41) and #572= GATCCGTCGGTTTCGATACCAGAGTCCAGCGGAGAGTCAGAGATAGTCAT C (SEQ ID No. 42) were annealed and ligated into pET23a+ that had been opened with BamHI. After transformation into JM109, the purified vector DNA was recovered and orientation of the insert was confirmed by DNA sequence analysis.

The following oligonucleotides were used for amplification of the selected Hu-Asp2(a) sequence:

#573=5'AAGGATCCTTTGTGGAGATGGTGGACAACCTG, (SEQ ID No. 43)
#554=GAAAGCTTTCATGACTCATCTGTCTGTGGAATGTTG (SEQ ID No. 44)

which placed BamHI and HindIII sites flanking the 5' and 3' ends of the insert, respectively. The Hu-Asp2(a) sequence was amplified from the full length Hu-Asp2(a) cDNA cloned into pcDNA3.1 using the Advantage-GC cDNA PCR [Clontech] following the manufacturer's supplied protocol using annealing & extension at 68°C in a two-step PCR cycle for 25 cycles. The insert and vector were cut with BamHI and HindIII, purified by electrophoresis through an agarose gel, then ligated using the Rapid DNA Ligation kit [Boehringer Mannheim]. The ligation reaction was used to transform the *E. coli* strain JM109 [Promega] and colonies were picked for the purification of plasmid (Qiagen, Qiaprep minispin) and DNA sequence

analysis . For inducible expression using induction with isopropyl
b-D-thiogalactopyranoside (IPTG), the expression vector was transferred into *E. coli*
strain BL21 (Statagene). Bacterial cultures were grown in LB broth in the presence of
ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with
5 1 mM IPTG for 4 hour at 37°C. The cell pellet was harvested by centrifugation.

To assist purification, a 6-His tag can be introduced into any of the above
constructs following the T7 leader by opening the construct at the BamHI site and
then ligating in the annealed, phosphorylated oligonucleotides containing the six
histidine sequence #565=GATCGCATCATCACCATCACCATG (SEQ ID No. 45),
10 #566=GATCCATGGTGATGGTGATGATGC (SEQ ID No. 46). The 5' overhang for
each set of oligonucleotides was designed such that it allowed ligation into the BamHI
site but not subsequent digestion with BamHI.

Preparation of Bacterial Pellet:

36.34g of bacterial pellet representing 10.8L of growth was dispersed into a
15 total volume of 200ml using a 20mm tissue homogenizer probe at 3000 to 5000 rpm
in 2M KCl, 0.1M Tris, 0.05M EDTA, 1mM DTT. The conductivity adjusted to about
193mMhos with water. After the pellet was dispersed, an additional amount of the
KCl solution was added, bringing the total volume to 500 ml. This suspension was
homogenized further for about 3 minutes at 5000 rpm using the same probe. The
20 mixture was then passed through a Rannie high-pressure homogenizer at 10,000psi.

In all cases, the pellet material was carried forward, while the soluble fraction
was discarded. The resultant solution was centrifuged in a GSA rotor for 1 hour at
12,500 rpm. The pellet was resuspended in the same solution (without the DTT) using
the same tissue homogenizer probe at 2,000 rpm. After homogenizing for 5 minutes
25 at 3000 rpm, the volume was adjusted to 500ml with the same solution, and spun for 1
hour at 12,500 rpm. The pellet was then resuspended as before, but this time the final
volume was adjusted to 1.5L with the same solution prior to homogenizing for 5
minutes. After centrifuging at the same speed for 30 minutes, this procedure was
repeated. The pellet was then resuspended into about 150ml of cold water, pooling
30 the pellets from the six centrifuge tubes used in the GSA rotor. The pellet has

homogenized for 5 minutes at 3,000 rpm, volume adjusted to 250ml with cold water, then spun for 30 minutes. Weight of the resultant pellet was 17.75g.

Summary: Lysis of bacterial pellet in KCl solution, followed by centrifugation in a GSA rotor was used to initially prepare the pellet. The same solution was then used an additional three times for resuspension/homogenization. A final water wash/homogenization was then performed to remove excess KCl and EDTA.

Solubilization of Recombinant Hu-Asp2(a):

A ratio of 9-10ml/gram of pellet was utilized for solubilizing the rHuAsp2L from the pellet previously described. 17.75g of pellet was thawed, and 150ml of 8M guanidine HCl, 5mM β ME, 0.1% DEA, was added. 3M Tris was used to titrate the pH to 8.6. The pellet was initially resuspended into the guanidine solution using a 20 mm tissue homogenizer probe at 1000 rpm. The mixture was then stirred at 4°C for 1 hour prior to centrifugation at 12,500 rpm for 1 hour in GSA rotor. The resultant supernatant was then centrifuged for 30 minutes at 40,000 x g in an SS-34 rotor. The final supernatant was then stored at -20°C, except for 50 ml.

Immobilized Nickel Affinity Chromatography of Solubilized Recombinant Hu-Asp2(a):

The following solutions were utilized:

A) 6M Guanidine HCl, 0.1M NaP, pH 8.0, 0.01M Tris, 5mM β ME, 0.5mM Imidazole

A') 6M Urea, 20mM NaP, pH 6.80, 50mM NaCl

B') 6M Urea, 20mM NaP, pH 6.20, 50mM NaCl, 12mM Imidazole

C') 6M Urea, 20mM NaP, pH 6.80, 50mM NaCl, 300mM Imidazole

Note: Buffers A' and C' were mixed at the appropriate ratios to give intermediate concentrations of Imidazole.

The 50ml of solubilized material was combined with 50ml of buffer A prior to adding to 100-125ml Qiagen Ni-NTA SuperFlow (pre-equilibrated with buffer A) in a 5 x

10cm Bio-Rad econo column. This was shaken gently overnight at 4°C in the cold room.

Chromatography Steps:

- 5 Drained the resultant flow through.
Washed with 50ml buffer A (collecting into flow through fraction)
Washed with 250ml buffer A (wash 1)
Washed with 250ml buffer A (wash 2)
Washed with 250ml buffer A'
10 Washed with 250ml buffer B'
Washed with 250ml buffer A'
Eluted with 250ml 75mM Imidazole
Eluted with 250ml 150mM Imidazole (150-1)
Eluted with 250ml 150mM Imidazole (150-2)
15 Eluted with 250ml 300mM Imidazole (300-1)
Eluted with 250ml 300mM Imidazole (300-2)
Eluted with 250ml 300mM Imidazole (300-3)

Chromatography Results:

- 20 The Hu-Asp(a) eluted at 75mM Imidazole through 300mM Imidazole. The 75mM fraction, as well as the first 150mM Imidazole (150-1) fraction contained contaminating proteins as visualized on Coomassie Blue stained gels. Therefore, fractions 150-2 and 300-1 will be utilized for refolding experiments since they contained the greatest amount of protein as visualized on a Coomassie Blue stained
25 gel.

Refolding Experiments of Recombinant Hu-Asp2(a):

Experiment 1:

- Forty ml of 150-2 was spiked with 1M DTT, 3M Tris, pH 7.4 and DEA to a final
30 concentration of 6mM, 50mM, and 0.1% respectively. This was diluted suddenly

(while stirring) with 200ml of (4°C) cold 20mM NaP, pH 6.8, 150mM NaCl. This dilution gave a final Urea concentration of 1M. This solution remained clear, even if allowed to set open to the air at room temperature (RT) or at 4°C .

After setting open to the air for 4-5 hours at 4°C, this solution was then dialyzed overnight against 20 mM NaP, pH 7.4, 150 mM NaCl, 20% glycerol. This method effectively removes the urea in the solution without precipitation of the protein.

Experiment 2:

Some of the 150-2 eluate was concentrated 2x on an Amicon Centriprep, 10,000 MWCO, then treated as in Experiment 1. This material also stayed in solution, with no visible precipitation.

Experiment 3:

89ml of the 150-2 eluate was spiked with 1M DTT, 3M Tris, pH 7.4 and DEA to a final concentration of 6mM, 50mM, and 0.1% respectively. This was diluted suddenly (while stirring) with 445 ml of (4°C) cold 20 mM NaP, pH 6.8, 150 mM NaCl. This solution appeared clear, with no apparent precipitation. The solution was removed to RT and stirred for 10 minutes prior to adding MEA to a final concentration of 0.1 mM. This was stirred slowly at RT for 1 hour. Cystamine and CuSO₄ were then added to final concentrations of 1 mM and 10 µM respectively. The solution was stirred slowly at RT for 10 minutes prior to being moved to the 4°C cold room and shaken slowly overnight, open to the air.

The following day, the solution (still clear, with no apparent precipitation) was centrifuged at 100,000 x g for 1 hour. Supernatants from multiple runs were pooled, and the bulk of the stabilized protein was dialyzed against 20mM NaP, pH 7.4, 150 mM NaCl, 20% glycerol. After dialysis, the material was stored at -20°C.

Some (about 10 ml) of the protein solution (still in 1M Urea) was saved back for biochemical analyses, and frozen at -20°C for storage.

Example 10

Expression of Hu-Asp2 and Derivatives in Insect Cells

Any materials (vectors, host cells, etc.) and methods that are useful to express Hu-Asp2(a) should in principle be equally effective for expression of Hu-Asp2(b).

5 *Expression by baculovirus infection.*

The coding sequence of Hu-Asp2(a) and Hu-Asp2(b) and several derivatives were engineered for expression in insect cells using the PCR. For the full-length sequence, a 5'-sense oligonucleotide primer that modified the translation initiation site to fit the Kozak consensus sequence was paired with a 3'-antisense primer that contains the natural translation termination codon in the Hu-Asp2 sequence. PCR amplification of the pcDNA3.1(hygro)/Hu-Asp2(a) template was used to prepare two derivatives of Hu-Asp2(a) or Hu-Asp2(b) that delete the C-terminal transmembrane domain (SEQ ID Nos. 29-30 and 50-51, respectively) or delete the transmembrane domain and introduce a hexa-histidine tag at the C-terminus (SEQ ID Nos. 31-32 and 52-53) respectively, were also engineered using PCR. The same 5'-sense oligonucleotide primer described above was paired with either a 3'-antisense primer that (1) introduced a translation termination codon after codon 453 (SEQ ID No. 3) or (2) incorporated a hexa-histidine tag followed by a translation termination codon in the PCR using pcDNA3.1(hygro)/Hu-Asp-2(a) as the template. In all cases, the PCR reactions were performed amplified for 15 cycles using *Pwo*I DNA polymerase (Boehringer-Mannheim) as outlined by the supplier. The reaction products were digested to completion with *Bam*HI and *Not*I and ligated to *Bam*HI and *Not*I digested baculovirus transfer vector pVL1393 (Invitrogen). A portion of the ligations was used to transform competent *E. coli* DH5_ cells followed by antibiotic selection on LB-Amp. Plasmid DNA was prepared by standard alkaline lysis and banding in CsCl to yield the baculovirus transfer vectors pVL1393/Asp2(a), pVL1393/Asp2(a)ΔTM and pVL1393/Asp2(a)ΔTM(His)₆. Creation of recombinant baculoviruses and infection of sf9 insect cells was performed using standard methods.

30

Expression by transfection

Transient and stable expression of Hu-Asp2(a) Δ TM and Hu-Asp2(a) Δ TM(His)₆ in High 5 insect cells was performed using the insect expression vector pIZ/V5-His. The DNA inserts from the expression plasmids vectors pVL1393/Asp2(a), pVL1393/Asp2(a) Δ TM and pVL1393/Asp2(a) Δ TM(His)₆ were excised by double digestion with *Bam*HI and *Not*I and subcloned into *Bam*HI and *Not*I digested pIZ/V5-His using standard methods. The resulting expression plasmids, referred to as pIZ/Hu-Asp2 Δ TM and pIZ/Hu-Asp2 Δ TM(His)₆, were prepared as described above.

For transfection, High 5 insect cells were cultured in High Five serum free medium supplemented with 10 μ g/ml gentamycin at 27 °C in sealed flasks. Transfections were performed using High five cells, High five serum free media supplemented with 10 μ g/ml gentamycin, and InsectinPlus liposomes (Invitrogen, Carlsbad, CA) using standard methods.

For large scale transient transfections, 1.2×10^7 high five cells were plated in a 150 mm tissue culture dish and allowed to attach at room temperature for 15-30 minutes. During the attachment time the DNA/ liposome mixture was prepared by mixing 6 ml of serum free media, 60 μ g Hu-Asp2(a) Δ TM/pIZ (+/- His) DNA and 120 μ l of Insectin Plus and incubating at room temperature for 15 minutes. The plating media was removed from the dish of cells and replaced with the DNA/liposome mixture for 4 hours at room temperature with constant rocking at 2 rpm. An additional 6 ml of media was added to the dish prior to incubation for 4 days at 27 °C in a humid incubator. Four days post transfection the media was harvested, clarified by centrifugation at 500 x g, assayed for Hu-Asp2(a) expression by Western blotting.

For stable expression, the cells were treated with 50 μ g/ml Zeocin and the surviving pool used to prepared clonal cells by limiting dilution followed by analysis of the expression level as noted above.

Purification of Hu-Asp2(a) Δ TM and Hu-Asp2(a) Δ TM(His)₆

Removal of the transmembrane segment from Hu-Asp2(a) resulted in the secretion of the polypeptide into the culture medium. Following protein production by either baculovirus infection or transfection, the conditioned medium was harvested, clarified by centrifugation, and dialyzed against Tris-HCl (pH 8.0). This material was then purified by successive chromatography by anion exchange (Tris-HCl, pH 8.0) followed by cation exchange chromatography (Acetate buffer at pH 4.5) using NaCl gradients. The elution profile was monitored by (1) Western blot analysis and (2) by activity assay using the peptide substrate described in Example 12. For the Hu-Asp2(a) Δ TM(His)₆, the conditioned medium was dialyzed against Tris buffer (pH 8.0) and purified by sequential chromatography on IMAC resin followed by anion exchange chromatography.

Amino-terminal sequence analysis of the purified Hu-Asp2(a) Δ TM(His)₆ protein revealed that the signal peptide had been cleaved [TQHGIRLPLR, corresponding to SEQ ID NO: 32, residues 22-3].

Example 11

Expression of Hu-Asp2(a) and Hu-Asp(b) in CHO cells

The materials (vectors, host cells, etc.) and methods described herein for expression of Hu-Asp2(a) are intended to be equally applicable for expression of Hu-Asp2(b).

Heterologous expression of Hu-Asp-2(a) in CHO-K1 cells

The entire coding sequence of Hu-Asp2(a) was cloned into the mammalian expression vector pcDNA3.1(+)^{Hygro} (Invitrogen, Carlsbad, CA) which contains the CMV immediate early promoter and bGH polyadenylation signal to drive over expression. The expression plasmid, pcDNA3.1(+)^{Hygro}/Hu-Asp2(a), was prepared by alkaline lysis and banding in CsCl and completely sequenced on both strands to verify the integrity of the coding sequence.

Wild-type Chinese hamster ovary cells (CHO-K1) were obtained from the ATCC. The cells were maintained in monolayer cultures in α -MEM containing 10%

09658314-092200

FCS at 37°C in 5% CO₂. Two 100 mm dishes of CHO-K1 cells (60% confluent) were transfected with pcDNA3.1(+)/Hygro alone (mock) or pcDNA3.1(+)/Hygro/Hu-Asp2(a) or pcDNA3.1(+)/Hygro/Hu-Asp2(b) using the cationic liposome DOTAP as recommended by the supplier (Roche, Indianapolis, IN).

5 The cells were treated with the plasmid DNA/liposome mixtures for 15 hours and then the medium replaced with growth medium containing 500 Units/ml hygromycin B. In the case of pcDNA3.1(+)/Hygro/Hu-Asp2(a) or (b) transfected CHO-K1 cells, individual hygromycin B-resistant cells were cloned by limiting dilution. Following clonal expansion of the individual cell lines, expression of Hu-Asp2(a) or Hu-Asp2(b)

10 protein was assessed by Western blot analysis using a polyclonal rabbit antiserum raised against recombinant Hu-Asp2 prepared by expression in *E. coli*. Near confluent dishes of each cell line were harvested by scraping into PBS and the cells recovered by centrifugation. The cell pellets were resuspended in cold lysis buffer (25 mM Tris-HCl (pH 8.0)/5 mM EDTA) containing protease inhibitors and the cells

15 lysed by sonication. The soluble and membrane fractions were separated by centrifugation (105,000 x g, 60 min) and normalized amounts of protein from each fraction were then separated by SDS-PAGE. Following electrotransfer of the separated polypeptides to PVDF membranes, Hu-Asp-2(a) or Hu-Asp2(b) protein was detected using rabbit anti-Hu-Asp2 antiserum (1/1000 dilution) and the

20 antibody-antigen complexes were visualized using alkaline phosphatase conjugated goat anti-rabbit antibodies (1/2500). A specific immunoreactive protein with an apparent Mr value of 65 kDa was detected in pcDNA3.1(+)/Hygro/Hu-Asp2 transfected cells and not mock-transfected cells. Also, the Hu-Asp2 polypeptide was only detected in the membrane fraction, consistent with the presence of a signal

25 peptide and single transmembrane domain in the predicted sequence. Based on this analysis, clone #5 had the highest expression level of Hu-Asp2(a) protein and this production cell lines was scaled up to provide material for purification.

Purification of recombinant Hu-Asp-2(a) from CHO-K1/Hu-Asp2 clone #5

30 In a typical purification, clone #5 cell pellets derived from 20 150 mm dishes of confluent cells, were used as the starting material. The cell pellets were

resuspended in 50 ml cold lysis buffer as described above. The cells were lysed by polytron homogenization (2 x 20 sec) and the lysate centrifuged at 338,000 x g for 20 minutes. The membrane pellet was then resuspended in 20 ml of cold lysis buffer containing 50 mM β -octylglucoside followed by rocking at 4 °C for 1 hour. The detergent extract was clarified by centrifugation at 338,000 x g for 20 minutes and the supernatant taken for further analysis.

The β -octylglucoside extract was applied to a Mono Q anion exchange column that was previously equilibrated with 25 mM Tris-HCl (pH 8.0)/50 mM β -octylglucoside. Following sample application, the column was eluted with a linear gradient of increasing NaCl concentration (0-1.0 M over 30 minutes) and individual fractions assayed by Western blot analysis and for β -secretase activity (see below). Fractions containing both Hu-Asp-2(a) immunoreactivity and β -secretase activity were pooled and dialyzed against 25 mM NaOAc (pH 4.5)/50 mM β -octylglucoside. Following dialysis, precipitated material was removed by centrifugation and the soluble material chromatographed on a MonoS cation exchange column that was previously equilibrated in 25 mM NaOAc (pH 4.5)/ 50 mM β -octylglucoside. The column was eluted using a linear gradient of increasing NaCl concentration (0-1.0 M over 30 minutes) and individual fractions assayed by Western blot analysis and for β -secretase activity. Fractions containing both Hu-Asp2 immunoreactivity and β -secretase activity were combined and determined to be >95% pure by SDS-PAGE/Coomassie Blue staining.

The same methods were used to express and purify Hu-Asp2(b).

Example 12

Assay of Hu-Asp2 β -secretase activity using peptide substrates

β -secretase assay

Recombinant human Asp2(a) prepared in CHO cells and purified as described in Example 11 was used to assay Asp2(a) proteolytic activity directly. Activity assays for Asp2(a) were performed using synthetic peptide substrates containing either the wild-type APP β -secretase site (SEVKM↓DAEFR), the Swedish KM→NL mutation

(SEVNL↓DAEFR), or the A β 40 and 42 γ -secretase sites (RRGGVV↓IA↓TVIVGER). Reactions were performed in 50 mM 2-[N-morpholino]ethane-sulfonate ("Na-MES," pH 5.5) containing 1% β -octylglucoside, 70 mM peptide substrate, and recombinant Asp2(a) (1-5 μ g protein) for various times at 37°C. The reaction products were
5 quantified by RP-HPLC using a linear gradient from 0-70 B over 30 minutes (A=0.1% TFA in water, B=0.1%TFA/10%water/90%AcCN). The elution profile was monitored by absorbance at 214 nm. In preliminary experiments, the two product peaks which eluted before the intact peptide substrate, were confirmed to have the sequence DAEFR and SEVNL using both Edman sequencing and MADLI-TOF mass
10 spectrometry. Percent hydrolysis of the peptide substrate was calculated by comparing the integrated peak areas for the two product peptides and the starting material derived from the absorbance at 214 nm. The sequence of cleavage/hydrolysis products was confirmed using Edman sequencing and MADLI-TOF mass spectrometry.

15 The behavior of purified Asp2(a) in the proteolysis assays was consistent with the prior anti-sense studies which indicated that Asp2(a) possesses β -secretase activity. Maximal proteolysis was seen with the Swedish β -secretase peptide, which, after 6 hours, was about 10-fold higher than wild type APP.

The specificity of the protease cleavage reaction was determined by
20 performing the β -secretase assay in the presence of 8 μ M pepstatin A and the presence of a cocktail of protease inhibitors (10 μ M leupeptin, 10 μ M E64, and 5 mM EDTA). Proteolytic activity was insensitive to both the pepstatin and the cocktail, which are inhibitors of cathepsin D (and other aspartyl proteases), serine proteases, cysteinyl proteases, and metalloproteases, respectively.

25 Hu-Asp2(b) when similarly expressed in CHO cells and purified using identical conditions for extraction with β -octylglucoside and sequential chromatography over Mono Q and Mono S also cleaves the Swedish β -secretase peptide in proteolysis assays using identical assay conditions.

Collectively, this data establishes that both forms of Asp2 (Hu-Asp2(a) and
30 Hu-Asp2(b)) act directly in cell-free assays to cleave synthetic APP peptides at the β -

secretase site, and that the rate of cleavage is greatly increased by the Swedish KM-NL mutation that is associated with Alzheimer's disease.

An alternative β -secretase assay utilizes internally quenched fluorescent substrates to monitor enzyme activity using fluorescence spectroscopy in a single sample or multiwell format. Each reaction contained 50 mM Na-MES (pH 5.5), peptide substrate MCA-EVKMDAEF[K-DNP] (BioSource International) (50 μ M) and purified Hu-Asp-2 enzyme. These components were equilibrated to 37 °C for various times and the reaction initiated by addition of substrate. Excitation was performed at 330 nm and the reaction kinetics were monitored by measuring the fluorescence emission at 390 nm. To detect compounds that modulate Hu-Asp-2 activity, the test compounds were added during the preincubation phase of the reaction and the kinetics of the reaction monitored as described above. Activators are scored as compounds that increase the rate of appearance of fluorescence while inhibitors decrease the rate of appearance of fluorescence.

Example 13

Demonstration that Asp1 processes APP at the α -secretase site

Increased expression of an α -secretase candidate gene in human cells would be expected to increase basal release of sAPP α and to decrease release of A β peptides. This the effect was observed when full length human Asp1 is co-expressed with APP in HEK293 cells. The experiment utilized the APP 695 amino acid isoform which had been modified by the addition of a pair of lysine residues to the C-terminus (APP-KK). The C-terminal di-lysine motif increases the intracellular half-life of glycosylated APP and consequently the production of both sAPP α and A β . As shown in Table 5, cotransfection of HEK293 cells with APP-KK with Asp1 increased the production of sAPP α by 3.5 fold (p<0.001) and decreased the production of A β 40 by 2.8 fold. Thus, Asp1 acts directly or indirectly to facilitate constitutive α -secretase cleavage and this effect is competitive with the amyloidogenic processing of APP to A β peptides. This implies that mutations or genetic polymorphisms in Asp1 may

affect A β production by affecting the balance between the competing pathways for constitutive α -secretase cleavage and A β peptide production.

Table 5.

Asp1 stimulates basal release of sAPP α from HEK293 cells after cotransfection with APP-KK.

Transfection	sAPP α μ g/ml	Fold Increase	A β 40 pg/ml	Fold Decrease
Asp1	3.5 + 1.1	+3.5	113 + 7	-2.8
pcDNA	1.0 + 0.2		321 + 18	

5

10

15

20

25

30

Specific methods used were as follows. The full length Asp1 cDNA was cloned into the vector pcDNA3.1/hygro+(Invitrogen) for transfection studies as previously described (Yan *et al.*, (1999) *Nature* 402: 533-537). The APP-KK cDNA was cloned into the vector pIRES (Clontech) also as previously described. HEK293 cells were transfected with expression constructs using the Lipofectamine Plus reagent from Gibco/BRL. Cells were seeded in 24 well tissue culture plates to a density of 70-80% confluence. Four wells per plate were transfected with 2 μ g DNA (3:1, APP:Asp1 or empty pcDNA3.1./hygro+ vector), 8 μ l Plus reagent, and 4 μ l Lipofectamine in OptiMEM. OptiMEM was added to a total volume of 1 ml, distributed 200 μ l per well and incubated 3 hours. Care was taken to hold constant the ratios of the two plasmids used for cotransfection as well as the total amount of DNA used in the transfection. The transfection media was replaced with DMEM supplemented with 10% FBS and NaPyruvate, with antibiotic/antimycotic and the cells were incubated under normal conditions (37°, 5% CO₂) for 48 hours. The conditioned media were removed to polypropylene tubes and stored at -80°C until assayed for the content of sAPP α or A β 40/A β 42 by enzyme-linked immunosorbent assay (EIA) as described above in Example 6. The A β EIA followed the protocol of Pirttila *et al.* (*Neuro. Lett.* (1999) 249: 21-4) using the 6E10 monoclonal antibody (Senetek) as a capture antibody and biotinylated rabbit antiserum 162 or 165 (New York State Institute for Basic Research, Staten Island, NY) for detection of A β 40 and A β 42, respectively. The 6E10 antibody recognizes residues 1-16 of the A β peptide.

The sAPP α EIA used LN27 antibody as a capture antibody and biotinylated 6E10 for detection as described previously (Yan *et al.*, (1999) *supra.*). The LN27 antibody recognized the first 20 amino acids of the human APP peptide.

Increased α -secretase activity and concomitant reduction of A β production *in vivo* represents an effect that may be desirable for the prevention, treatment (*e.g.*, to show the progression of), or cure of Alzheimer's disease. Thus, the activities demonstrated in this example provide an indication that modulators of Asp1 activity, that achieve the same effects *in vivo*, will have utility for Alzheimer's disease therapy. Screening methods for such modulators are contemplated as an aspect of the invention.

Example 14

Expression of Pre-pro-Hu-Asp1 and Derivatives in Insect Cells

Expression of hu-Asp-1 TM(His)⁶ by baculovirus infection.

The coding sequence of pre-pro-Hu-Asp1 was engineered for production as a soluble, secreted form by insect cells. PCR primers were designed to (1) delete the predicted transmembrane domain and cytoplasmic tail of Asp1 and (2) to introduce a Kozak consensus sequence for efficient translational initiation. The primers sequences were as follows: sense CGCTTTAAGCTTGCCACCATGGGCGCA CTGGCCCGGGCG (SEQ ID NO: 74) and antisense CGCTTTCTCGAGCTAA TGGTGATGGTGATGGTGCCACAAAATGGGCTCGCTCAAAGA (SEQ ID NO: 75) which replaced the deleted C-terminal transmembrane and cytoplasmic domains with a hexahistidine purification tag.

PCR reactions were carried out with 100 ng of full length Asp1 pcDNA 3.1 hygro+ construct, 200 M NTPs, 300 nM of each primer, 1x reaction buffer containing 2 mM MgSO₄, and 5 units of Pwo I DNA polymerase (Roche Biochemicals). The reactions were cycled under the following conditions: 94°C for 5 minutes followed by 15 cycles of 94°C for 30 seconds and 72°C for 30 seconds, and then a final extension reaction at 72°C for 10 minutes. The predicted amino acid sequence of this PCR generated derivative (denoted as Asp-1 Δ TM(His)₆) is set out as SEQ ID NO: 66.

002260-4789960

The reaction product was digested to completion with HindIII-XhoI and ligated into the expression vector pIB (Invitrogen) to yield the pIB/Asp-1ΔTM(His)₆ construct. Creation of recombinant baculovirus and infection of sf9 insect cells was performed using standard methods known in the art. Sf9 cells were transfected with either the pIB vector alone or the pIB/Asp-1ΔTM(His)₆ construct utilizing Insectin Plus reagent (Invitrogen) according to the manufacturer's instructions. After the transfection, the cells were cultured in High Five serum-free media (Invitrogen) for 3 days. Subsequently, the conditioned medium was harvested and subjected to Western blot analysis. This analysis revealed specific expression and secretion of immunoreactive Asp-1ΔTM(His)₆ polypeptide into the extracellular medium. The secreted proteins were detected on the Western blot with either the India probe (Pierce Chemicals) specific for the hexahistidine sequence tag or using a rabbit polyclonal antiserum. The polyclonal antisera (denoted as UP-199) was generated by injecting rabbits with recombinant Asp-1ΔTM(His)₆ (SEQ ID NO: 66). This recombinant peptide was prepared by heterologous expression in *E.coli*. The UP-199 antibody recognizes the processed form of Asp-1ΔTM.

Direct analysis with the polyclonal antiserum (UP-199) revealed an immunoreactive band of the expected molecular weight (50 kDa) only in pIB/Asp-1ΔTM(His)₆ transfected cells. This signal was significantly enhanced in concentrated conditioned medium. A similar pattern was obtained using the India probe. No signal was detected in conditioned medium derived from mock-transfected cells using either UP-199 antisera or the India probe.

Based on this result, transient and stable transfections of the pIB/Asp-1ΔTM(His)₆ construct in sf9 insect cells were carried out as described above. Four days post transient transfection, the culture medium was collected to provide material for further characterization. In parallel, sf9 cells were stably transfected with the pIB/Asp-1ΔTM(His)₆ construct and cultured in High Five serum-free medium (Invitrogen) supplemented with 50 μg/ml blasticidin for approximately 2 weeks. After blasticidin selection, the resistant pool of cells was expanded to provide a stable source of conditioned medium for Asp-1ΔTM(His)₆ purification.

Purification of recombinant Asp-1 Δ TM(His)₆

Conditioned media, from either transient or stably transfected sf9 cells, were concentrated approximately 10-fold using a stirred cell concentrator equipped with a 30,000 MWCO membrane (Spectrum Medical Industries). This concentrate was then subjected to ammonium sulfate precipitation to further concentrate the sample and provide partial purification. Material precipitating between 0-40% saturation was discarded and the resulting supernatant was brought to 80% saturation. Western blot analysis of the various ammonium sulfate precipitated fractions revealed that the majority of the immunoreactive material was contained within the 40-80% ammonium sulfate pellet. As a result, this material was subjected to further purification.

The 40-80% ammonium sulfate pellet was redissolved in approximately 1/20 the original volume of Ni+-NTA loading buffer (25 mM Tris-HCl (pH 8.5)/0.5 M NaCl/10 mM imidazole). Subsequently, the sample was applied to a Ni+-NTA column previously equilibrated in Ni+-NTA buffer. Following sample application, the column was washed with starting buffer (25 mM Tris-HCl (pH 8.5)/ 0.5 M NaCl/ 20 mM imidazole) until the A^{280nm} of the column effluent returned to zero. After washing, the bound recombinant protein was eluted off the column with a linear gradient of Ni+-NTA buffer containing increasing concentrations (10 mM, 50 mM, 100 mM, 250 mM, and 500 mM) of imidazole. The elution profile was monitored by Western blot analysis using the UP-199 antiserum. Immunoreactive Asp-1 Δ TM(His)₆ was detected in the column load and eluted at 50 mM imidazole. NuPAGE gel analysis of the 50 mM imidazole fraction demonstrated a purity of Asp-1 Δ TM(His)₆ of approximately 50%, therefore further purification was required.

The positive fractions, eluted off the Ni+-NTA column, were then pooled (denoted as post-IMAC pool), concentrated using a YM30 membrane (Amicon), and dialyzed with 25 mM Tris-HCl (pH 8.0). The dialyzed post-IMAC pool was fractionated by MonoQ anion exchange chromatography (Amersham-Pharmacia Biotech) gradient elution containing increasing concentrations (0 -0.5 M) of NaCl (Buffer A: 25 mM Tris-HCl (pH 8.0) and Buffer B: 25 mM Tris-HCl (pH 8.0)/ 0.5 M

NaCl). The elution profile was determined by Western blot analysis which indicated immunoreactive fractions as those displaying immunoreactivity with the UP-199 antisera. NuPAGE gel analysis with silver staining demonstrated that the material prepared in this manner was >90% pure. The immunoactive fractions eluted off the MonoQ anion exchange column were pooled, dialyzed with 25 mM HEPES-Na⁺ (pH 8.0), and stored at 4°C until further analysis.

Acid-activation of recombinant Asp-1 TM(His)₆

Recombinant Asp-1ΔTM(His)₆ migrated with an apparent molecular weight of 50 kD. Direct N-terminal sequence analysis carried out by automated Edman degradation for 20 cycles revealed a unique sequence beginning at Glu³ (SEQ ID NO: 67), confirming the identity of the recombinant protein. Computer assisted prediction of the signal peptidase cleavage site indicated that the pro-form should initiate at Ala¹, suggesting either an unusual processing site by the signal peptidase during secretion or an additional processing step that removes an additional two amino acid residues.

To investigate the mechanism of pro-Asp-1ΔTM(His)₆ activation, aliquots of the purified protein were incubated in various acidic environments with pH values ranging from 3.0-8.0 at 37°C for 2 hours. Subsequently, the recombinant proteins were analyzed by Western blot. A faster migrating polypeptide species was detected after incubation at pH values of 4.0, 4.5 and 5.0. The polypeptide migration was unaltered after incubation in environments which were either more acidic (pH 3.0 and 3.5) or more basic (pH 6.0, 7.0, and 8.0). Sequence analysis of this faster migrating species revealed that it initiated exclusively at Ala⁴³, consistent with removal of a 42 amino acid residue segment of the pro-peptide that was induced by treatment of the pro-enzyme at pH 4.5. The predicted amino acid sequence of the acid processed form of Asp-1ΔTM(His)₆ is set out as SEQ ID NO: 68.

To purify the acid-activated form of Asp-1ΔTM(His)₆, the Asp-1ΔTM(His)₆ post-IMAC pool (generated as described above) was dialyzed to pH 4.5 and then subjected to affinity chromatography on either pepstatin A agarose or sulfolink-PHA-292593E. Following sample application, the column was washed with

25 mM NaOAc (pH 4.5) and eluted with 50 mM Na-BO₃ (pH 9.5). The positive fractions eluted off the columns were dialyzed with 25 mM Hepes-Na (pH 7.5) overnight at 4°C which resulted in quantitative conversion of the pro-enzyme to the acid-processed form (SEQ ID NO: 68) described above. Western blot analysis of the elution profile revealed quantitative retention of immunoreactive Asp-1ΔTM(His)₆ on both affinity resins as evidenced by the lack of Asp-1ΔTM(His)₆ in the unbound fraction as detected by UP-199 immunoreactivity on a Western blot. Step elution 50 mM NaBO₃ at pH 9.5 resulted in elution of immunoreactive Asp-1 TM(His)₆, with variable recovery.

Comparison of the properties of the recombinant soluble catalytic domain of Asp1 with the properties determined for Asp2 (see Example 10) revealed a number of significant differences. Processing of the pre-pro forms of either enzyme is distinct, with Asp1 undergoing efficient processing by the signal peptidase and additional processing to remove two additional amino acid residues from the N-terminus.

Further processing of the pro-form of Asp1 was not detected in neutral pH. In contrast, recombinant Asp2 produced, under similar conditions, yields an equimolar mixture of the pro-form and a processed form that has 24 amino acid residues of the pro-segment removed.

Another distinction between the processing of these two enzymes involves processing initiated by acid-treatment. Systematic analysis of acid-induced processing of pro-Asp2 revealed that the purified polypeptide did not self-process. In contrast, acid dependent processing of pro-Asp1 was readily demonstrated (as described above). Alignment of the self-processing site in Asp1 with the processing site in Asp2 revealed that these two enzymes are processed at the same position, which is a different method of processing as compared with that of other known human aspartyl proteases.

In addition to providing valuable information about Asp1 activity, the discovery of a site of apparent autocatalytic processing of Asp1 provides an indication of a peptide sequences (surrounding Ala⁴³) that could be useful for performing

screening assays to identify modulators of Asp1 activity. This idea is explored in greater detail in Example 15.

Example 15

5 Development of an enzymatic assay for Asp-1 Δ TM(His)₆

The relationship between Asp1 and APP processing was explored by determining if APP α -secretase, APP β -secretase, or APP γ -secretase peptide substrates were cleaved by recombinant Asp-1 Δ TM(His)₆. These peptide substrates included the α -secretase specific substrates A β ₁₀₋₂₀ and A β ₁₂₋₂₈, the β -secretase specific substrates PHA-95812E (SEVKMDAEFR; SEQ ID NO: 64) and PHA-247574E (SEVNLDAEFR; SEQ ID NO: 63), and γ -secretase specific substrate PHA-179111E (RRGGVVIATVIVGER; SEQ ID NO: 76). Each reaction consisted of incubating a peptide substrate (100 nM) with recombinant Asp-1 Δ TM(His)₆ for 15 hours at pH 4.5 at 37°C. Reaction products were quantified by RP-HPLC at A^{214 nm}. The elution profiles for Asp-1 Δ TM(His)₆ were compared to those obtained from parallel Asp1 experiments. The identity of the cleavage products was determined by MADLI-TOF mass spectrometry. Table 6 summarizes the Asp1 substrates and indicates the cleavage site.

Table 6

Substrate Preferences of Asp-1 Δ TM										SEQ ID NO:
P4	P3	P2	P1		P1'	P2'	P3'	P4'		
G	L	A	L		A	L	E	P	Self Activation	69
E	V	K	M		D	A	E	F	β -Secretase, WT	70
E	V	N	L		D	A	E	F	β -Secretase, Sw	71
L	V	F	F		A	E	D	V	A β ₁₂₋₂₈ (α -Secretase)	72
K	L	V	F		F	A	E	D	A β ₁₂₋₂₈ (α -Secretase)	73

The peptides in Table 6 are described using the nomenclature by Schechter and Berger (*Biochem. Biophys. Res. Commun.* 27:157(1967) and *Biochem.*

Biophys. Res. Commun. 32:898 (1968)), in which the amino acid residues in the peptide substrate that undergo the cleavage are defined as $P_1 \dots P_n$ toward the N-terminus and $P_1' \dots P_n'$ toward the C-terminus. Therefore, the scissile bond is between the P_1 and the P_1' residue of the peptide subunits and is denoted herein throughout with a hyphen between the P_1 and the P_1' .

Digestion of the α -secretase substrate (A_{12-28}) revealed two Asp1 cleavage sites. The major product was cleaved at $\text{Phe}^{20}\text{Ala}^{21}$ and the minor product was cleaved at $\text{Phe}^{19}\text{Phe}^{20}$ (referring to the numbering convention in the APP A β) peptide. Analysis of the cleavage products obtained from the β -secretase peptide substrates revealed that both the wild-type (PHA-95812E) and the Swedish mutation (PHA-247574E) substrates were hydrolyzed exclusively at the β -secretase site. Also, the relative rates of Asp-1-dependent hydrolysis of the β -secretase peptide substrate containing the Swedish mutation was cleaved at least 10-times faster than the corresponding wild-type peptide. Conversion of the γ -secretase peptide substrate was not detected under these reaction conditions.

Measurement of the cleavage of the α -secretase and β -secretase substrates can also be carried out with substrates comprising detectable labels such as radioactive, enzymatic, chemiluminescent or fluorescent labels. For example, the peptide substrates could comprise internally quenched labels that result in increased detectability after cleavage of the peptide substrates due to separation of the labels upon cleavage. The peptide substrates can be modified to have attached a paired fluorophore and quencher such as 7-amino-4-methyl coumarin and dinitrophenol, respectively.

This example illustrates the α -secretase and β -secretase activity exhibited by Asp-1, confirming the APP processing activity of Asp1 indicating, *e.g.*, in Examples 7 and 13. The substrates described herein may be used in combination with recombinant Asp1 to measure Asp1 proteolytic activity at the α -secretase and β -secretase processing sites. These substrates are useful in screening assays for identification of modulators of Asp1 proteolytic activity.

In particular, production of A β species through the processing of APP at β - and γ -secretase sites may play a central role in Alzheimer's disease pathogenesis, and processing at the α -secretase site may have a protective role and may prevent A β production. Thus, a therapeutic and/or prophylactic indication exists for molecules that can increase Asp1 α -secretase activity and/or decrease Asp1 β -secretase activity *in vivo*. The present invention includes screening assays for such modulators, and the foregoing substrate peptides are useful in such assays.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples.

Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the invention. The entire disclosure of all publications cited herein are hereby incorporated by reference.

What is claimed is:

1. A purified polynucleotide comprising a nucleotide sequence encoding a polypeptide that comprises a fragment of a human Asp1 protein (hu-Asp1),
5 wherein said polynucleotide lacks nucleotide sequence encoding at least one portion of the hu-Asp1 protein, selected from the group consisting of (a) the transmembrane domain of said hu-Asp1 protein; and (b) the amino-terminal propeptide of said hu-Asp1 protein; and
10 wherein the polypeptide encoded by said polynucleotide retains amyloid precursor protein (APP) proteolytic activity characteristic of said human Asp1 protein.
2. A polynucleotide according to claim 1, wherein the polypeptide has hu-Asp1 α -secretase activity.
- 15 3. A polynucleotide according to claim 1, wherein the polypeptide has hu-Asp1 β -secretase activity.
4. A polynucleotide according to claim 1, wherein said polynucleotide
20 lacks nucleotide sequence encoding the transmembrane domain of said hu-Asp1 protein.
5. A polynucleotide according to claim 4, wherein the polynucleotide comprises a nucleotide sequence that encodes a fragment of hu-Asp1 having the
25 amino acid sequence set forth as SEQ ID NO: 2, and wherein the polynucleotide lacks sequence encoding the transmembrane domain amino acids 469-492 of SEQ ID NO: 2.

6. A polynucleotide according to claim 5 wherein the polynucleotide further lacks nucleotide sequence encoding the cytoplasmic domain amino acids 493-518 of SEQ ID NO: 2.

5 7. A polynucleotide according to claim 6, wherein said polynucleotide further lacks nucleotide sequence encoding amino acids 1-62 of SEQ ID NO: 2.

8. A polynucleotide according to claim 1, wherein said polynucleotide lacks nucleotide sequence encoding the amino-terminal propeptide of said hu-Asp1 protein.
10

9. A polynucleotide according to claim 8, wherein the polynucleotide comprises a nucleotide sequence that encodes a fragment of hu-Asp1 having the amino acid sequence set forth as SEQ ID NO: 2, and wherein the polynucleotide lacks sequence encoding the signal peptide and amino terminal propeptide amino acids 1-62 of SEQ ID NO: 2.
15

10. A vector comprising the polynucleotide of claim 1.

20 11. A host cell transformed or transfected with a vector of claim 10.

12. A host cell transformed or transfected with a polynucleotide of claim 1.

25

13. A polynucleotide comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleic acid comprising the complement of the nucleotide sequence set forth in SEQ ID NO: 1, wherein the polynucleotide encodes a polypeptide having amyloid precursor protein (APP) processing activity, and

5 wherein said polynucleotide lacks nucleotide sequence encoding a transmembrane domain and said encoded polypeptide lacks a transmembrane domain.

14. A polynucleotide comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleic acid comprising the complement of the nucleotide sequence set forth in SEQ ID NO: 1, wherein the polynucleotide encodes a polypeptide having amyloid precursor protein (APP) processing activity, and

10 wherein said polynucleotide lacks nucleotide sequence encoding a propeptide and said encoded polypeptide lacks a propeptide.

15. A purified polypeptide that comprises a fragment of a human Asp1 protein (hu-Asp1),

wherein said polypeptide lacks at least one portion of the hu-Asp1 protein selected from the group consisting of (a) the transmembrane domain of said hu-Asp1 protein; and (b) the amino-terminal propeptide of said hu-Asp1 protein; and

20 wherein the polypeptide retains amyloid precursor protein (APP) proteolytic activity characteristic of said human Asp1 protein.

16. A polypeptide according to claim 15, wherein the polypeptide has hu-Asp1 α -secretase activity.

17. A polypeptide according to claim 15, wherein the polypeptide has hu-Asp1 β -secretase activity.

18. A polypeptide according to claim 15, wherein said polypeptide lacks the transmembrane domain of said hu-Asp1 protein.

19. A polypeptide according to claim 18, wherein the polypeptide comprises a fragment of hu-Asp1 having the amino acid sequence set forth as SEQ ID NO: 2, and wherein the polypeptide lacks transmembrane domain amino acids 469-492 of SEQ ID NO: 2.

5

20. A polypeptide according to claim 19 which further lacks cytoplasmic domain amino acids 493-518 of SEQ ID NO: 2.

21. A polypeptide according to claim 20, wherein said polypeptide further lacks amino acids 1-62 of SEQ ID NO: 2.

10

22. A polypeptide according to claim 15 that lacks the amino-terminal propeptide of said hu-Asp1 protein.

23. A polypeptide according to claim 22 that further lacks the signal peptide of the hu-Asp1 protein.

15

24. A polypeptide according to claim 23 that comprises a fragment of hu-Asp1 having the amino acid sequence set forth as SEQ ID NO: 2, wherein the polypeptide lacks signal peptide and amino terminal propeptide amino acids 1-62 of SEQ ID NO: 2.

20

25. A polypeptide comprising an amino acid sequence at least 95% identical to a fragment of the hu-Asp1 protein having the amino acid sequence of SEQ ID NO: 2,

25

wherein said polypeptide lacks at least a transmembrane domain or an amino-terminal propeptide characteristic of a hu-Asp1 protein; and

wherein the polypeptide has amyloid precursor protein (APP) proteolytic activity characteristic of said human Asp1 protein.

30

26. A method of identifying agents that modulate amyloid precursor protein (APP) processing activity of human hu-Asp1 aspartyl protease (hu-Asp1), comprising steps of:

(a) contacting amyloid precursor protein (APP) and purified and isolated hu-Asp1 in the presence and absence of a test agent;

(b) determining APP processing activity of the hu-Asp1 in the presence and absence of the test agent; and

(c) identifying agents that modulate APP processing activity of hu-Asp1 by comparing the APP processing activity of the hu-Asp1 in the presence and absence of the test agent, wherein reduced activity in the presence of the test agent identifies an agent that inhibits hu-Asp1 activity and increased activity in the presence of the test agent identifies an agent that enhances hu-Asp1 activity.

27. A method according to claim 26, wherein the hu-Asp1 comprises a polypeptide purified and isolated from a cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes hu-Asp1.

28. A method according to claim 27 wherein the nucleotide sequence is selected from the group consisting of:

(a) a nucleotide sequence encoding the hu-Asp1 amino acid sequence set forth in SEQ ID NO: 2;

(b) a nucleotide sequence encoding a fragment of hu-Asp1 (SEQ ID NO: 2), wherein said fragment exhibits aspartyl protease activity characteristic of hu-Asp1;

(c) a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to a hu-Asp1-encoding polynucleotide (SEQ ID NO: 1).

29. A method according to claim 27, wherein the nucleotide sequence encodes a hu-Asp1 amino acid sequence lacking transmembrane amino acids 469-492 of SEQ ID NO: 2.

30. A method according to claim 29, wherein the nucleotide sequence encodes a hu-Asp1 amino acid sequence further lacking the cytoplasmic domain amino acids 493-518 of SEQ ID NO: 2.

5 31. A method according to claim 30, wherein the nucleotide sequence encodes a hu-Asp1 amino acid sequence further lacking amino terminal amino acids 1-62 of SEQ ID NO: 2.

10 32. A method according to claim 26 wherein the step (b) comprises determining an α -secretase APP processing activity of the hu-Asp1 protein.

15 33. A method according to claim 26 wherein the determining step comprises measuring the production of amyloid alpha peptide by the cell in the presence and absence of the test agent.

34. A method according to claim 26 wherein step (b) comprises determining a β -secretase APP processing activity of the hu-Asp1 protein.

20 35. A method according to claim 26 wherein the determining step comprises measuring the production of amyloid beta peptide by the cell in the presence and absence of the test agent.

25 36. A method according to claim 26, further comprising a step of treating Alzheimer's Disease with an agent identified as a modulator of APP processing activity of hu-Asp1 according to steps (a)-(c).

37. A method for identifying agents that modulate the amyloid precursor protein (APP) processing activity of human Asp1 aspartyl protease (hu-Asp1), comprising the steps of:

(a) contacting hu-Asp1 and amyloid precursor protein (APP) in the presence and absence of a test agent, wherein the contacting comprises growing a host cell transformed or transfected with a polynucleotide comprising a nucleotide sequence encoding the hu-Asp1 in the presence and absence of the test agent;

5 (b) determining the APP processing activity of the hu-Asp1 in the presence and absence of the test agent; and

(c) identifying an agent that modulates APP processing activity by comparing the APP processing activity of the hu-Asp1 polypeptide in the presence of the test agent to the activity in the absence of the test agent, wherein reduced activity
10 in the presence of the test agent identifies an agent that inhibits hu-Asp1 APP processing activity and increased activity in the presence of the test agent identifies an agent that enhances hu-Asp1 APP processing activity.

38. A method according to claim 37, wherein the determining step
15 comprises assaying for cleavage of APP at the α -secretase processing site.

39. A method according to claim 38 wherein the determining step comprises measuring the production of amyloid alpha peptide by the cell in the presence and absence of the test agent.
20

40. A method according to claim 37, wherein the determining step comprises assaying for cleavage of APP at the β -secretase processing site.

41. A method according to claim 37, wherein the host cell expresses APP.
25

42. A method according to claim 37, wherein the host cell expresses an APP having an amino acid sequence that includes a carboxy-terminal di-lysine.

43. A method according to claim 37, wherein the host cell expresses as APP comprising the Swedish mutation (K→ N, M→L) adjacent to the β-secretase processing site.

5 44. A method according to claim 37 wherein the determining step comprises measuring the production of amyloid beta peptide by the cell in the presence and absence of the test agent.

10 45. A method according to claim 37 wherein the nucleotide sequence is selected from the group consisting of:

(a) a nucleotide sequence encoding the hu-Asp1 amino acid sequence set forth in SEQ ID NO: 2;

(b) nucleotide sequence encoding a fragment of hu-Asp1 (SEQ ID NO: 2), wherein said fragment exhibits aspartyl protease activity characteristic of hu-Asp1; and

15 (c) a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to a hu-Asp1-encoding polynucleotide (SEQ ID NO: 1).

20 46. A method according to claim 37 wherein the host cell comprises a vector that comprises the polynucleotide.

25 47. A method according to claim 37, further comprising a step for treating Alzheimer's Disease with an agent identified as a modulator of hu-Asp1 according to steps (a)-(c).

48. A method for identifying agents that modulate the APP processing activity of hu-Asp1 aspartyl protease, comprising the steps of:

(a) contacting an hu-Asp1 aspartyl protease and amyloid precursor protein (APP) in the presence and absence of a test agent, wherein the hu-Asp1 aspartyl protease is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions to a hu-Asp1-encoding polynucleotide set out as SEQ ID NO: 1;

(b) determining the APP processing activity of the hu-Asp1 aspartyl protease in the presence and absence of the test agent; and

(c) comparing the APP processing activity of the hu-Asp1 aspartyl protease in the presence of the test agent to the activity in the absence of the agent to identify agents that modulate the activity of the hu-Asp1 aspartyl protease, wherein a modulator that is an hu-Asp1 inhibitor reduces APP processing and a modulator that is an hu-Asp1 agonist increases such processing.

49. A method of claim 48, wherein the hu-Asp1 aspartyl protease is purified and isolated.

50. A method of claim 48, further comprising a step of treating Alzheimer's Disease with an agent identified as an inhibitor of hu-Asp1 according to steps (a)-(c).

51. A method of claim 48, wherein the APP processing activity of hu-Asp1 is cleavage of APP peptide within the α -secretase processing site.

52. A method of claim 48, wherein the APP processing activity of hu-Asp1 is cleavage of APP peptide at the β -secretase processing site.

53. A method for assaying hu-Asp1 α -secretase activity comprising the steps of:

(a) contacting hu-Asp1 enzyme with an amyloid precursor protein (APP) substrate, wherein said substrate contains an α -secretase cleavage site; and

5 (b) measuring cleavage of the APP substrate at the α -cleavage site, thereby assaying hu-Asp1 α -secretase activity.

54. A method according to claim 53, wherein the hu-Asp1 enzyme comprises a polypeptide produced in a cell transformed or transfected with a
10 polynucleotide comprising a nucleotide sequence that encodes hu-Asp1 or a fragment thereof that retains Asp1 α -secretase activity.

55. A method of claim 54, wherein the hu-Asp1 enzyme is purified and isolated from said cell.

56. A method according to claim 54, wherein the nucleotide sequence encodes a polypeptide that comprises the hu-Asp1 amino acid sequence set forth in
SEQ ID NO: 2 or a fragment thereof, wherein said fragment retains α -secretase activity.

57. A method according to claim 54, wherein the polynucleotide sequence encodes a hu-Asp1 amino acid sequence lacking the transmembrane amino acids 469-
492 of SEQ ID NO: 2.

58. A method according to claim 57, wherein the polynucleotide sequence encodes a hu-Asp1 amino acid sequence further lacking the cytoplasmic domain
amino acids 493-518 of SEQ ID NO: 2.

59. A method according to any one of claims 55, wherein the hu-Asp1
30 lacks amino terminal amino acids 1-62 of SEQ ID NO: 2.

60. A method according to claim 53 wherein the contacting step comprises growing a cell transfected or transformed with a polynucleotide encoding hu-Asp1 enzyme or a fragment thereof that retains hu-Asp1 α -secretase activity, wherein the cell is grown under conditions in which the cell expresses the hu-Asp1 enzyme in the presence of the APP substrate.

61. A method of claim 60, wherein said cell expresses a polynucleotide encoding an APP substrate containing an α -secretase cleavage site, and wherein the contacting step comprises growing the cell under conditions in which the cell expresses the hu-Asp1 enzyme and the APP substrate.

62. A method of claim 53, wherein the APP substrate α -secretase cleavage site comprises the amino acid sequence LVFFAEDF or KLVFFAED.

63. A method of claims 62, wherein the APP substrate comprises a detectable label.

65. A method of claim 53, wherein the detectable label is selected from the group consisting of radioactive labels, enzymatic labels and fluorescent labels.

66. A method of claim 53, wherein the APP substrate comprises a human APP isoform and further comprises a carboxy-terminal di-lysine.

67. A method of claim 53, wherein the APP substrate comprises a human APP isoform and the determining step comprises measuring the production of amyloid alpha peptide (sAPP α).

68. A method of claim 66, wherein the method further comprises steps of:
(c) determining the level of hu-Asp1 α -secretase activity in the presence and absence of a modulator of hu-Asp1 α -secretase activity; and
(d) comparing the hu-Asp1 α -secretase activity in the presence and absence of the modulator, wherein modulators that increase hu-Asp1 α -secretase activity are identified as candidate Alzheimer's disease therapeutics.

69. A method of claim 67, wherein the method further comprises a step of treating Alzheimer's Disease with said candidate Alzheimer's disease therapeutic.

70. An Asp1 protease substrate peptide or fragment thereof, wherein said peptide comprises an amino acid sequence consisting of fifty or fewer amino acid, said amino acid sequence including the Asp1 cleavage site having the amino acid sequence GLALALEP.

71. The substrate of claim 68, wherein the substrate comprises a detectable label.

72. A method for assaying hu-Asp1 proteolytic activity comprising the steps:

- (a) contacting hu-Asp1 enzyme with an Asp1 substrate according to claim 69 under acidic conditions, and
- (b) determining the level of hu-Asp1 proteolytic activity.

73. A method according to claim 72, wherein the hu-Asp1 enzyme comprises a polypeptide produced in cell transformed or transfected with a polynucleotide comprising the nucleotide sequence that encodes hu-Asp1.

74. A method of claim 72, wherein the hu-Asp1 enzyme is purified and isolated from said cell.

75. A method according to claim 73, wherein the nucleotide sequence encodes a polypeptide that comprises the hu-Asp1 amino acid sequence set forth in SEQ ID NO: 2 or a fragment thereof, wherein said fragment retains proteolytic activity.

5

76. A composition comprising an agent that modulates APP processing activity of hu-Asp1 according to the method of claim 26 in a pharmaceutically acceptable carrier.

10

77. A composition comprising an agent that modulates APP processing activity of hu-Asp1 according to the method of claim 37 in a pharmaceutically acceptable carrier.

15

78. A composition comprising an agent that modulates APP processing activity of hu-Asp1 according to the method of claim 48 in a pharmaceutically acceptable carrier.

20

0966344-092200

Abstract of the Disclosure

The present invention provides the enzyme and enzymatic procedures for cleaving the β secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. An enzyme that cleaves the α -
5 secretase site of APP also is provided. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.

0022604768960

FIGURE 1 (1)

ATGGGCGCACTGGCCCCGGGCGCTGCTGCTGCCTCTGCTGGCCCAGTGGCTCCTGCGCGCC
 M G A L A R A L L L P L L A Q W L L R A
 CCCCCGAGCTGGCCCCCGCGCCCTTCACGCTGCCCTCCGGGTGGCCGCGGCCACGAAC
 A P E L A P A P F T L P L R V A A A T N
 CGCGTAGTTGCGCCACCCCGGGACCCGGGACCCCTGCCGAGCGCCACGCCGACGGCTTG
 R V V A P T P G P G T P A E R H A D G L
 GCGCTCGCCCTGGAGCCTGCCCTGGCGTCCCCCGGGCGCCGCCAACTTCTTGCCCATG
 A L A L E P A L A S P A G A A N F L A M
 GTAGACAACCTGCAGGGGACTCTGGCCGCGGCTACTACCTGGAGATGCTGATCGGGACC
 V D N L Q G D S G R G Y Y L E M L I G T
 CCCCCGAGAAGCTACAGATTCTCGTTGACACTGGAAGCAGTAACCTTGCCGTGGCAGGA
 P P Q K L Q I L V D T G S S N F A V A G
 ACCCCGCACTCCTACATAGACACGTACTTTGACACAGAGAGGTCTAGCACATACCGCTCC
 T P H S Y I D T Y F D T E R S S T Y R S
 AAGGGCTTTGACGTCACAGTGAAGTACACACAAGGAAGCTGGACGGGCTTCGTTGGGGAA
 K G F D V T V K Y T Q G S W T G F V G E
 GACCTCGTCACCATCCCCAAAGGCTTCAATACTTCTTTTCTTGTCAACATTGCCACTATT
 D L V T I P K G F N T S F L V N I A T I
 TTTGAATCAGAGAATTTCTTTTTCCTGGGATTAAATGGAATGGAATACTTGGCCTAGCT
 F E S E N F F L P G I K W N G I L G L A
 TATGCCACACTTGCCAAGCCATCAAGTTCTCTGGAGACCTTCTTCGACTCCCTGGTGACA
 Y A T L A K P S S S L E T F F D S L V T
 CAAGCAAACATCCCCAACGTTTTCTCCATGCAGATGTGTGGAGCCGGCTTGCCCGTTGCT
 Q A N I P N V F S M Q M C G A G L P V A
 GGATCTGGGACCAACGGAGGTAGTCTTGTCTTGGGTGGAATTGAACCAAGTTTGTATAAA
 G S G T N G G S L V L G G I E P S L Y K
 GGAGACATCTGGTATACCCCTATTAAGGAAGAGTGGTACTACCAGATAGAAATTCTGAAA
 G D I W Y T P I K E E W Y Y Q I E I L K
 TTGGAAATTTGGAGGCCAAAGCCTTAATCTGGACTGCAGAGAGTATAACGCAGACAAGGCC
 L E I G G Q S L N L D C R E Y N A D K A
 ATCGTGGACAGTGGCACCAACGCTGCTGCGCCTGCCCCAGAAGGTGTTTGATGCGGTGGTG
 I V D S G T T L L R L P Q K V F D A V V
 GAAGCTGTGGCCCGCGCATCTCTGATTCCAGAATTCTCTGATGGTTTCTGGACTGGGTCC
 E A V A R A S L I P E F S D G F W T G S
 CAGCTGGCGTGCTGGACGAATTCGGAACACCTTGGTCTTACTTCCCTAAAAATCTCCATC
 Q L A C W T N S E T P W S Y F P K I S I
 TACCTGAGAGATGAGAACTCCAGCAGGTCAATTCGTATCACAATCCTGCCTCAGCTTTAC
 Y L R D E N S S R S F R I T I L P Q L Y
 ATTCAGCCCATGATGGGGGCGGCGCTGAATTATGAATGTTACCGATTTCGGCATTTCCTCCA
 I Q P M M G A G L N Y E C Y R F G I S P

TCCACAAATGCGCTGGTGATCGGTGCCACGGTGATGGAGGGCTTCTACGTCATCTTCGAC
S T N A L V I G A T V M E G F Y V I F D
AGAGCCCAGAAGAGGGTGGGCTTCGCAGCGAGCCCCCTGTGCAGAAATTGCAGGTGCTGCA

002250"428960

FIGURE 1 (2)

R A Q K R V G F A A S P C A E I A G A A
GTGTCTGAAATTTCCGGGCCTTTCTCAACAGAGGATGTAGCCAGCAACTGTGTCCCCGCT
V S E I S G P F S T E D V A S N C V P A
CAGTCTTTGAGCGAGCCCATTGTTGTGGATTGTGTCCTATGCGCTCATGAGCGTCTGTGGA
Q S L S E P I L W I V S Y A L M S V C G
GCCATCCTCCTTGCTTAATCGTCCTGCTGCTGCTGCCGTTCCGGTGTCAGCGTCGCCCC
A I L L V L I V L L L L P F R C Q R R P
CGTGACCCTGAGGTCGTCAATGATGAGTCCTCTCTGGTCAGACATCGCTGGAAATGAATA
R D P E V V N D E S S L V R H R W K
GCCAGGCCTGACCTCAAGCAACCATGAACTCAGCTATTAAGAAAATCACATTTCCAGGGC
AGCAGCCGGGATCGATGGTGGCGCTTTCTCCTGTGCCCACCCGTCTTCAATCTCTGTTCT
GCTCCCAGATGCCTTCTAGATTCACTGTCTTTTGATTCTTGATTTTCAAGCTTTCAAATC
CTCCCTACTTCCAAGAAAAATAATTAAAAAAAAAACTTCATTCTAAACCAAAAAAAAAAAAA
AAAA

FIGURE 2 (1)

ATGGCCCAAGCCCTGCCCTGGCTCCTGCTGTGGATGGGCGCGGGAGTGCTGCCTGCCCAC
 M A Q A L P W L L L W M G A G V L P A H
 GGCACCCAGCACGGCATCCGGCTGCCCCTGCGCAGCGGCCTGGGGGGCGCCCCCTGGGG
 G T Q H G I R L P L R S G L G G A P L G
 CTGCGGCTGCCCCGGGAGACCGACGAAGAGCCCGAGGAGCCCGGCCGGAGGGGCAGCTTT
 L R L P R E T D E E P E E P G R R G S F
 GTGGAGATGGTGGACAACCTGAGGGGCAAGTCGGGGCAGGGCTACTACGTGGAGATGACC
 V E M V D N L R G K S G Q G Y Y V E M T
 GTGGGCAGCCCCCGCAGACGCTCAACATCCTGGTGGATACAGGCAGCAGTAACTTTGCA
 V G S P P Q T L N I L V D T G S S N F A
 GTGGGTGCTGCCCCCACCCTTCTCCTGCATCGCTACTACCAGAGGCAGCTGTCCAGCACA
 V G A A P H P F L H R Y Y Q R Q L S S T
 TACCGGGACCTCCGGAAGGGTGTGTATGTGCCCTACACCCAGGGCAAGTGGGAAGGGGAG
 Y R D L R K G V Y V P Y T Q G K W E G E
 CTGGGCACCGACCTGGTAAGCATCCCCCATGGCCCCAACGTCAGTGTGCGTGCCAACATT
 L G T D L V S I P H G P N V T V R A N I
 GCTGCCATCACTGAATCAGACAAGTTCTTCATCAACGGCTCCAAGTGGGAAGGCATCCTG
 A A I T E S D K F F I N G S N W E G I L
 GGGCTGGCCTATGCTGAGATTGCCAGGCTTTGTGGTGCTGGCTTCCCCCTCAACCAGTCT
 G L A Y A E I A R L C G A G F P L N Q S
 GAAGTGCTGGCCTCTGTGCGGAGGGAGCATGATCATTGGAGGTATCGACCACTCGCTGTAC
 E V L A S V G G S M I I G G I D H S L Y
 ACAGGCAGTCTCTGGTATACACCCATCCGGCGGGAGTGGTATTATGAGGTGATCATTGTG
 T G S L W Y T P I R R E W Y Y E V I I V
 CGGGTGGAGATCAATGGACAGGATCTGAAAATGGACTGCAAGGAGTACAACCTATGACAAG
 R V E I N G Q D L K M D C K E Y N Y D K
 AGCATTGTGGACAGTGGCACCACCAACCTTCGTTTGCCCCAAGAAAGTGTTTGAAGCTGCA
 S I V D S G T T N L R L P K K V F E A A
 GTCAAATCCATCAAGGCAGCCTCCTCCACGGAGAAGTTCCCTGATGGTTTCTGGCTAGGA
 V K S I K A A S S T E K F P D G F W L G
 GAGCAGCTGGTGTGCTGGCAAGCAGGCACCACCCCTTGGAACATTTTCCCAGTCATCTCA
 E Q L V C W Q A G T T P W N I F P V I S
 CTCTACCTAATGGGTGAGGTTACCAACCAGTCCTTCCGCATCACCATCCTTCCGCAGCAA
 L Y L M G E V T N Q S F R I T I L P Q Q
 TACCTGCGGCCAGTGGAAGATGTGGCCACGTCCCAAGACGACTGTTACAAGTTTGCCATC

FIGURE 2 (2)

Y L R P V E D V A T S Q D D C Y K F A I
TCACAGTCATCCACGGGCACTGTTATGGGAGCTGTTATCATGGAGGGCTTCTACGTTGTC
S Q S S T G T V M G A V I M E G F Y V V
TTTGATCGGGCCCCGAAAACGAATTGGCTTTGCTGTCAGCGCTTGCCATGTGCACGATGAG
F D R A R K R I G F A V S A C H V H D E
TTCAGGACGGCAGCGGTGGAAGGCCCTTTTGTACCTTGGACATGGAAGACTGTGGCTAC
F R T A A V E G P F V T L D M E D C G Y
AACATTCCACAGACAGATGAGTCAACCCTCATGACCATAGCCTATGTCATGGCTGCCATC
N I P Q T D E S T L M T I A Y V M A A I
TGCGCCCTCTTCATGCTGCCACTCTGCCTCATGGTGTGTCAGTGGCGCTGCCTCCGCTGC
C A L F M L P L C L M V C Q W R C L R C
CTGCGCCAGCAGCATGATGACTTTGCTGATGACATCTCCCTGCTGAAGTGAGGAGGCCCA
L R Q Q H D D F A D D I S L L K
TGGGCAGAAGATAGAGATTCCCCTGGACCACACCTCCGTGGTTCACCTTTGGTCACAAGTA
GGAGACACAGATGGCACCTGTGGCCAGAGCACCTCAGGACCCTCCCCACCCACCAAATGC
CTCTGCCCTTGATGGAGAAGGAAAAGGCTGGCAAGGTGGGTTCAGGGACTGTACCTGTAG
GAAACAGAAAAGAGAAGAAAGAAGCACTCTGCTGGCGGGAATACTCTTGGTACCTCAAA
TTTAAGTCGGGAAATTCTGCTGCTTGAACTTCAGCCCTGAACCTTTGTCCACCATTCCT
TTAAATTCTCCAACCCAAAGTATTCTTCTTTTCTTAGTTTCAGAAGTACTGGCATCACAC
GCAGGTTACCTTGGCGTGTGTCCCTGTGGTACCCTGGCAGAGAAGAGACCAAGCTTGTTT
CCCTGCTGGCCAAAGTCAGTAGGAGAGGATGCACAGTTTGCTATTTGCTTTAGAGACAGG
GACTGTATAACAAGCCTAACATTGGTGCAAAGATTGCCTCTTGAAAAAAAAAAAAA

FIGURE 3 (1)

ATGGCCCAAGCCCTGCCCTGGCTCCTGCTGTGGATGGGCGCGGGAGTGCTGCCTGCCAC
M A Q A L P W L L L W M G A G V L P A H

GGCACCCAGCACGGCATCCGGCTGCCCCCTGCGCAGCGGCCTGGGGGGCGCCCCCCTGGGG
G T Q H G I R L P L R S G L G G A P L G

CTGCGGCTGCCCCGGGAGACCGACGAAGAGCCCGAGGAGCCCGGCCGGAGGGGCAGCTTT
L R L P R E T D E E P E E P G R R G S F

GTGGAGATGGTGGACAACCTGAGGGGCAAGTCGGGGCAGGGCTACTACGTGGAGATGACC
V E M V D N L R G K S G Q G Y Y V E M T

GTGGGCAGCCCCCGCAGACGCTCAACATCCTGGTGGATACAGGCAGCAGTAACTTTGCA
V G S P P Q T L N I L V D T G S S N F A

GTGGGTGCTGCCCCCACCCTTCCTGCATCGCTACTACCAGAGGCAGCTGTCCAGCACA
V G A A P H P F L H R Y Y Q R Q L S S T

TACCGGGACCTCCGGAAGGGTGTGTATGTGCCCTACACCCAGGGCAAGTGGGAAGGGGAG
Y R D L R K G V Y V P Y T Q G K W E G E

CTGGGCACCGACCTGGTAAGCATCCCCCATGGCCCCAACGTCACTGTGCGTGCCAACATT
L G T D L V S I P H G P N V T V R A N I

GCTGCCATCACTGAATCAGACAAGTTCTTCATCAACGGCTCCAACCTGGGAAGGCATCCTG
A A I T E S D K F F I N G S N W E G I L

GGGCTGGCCTATGCTGAGATTGCCAGGCCTGACGACTCCCTGGAGCCTTTCTTTGACTCT
G L A Y A E I A R P D D S L E P F F D S

CTGGTAAAGCAGACCCACGTTCCCAACCTCTTCTCCCTGCAGCTTTGTGGTGCTGGCTTC
L V K Q T H V P N L F S L Q L C G A G F

CCCCTCAACCAGTCTGAAGTGCTGGCCTCTGTGCGAGGGAGCATGATCATTGGAGGTATC
P L N Q S E V L A S V G G S M I I G G I

GACCACTCGCTGTACACAGGCAGTCTCTGGTATACACCCATCCGGCGGGAGTGGTATTAT
D H S L Y T G S L W Y T P I R R E W Y Y

GAGGTCATCATTGTGCGGGTGGAGATCAATGGACAGGATCTGAAAATGGACTGCAAGGAG
E V I I V R V E I N G Q D L K M D C K E

TACAACTATGACAAGAGCATTGTGGACAGTGGCACCACCAACCTTCGTTTGCCCAAGAAA
Y N Y D K S I V D S G T T N L R L P K K

GTGTTTGAAGCTGCAGTCAAATCCATCAAGGCAGCCTCCTCCACGGAGAAGTTCCCTGAT
V F E A A V K S I K A A S S T E K F P D

FIGURE 3 (2)

GGTTTCTGGCTAGGAGAGCAGCTGGTGTGCTGGCAAGCAGGCACCACCCCTTGGAACATT
G F W L G E Q L V C W Q A G T T P W N I

TTCCCAGTCATCTCACTCTACCTAATGGGTGAGGTTACCAACCAGTCCTTCCGCATCACC
F P V I S L Y L M G E V T N Q S F R I T

ATCCTTCCGCAGCAATACCTGCGGCCAGTGGAAGATGTGGCCACGTCCCAAGACGACTGT
I L P Q Q Y L R P V E D V A T S Q D D C

TACAAGTTTGCCATCTCACAGTCATCCACGGGCACTGTTATGGGAGCTGTTATCATGGAG
Y K F A I S Q S S T G T V M G A V I M E

GGCTTCTACGTTGTCTTTGATCGGGCCCGAAAACGAATTGGCTTTGCTGTCAGCGCTTGC
G F Y V V F D R A R K R I G F A V S A C

CATGTGCACGATGAGTTCAGGACGGCAGCGGTGGAAGGCCCTTTTGTACCTTGGACATG
H V H D E F R T A A V E G P F V T L D M

GAAGACTGTGGCTACAACATTCCACAGACAGATGAGTCAACCCTCATGACCATAGCCTAT
E D C G Y N I P Q T D E S T L M T I A Y

GTCATGGCTGCCATCTGCGCCCTCTTCATGCTGCCACTCTGCCTCATGGTGTGTGCTAGTGG
V M A A I C A L F M L P L C L M V C Q W

CGCTGCCTCCGCTGCCTGCGCCAGCAGCATGATGACTTTGCTGATGACATCTCCCTGCTG
R C L R C L R Q Q H D D F A D D I S L L

AAGTGAGGAGGCCCATGGGCAGAAGATAGAGATTCCCCTGGACCACACCTCCGTGGTTCA
K

CTTTGGTCAACAAGTAGGAGACACAGATGGCACCTGTGGCCAGAGCACCTCAGGACCCTCC
CCACCCACCAAATGCCTCTGCCTTGATGGAGAAGGAAAAGGCTGGCAAGGTGGGTTCAG
GGACTGTACCTGTAGGAAACAGAAAAGAGAAGAAAGAAGCACTCTGCTGGCGGGAATACT
CTTGGTCACTCAAATTTAAGTCGGGAAATTCTGCTGCTTGAACTTCAGCCCTGAACCT
TTGTCCACCATTCCTTTAAATTCTCCAACCCAAAGTATTCTTCTTTTCTTAGTTTCAGAA
GTACTGGCATCACACGCAGGTTACCTTGGCGTGTGTCCCTGTGGTACCCTGGCAGAGAAG
AGACCAAGCTTTGTTTCCCTGCTGGCCAAAGTCAGTAGGAGAGGATGCACAGTTTGCTATT
TGCTTTAGAGACAGGGACTGTATAAACAAGCCTAACATTGGTGCAAAGATTGCCTCTTGA
ATTAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

FIGURE 4

ATGGCCCCAGCGCTGCACTGGCTCCTGCTATGGGTGGGCTCGGGAATGCTGCCTGCCAG
 M A P A L H W L L L W V G S G M L P A Q
 GGAACCCATCTCGGCATCCGGCTGCCCTTCGAGCGGCTGGCAGGGCCACCCCTGGGC
 G T H L G I R L P L R S G L A G P P L G
 CTGAGGCTGCCCCGGGAGACTGACGAGGAATCGGAGGAGCCTGGCCGGAGAGGCAGCTTT
 L R L P R E T D E E S E E P G R R G S F
 GTGGAGATGGTGGACAACCTGAGGGGAAAGTCCGGCCAGGGCTACTATGTGGAGATGACC
 V E M V D N L R G K S G Q G Y Y V E M T
 GTAGGCAGCCCCCACAGACGCTCAACATCCTGGTGGACACGGGCAGTAGTAACCTTTGCA
 V G S P P Q T L N I L V D T G S S N F A
 GTGGGGGCTGCCCCACACCTTTCTTCGATCGCTACTACCAGAGGCAGCTGTCCAGCACA
 V G A A P H P F L H R Y Y Q R Q L S S T
 TATCGAGACCTCCGAAAGGGTGTGTATGTGCCCTACACCCAGGGCAAGTGGGAGGGGGAA
 Y R D L R K G V Y V P Y T Q G K W E G E
 CTGGGCACCGACCTGGTGGCATCCCTCATGGCCCCAACGTCAGTGTGCGTGCCAACTT
 L G T D L V S I P H G P N V T V R A N I
 GCTGCCATCACTGAATCGGACAAGTTCTTCATCAATGGTTCCAAGTGGGAGGGCATCCTA
 A A I T E S D K F F I N G S N W E G I L
 GGGCTGGCCTATGCTGAGATTGCCAGGCCCGACGACTCTTTGGAGCCCTTCTTTGACTCC
 G L A Y A E I A R P D D S L E P F F D S
 CTGGTGAAGCAGACCCACATTCCTCAACATCTTTTCCCTGCAGCTCTGTGGCGCTGGCTTC
 L V K Q T H I P N I F S L Q L C G A G F
 CCCCTCAACCAGACCGAGGCACTGGCCTCGGTGGGAGGGAGCATGATCATTGGTGGTATC
 P L N Q T E A L A S V G G S M I I G G I
 GACCACTCGTATACACGGGCAGTCTCTGGTACACACCCATCCGGCGGGAGTGGTATTAT
 D H S L Y T G S L W Y T P I R R E W Y Y
 GAAGTGATCATTGTACGTGTGGAAATCAATGGTCAAGATCTCAAGATGGACTGCAAGGAG
 E V I I V R V E I N G Q D L K M D C K E
 TACAACTACGACAAGAGCATTGTGGACAGTGGGACCACCAACCTTCGCTTGCCCAAGAAA
 Y N Y D K S I V D S G T T N L R L P K K
 GTATTTGAAGCTGCCGTCAAGTCCATCAAGGCAGCCTCCTCGACGGAGAAGTTCCCGGAT
 V F E A A V K S I K A A S S T E K F P D
 GGCTTTTGGCTAGGGGAGCAGCTGGTGTGCTGGCAAGCAGGCACGACCCCTTGGAACATT
 G F W L G E Q L V C W Q A G T T P W N I
 TTCCAGTCATTTCACTTTACCTCATGGGTGAAGTCACCAATCAGTCTTCCGCATCACC
 F P V I S L Y L M G E V T N Q S F R I T
 ATCTTCTCAGCAATACCTACGGCCGGTGGAGGACGTGGCCACGTCCCAAGACGACTGT
 I L P Q Q Y L R P V E D V A T S Q D D C
 TACAAGTTCTGCTGTCTCACAGTCATCCACGGGCACTGTTATGGGAGCCGTATCATGGAA
 Y K F A V S Q S S T G T V M G A V I M E
 GGTTTCTATGTCGTCTTCGATCGAGCCCCGAAAGCGAATTGGCTTTGCTGTGACGCTTGC
 G F Y V V F D R A R K R I G F A V S A C
 CATGTGCACGATGAGTTTCAGGACGGCGGCAGTGGGAAGGTCCGTTTGTACGGCAGACATG
 H V H D E F R T A A V E G P F V T A D M
 GAAGACTGTGGCTACAACATTCCCCAGACAGATGAGTCAACACTTATGACCATAGCCTAT
 E D C G Y N I P Q T D E S T L M T I A Y
 GTCATGGCGGCCATCTGCGCCCTCTTCATGTTGCCACTCTGCCTCATGGTATGTGAGTGG
 V M A A I C A L F M L P L C L M V C Q W
 CGCTGCCTGCGTTGCTGCGCCACCAGCAGATGACTTTGCTGATGACATCTCCCTGCTC
 R C L R C L R H Q H D D F A D D I S L L
 AAGTAAGGAGGCTCGTGGGCAGATGATGGAGACGCCCCCTGGACCACATCTGGGTGGTTCC
 K
 CTTTGGTCACATGAGTTGGAGCTATGGATGGTACCTGTGGCCAGAGCACCTCAGGACCCT
 CACCAACCTGCCAATGCTTCTGGCGTGACAGAACAGAGAAATCAGGCAAGCTGGATTACA
 GGGCTTGCACCTGTAGGACACAGGAGAGGGGAAGCAAGCAGCGTTCTGGTGGCAGGAATAT
 CCTTAGGCACCACAACTTGAGTTGGAAATTTTGTGCTTGAAGCTTCAGCCCTGACCCT
 CTGCCCAGCATCCTTTAGAGTCTCCAACCTAAAGTATTCTTTATGTCTTCCAGAAGTAC

TGGCGTCATACTCAGGCTACCCGGCATGTGTCCCTGTGGTACCCTGGCAGAGAAAGGGCC
AATCTCATTCCCTGCTGGCCAAAGTCAGCAGAAGAAGGTGAAGTTGCCAGTTGCTTTAG
TGATAGGGACTGCAGACTCAAGCCTACACTGGTACAAAGACTGCGTCTTGAGATAAACAA
GAA

002250428960
096334 092200

FIGURE 5

```

1 MAQALPWLLLWMGAGVLP AHGTQH GIRLPLRSGLG GAPLGLRLPRETDEE 50
  ||||| . . . ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1 MAPALHWLLLWVGSGMLPAQGTHL GIRLPLRSGLAGPPLGLRLPRETDEE 50
  ||||| . . . ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
51 PEEPGRRGSFVEMVDNLRGKSGQGYVEMTVGSP PQTNLILVDTGSSNFA 100
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
51 SEEPGRRGSFVEMVDNLRGKSGQGYVEMTVGSP PQTNLILVDTGSSNFA 100
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
101 VGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGWEGELGTDLV SIPH 150
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
101 VGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGWEGELGTDLV SIPH 150
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
151 GPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDS 200
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
151 GPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDS 200
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
201 LVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHS LYTGSLW 250
  ||||| : ||| : ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
201 LVKQTHIPNIFSLQLCGAGFPLNQTEALASVGGSMIIGGIDHS LYTGSLW 250
  ||||| : ||| : ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
251 YTPIRREWYIEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLR LRPKK 300
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
251 YTPIRREWYIEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLR LRPKK 300
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
301 VFEEAAVKSIIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLY LMG 350
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
301 VFEEAAVKSIIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLY LMG 350
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
351 EVTNQSFRTILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIME 400
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| : |||||
351 EVTNQSFRTILPQQYLRPVEDVATSQDDCYKFAVSQSSTGTVMGAVIME 400
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| : |||||
401 GFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQT 450
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
401 GFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTADMEDCGYNIPQT 450
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
451 DESTLMTIAYVMAAICALFMLPLCLMVCQWRCLRCLRQHQHDDFADDISLL 500
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
451 DESTLMTIAYVMAAICALFMLPLCLMVCQWRCLRCLRHQHDDFADDISLL 500
  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
501 K 501
  |
501 K 501

```

FIGURE 6 (1)

ATGGCTAGCATGACTGGTGGACAGCAAATGGGTGCGGGATCCACCCAGCACGGCATCCGG
M A S M T G G Q Q M G R G S T Q H G I R

CTGCCCCGCGCAGCGGCCTGGGGGGCGCCCCCTGGGGCTGCGGCTGCCCCGGGAGACC
L P L R S G L G G A P L G L R L P R E T

GACGAAGAGCCCGAGGAGCCCGGCCGGAGGGGCAGCTTTGTGGAGATGGTGGACAACCTG
D E E P E E P G R R G S F V E M V D N L

AGGGGCAAGTCGGGGCAGGGCTACTACGTGGAGATGACCGTGGGCAGCCCCCGCAGACG
R G K S G Q G Y Y V E M T V G S P P Q T

CTCAACATCCTGGTGGATACAGGCAGCAGTAACCTTTGCAGTGGGTGCTGCCCCCACCC
L N I L V D T G S S N F A V G A A P H P

TTCCTGCATCGCTACTACCAGAGGCAGCTGTCCAGCACATACCGGGACCTCCGGAAGGGC
F L H R Y Y Q R Q L S S T Y R D L R K G

GTGTATGTGCCCTACACCCAGGGCAAGTGGGAAGGGGAGCTGGGCACCGACCTGGTAAGC
V Y V P Y T Q G K W E G E L G T D L V S

ATCCCCCATGGCCCCAACGTCACTGTGCGTGCCAACATTGCTGCCATCACTGAATCAGAC
I P H G P N V T V R A N I A A I T E S D

AAGTTCTTCATCAACGGCTCCAAGTGGGAAGGCATCCTGGGGCTGGCCTATGCTGAGATT
K F F I N G S N W E G I L G L A Y A E I

GCCAGGCCTGACGACTCCCTGGAGCCTTTCTTTGACTCTCTGGTAAAGCAGACCCACGTT
A R P D D S L E P F F D S L V K Q T H V

CCCAACCTCTTCTCCCTGCAGCTTTGTGGTGGCTGGCTTCCCCCTCAACCAGTCTGAAGTG
P N L F S L Q L C G A G F P L N Q S E V

CTGGCCTCTGTGCGAGGGAGCATGATCATTGGAGGTATCGACCACTCGCTGTACACAGGC
L A S V G G S M I I G G I D H S L Y T G

AGTCTCTGGTATACACCCATCCGGCGGGAGTGGTATTATGAGGTCATCATTGTGCGGGTG
S L W Y T P I R R E W Y Y E V I I V R V

GAGATCAATGGACAGGATCTGAAAATGGACTGCAAGGAGTACAACCTATGACAAGAGCATT
E I N G Q D L K M D C K E Y N Y D K S I

GTGGACAGTGGCACCACCAACCTTCGTTTGCCCAAGAAAGTGTGGAAGCTGCAGTCAAA
V D S G T T N L R L P K K V F E A A V K

TCCATCAAGGCAGCCTCCTCCACGGAGAAGTTCCCTGATGGTTTCTGGCTAGGAGAGCAG
S I K A A S S T E K F P D G F W L G E Q

CTGGTGTGCTGGCAAGCAGGCACCACCCCTTGGAAACATTTTCCCAGTCATCTCACTCTAC
L V C W Q A G T T P W N I F P V I S L Y

CTAATGGGTGAGGTTACCAACCAGTCCTTCCGCATCACCATCCTTCCGCAGCAATACCTG
L M G E V T N Q S F R I T I L P Q Q Y L

CGGCCAGTGGAAGATGTGGCCACGTCCCAAGACGACTGTTACAAGTTTGCCATCTCACAG

FIGURE 6 (2)

R P V E D V A T S Q D D C Y K F A I S Q
TCATCCACGGGCACTGTTATGGGAGCTGTTATCATGGAGGGCTTCTACGTTGTCTTTGAT
S S T G T V M G A V I M E G F Y V V F D
CGGGCCCGAAAACGAATTGGCTTTGCTGTCAGCGCTTGCCATGTGCACGATGAGTTCAGG
R A R K R I G F A V S A C H V H D E F R
ACGGCAGCGGTGGAAGGCCCTTTTGTACCTTGGACATGGAAGACTGTGGCTACAACATT
T A A V E G P F V T L D M E D C G Y N I
CCACAGACAGATGAGTCATGA
P Q T D E S *

FIGURE 7 (1)

ATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGCGGATCGATGACTATCTCTGACTCT
M A S M T G G Q Q M G R G S M T I S D S

CCGCGTGAACAGGACGGATCCACCCAGCACGGCATCCGGCTGCCCTGCGCAGCGGCCTG
P R E Q D G S T Q H G I R L P L R S G L

GGGGGCGCCCCCTGGGGCTGCGGCTGCCCCGGGAGACCGACGAAGAGCCCAGGAGCCC
G G A P L G L R L P R E T D E E P E E P

GGCCGGAGGGGCAGCTTTGTGGAGATGGTGGACAACCTGAGGGGCAAGTCGGGGCAGGGC
G R R G S F V E M V D N L R G K S G Q G

TACTACGTGGAGATGACCGTGGGCAGCCCCCGCAGACGCTCAACATCCTGGTGGATACA
Y Y V E M T V G S P P Q T L N I L V D T

GGCAGCAGTAACTTTGCAGTGGGTGCTGCCCCCACCCTTCCTGCATCGCTACTACCAG
G S S N F A V G A A P H P F L H R Y Y Q

AGGCAGCTGTCCAGCACATACCGGGACCTCCGGAAGGGCGTGATGTGCCCTACACCCAG
R Q L S S T Y R D L R K G V Y V P Y T Q

GGCAAGTGGGAAGGGGAGCTGGGCACCGACCTGGTAAGCATCCCCATGGCCCCAACGTC
G K W E G E L G T D L V S I P H G P N V

ACTGTGCGTGCCAACATTGCTGCCATCACTGAATCAGACAAGTTCTTCATCAACGGCTCC
T V R A N I A A I T E S D K F F I N G S

AACTGGGAAGGCATCCTGGGGCTGGCCTATGCTGAGATTGCCAGGCCTGACGACTCCCTG
N W E G I L G L A Y A E I A R P D D S L

GAGCCTTTCTTTGACTCTCTGGTAAAGCAGACCCACGTTCCCAACCTCTTCTCCCTGCAG
E P F F D S L V K Q T H V P N L F S L Q

CTTTGTGGTGGCTGGCTTCCCCCTCAACCAGTCTGAAGTGGCTGGCCTCTGTGCGGAGGGAGC
L C G A G F P L N Q S E V L A S V G G S

ATGATCATTGGAGGTATCGACCACTCGCTGTACACAGGCAGTCTCTGGTATACACCCATC
M I I G G I D H S L Y T G S L W Y T P I

CGGCGGGAGTGGTATTATGAGGTCATCATTGTGCGGGTGGAGATCAATGGACAGGATCTG
R R E W Y Y E V I I V R V E I N G Q D L

AAAATGGACTGCAAGGAGTACAACATATGACAAGAGCATTGTGGACAGTGGCACCACCAAC
K M D C K E Y N Y D K S I V D S G T T N

CTTCGTTTGGCCAAGAAAGTGTGTTGAAGCTGCAGTCAAATCCATCAAGGCAGCCTCCTCC
L R L P K K V F E A A V K S I K A A S S

ACGGAGAAGTTCCCTGATGGTTTCTGGCTAGGAGAGCAGCTGGTGTGCTGGCAAGCAGGC
T E K F P D G F W L G E Q L V C W Q A G

ACCACCCCTTGAACATTTTCCCAGTCATCTCACTCTACCTAATGGGTGAGGTTACCAAC
T T P W N I F P V I S L Y L M G E V T N

FIGURE 7 (2)

CAGTCCTTCCGCATCACCATCCTTCCGCAGCAATACCTGCGGCCAGTGGGAAGATGTGGCC
Q S F R I T I L P Q Q Y L R P V E D V A

ACGTCCCAAGACGACTGTTACAAGTTTGCCATCTCACAGTCATCCACGGGCACTGTTATG
T S Q D D C Y K F A I S Q S S T G T V M

GGAGCTGTTATCATGGAGGGCTTCTACGTTGTCTTTGATCGGGCCCCGAAAACGAATTGGC
G A V I M E G F Y V V F D R A R K R I G

TTTGCTGTCAGCGCTTGCCATGTGCACGATGAGTTCAGGACGGCAGCGGTGGAAGGCCCT
F A V S A C H V H D E F R T A A V E G P

TTTGTCACCTTGGACATGGAAGACTGTGGCTACAACATTCCACAGACAGATGAGTCATGA
F V T L D M E D C G Y N I P Q T D E S *

002260-4E8960

FIGURE 8 (1)

ATGACTCAGCATGGTATTCGTCTGCCACTGCGTAGCGGTCTGGGTGGTGCTCCACTGGGT
 M T Q H G I R L P L R S G L G G A P L G -
 CTGCGTCTGCCCCGGGAGACCGACGAAGAGCCCGAGGAGCCCGGCCGGAGGGGCAGCTTT
 L R L P R E T D E E P E E P G R R G S F -
 GTGGAGATGGTGGACAACCTGAGGGGCAAGTCGGGGCAGGGCTACTACGTGGAGATGACC
 V E M V D N L R G K S G Q G Y Y V E M T -
 GTGGGCAGCCCCCGCAGACGCTCAACATCCTGGTGGATACAGGCAGCAGTAACCTTTGCA
 V G S P P Q T L N I L V D T G S S N F A -
 GTGGGTGCTGCCCCCACCCTTCCTGCATCGCTACTACCAGAGGCAGCTGTCCAGCACA
 V G A A P H P F L H R Y Y Q R Q L S S T -
 TACCGGGACCTCCGGAAGGGCGTGATGTGCCCTACACCCAGGGCAAGTGGGAAGGGGAG
 Y R D L R K G V Y V P Y T Q G K W E G E -
 CTGGGCACCGACCTGGTAAGCATCCCCCATGGCCCCAACGTCACTGTGCGTGCCAACATT
 L G T D L V S I P H G P N V T V R A N I -
 GCTGCCATCACTGAATCAGACAAGTTCTTCATCAACGGCTCCAACCTGGGAAGGCATCCTG
 A A I T E S D K F F I N G S N W E G I L -
 GGGCTGGCCTATGCTGAGATTGCCAGGCCTGACGACTCCCTGGAGCCTTTCTTTGACTCT
 G L A Y A E I A R P D D S L E P F F D S
 CTGGTAAAGCAGACCCACGTTCCCAACCTCTTCTCCCTGCAGCTTTGTGGTGCTGGCTTC
 L V K Q T H V P N L F S L Q L C G A G F -
 CCCCTCAACAGTCTGAAGTGCTGGCCTCTGTCGGAGGGAGCATGATCATTGGAGGTATC
 P L N Q S E V L A S V G G S M I I G G I -
 GACCACTCGCTGTACACAGGCAGTCTCTGGTATACACCCATCCGGCGGGAGTGGTATTAT
 D H S L Y T G S L W Y T P I R R E W Y Y -
 GAGGTCATCATTGTGCGGGTGGAGATCAATGGACAGGATCTGAAAATGGACTGCAAGGAG
 E V I I V R V E I N G Q D L K M D C K E
 TACAACTATGACAAGAGCATTGTGGACAGTGGCACCACCAACCTTCGTTTGCCCAAGAAA
 Y N Y D K S I V D S G T T N L R L P K K -
 GTGTTTGAAGCTGCAGTCAAATCCATCAAGGCAGCCTCCTCCACGGAGAAGTTCCTGAT
 V F E A A V K S I K A A S S T E K F P D -
 GGTTCCTGGCTAGGAGAGCAGCTGGTGTGCTGGCAAGCAGGCACCACCCCTTGGAACATT
 G F W L G E Q L V C W Q A G T T P W N I -
 TTCCAGTCATCTCACTCTACCTAATGGGTGAGGTTACCAACCAGTCCTTTTCGCATCACC
 F P V I S L Y L M G E V T N Q S F R I T -
 ATCCTTCCGCAGCAATACCTGCGGCCAGTGGAAGATGTGGCCACGTCCCAAGACGACTGT
 I L P Q Q Y L R P V E D V A T S Q D D C -

002260-4E8990

FIGURE 8 (2)

TACAAGTTTGCCATCTCACAGTCATCCACGGGCACTGTTATGGGAGCTGTTATCATGGAG
Y K F A I S Q S S T G T V M G A V I M E -
GGCTTCTACGTTGTCTTTGATCGGGCCCGAAAACGAATTGGCTTTGCTGTCAGCGCTTGC
G F Y V V F D R A R K R I G F A V S A C -
CATTAG
H *

FIGURE 9




FIGURE 10




FIGURE 11

MAOALPWLLLWMGAGVLPAHGTQHGI~~RLPL~~RSGLGGAPLGLRLPRETDEE
PEEPGRRGSFVEMVDNLRGKSGQGYVEMTVGSPQTLN~~ILV~~DTGSSNFA
VGAAPHPFLHRYYQ~~RQLS~~STYRDLRKGVYVPYTQGWEGELGTDLVSI~~PH~~
GPNVTVRANIAAITE~~SDKFF~~INGSNWEGILGLAYAEIARPDDSLEPFFDS
LVKQTHVPNLFS~~LQ~~LCGAGFPLNQSEVLASVGGSMIIGGIDHS~~LYT~~GS~~LW~~
YTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSI~~VDS~~GTTNLR~~L~~PKK
VF~~EAAVKS~~IK~~AAS~~TEKF~~PDG~~FWLGEQLVCWQAGTTPWNIFPVISLYLMG
EVTNQSF~~RITILP~~QQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIME
GFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQT
DES

FIGURE 12

MAOALPWLLLWMGAGVLPAGHTQHGI RLP LRSGLGGAPLGLRLPRETDEE
PEEPGRRGSFVEMVDNLRGKSGQGYVEMTVGSP PQTLN ILVDTGSSNFA
VGAAPHFPLHRYYQRQLSSTYRDLRKGVYVPYTQGWEGELGTDLVSI PH
GPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDS
LVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLW
YTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLR LPKK
VFEEAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMG
EVTNQSFRTILPQQYL RPVEDVATSQDDCYKFAISQSSTGTVMGAVIME
GFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQT
DESHHHHHH

SEQUENCE LISTING

<110> Gurney, Mark
Bienkowski, Michael J.

<120> ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR, AND USES
THEREOF

<130> 28341/6280NCP

<140>

<141>

<150> 60/169,232

<151> 1999-12-06

<150> 09/416,901

<151> 1999-10-13

<150> 60/155,493

<151> 1999-09-23

<150> 09/404,133

<151> 1999-09-23

<150> PCT/US99/20881

<151> 1999-09-23

<150> 60/101,594

<151> 1998-09-24

<160> 76

<170> PatentIn Ver. 2.0

<210> 1

<211> 1804

<212> DNA

<213> Homo sapiens

<400> 1

atggggcgac	tggcccgggc	gctgctgctg	cctctgctgg	cccagtggtt	cctgcgcgcc	60
gccccggagc	tggccccgcg	gcccttcacg	ctgcccctcc	gggtggccgc	ggccacgaac	120
cgcgtagttg	cgcccacccc	gggacccggg	acccttgccg	agcgccacgc	cgacggcttg	180
gcgctcgccc	tggagcctgc	cctggcgctc	ccgcggggcg	ccgccaactt	cttggccatg	240
gtagacaacc	tgcaggggga	ctctggccgc	ggctactacc	tggagatgct	gatcgggacc	300
ccccgcgaga	agctacagat	tctcgttgac	actggaagca	gtaactttgc	cgtggcagga	360
accgcgact	cctacataga	cacgtacttt	gacacagaga	ggtctagcac	ataccgctcc	420
aagggtcttg	acgtcacagt	gaagtacaca	caagggaagct	ggacgggctt	cgttggggaa	480
gacctcgctc	ccatcccca	aggcttcaat	acttcttttc	ttgtcaacat	tgccactatt	540
tttgaatcag	agaattttct	tttgccctgg	attaaatgga	atggaatact	tggcctagct	600
tatgccacac	ttgccaaagg	atcaagttct	ctggagacct	tcttcgactc	cctgggtgaca	660
caagcaaaca	tccccaacgt	tttctccatg	cagatgtgtg	gagccgggct	gcccgttgct	720
ggatctggga	ccaacggagg	tagtcttgct	ttgggtggaa	ttgaaccaag	tttgataaaa	780
ggagacatct	ggtatacccc	tattaaggaa	gagtgtgact	accagataga	aattctgaaa	840
ttggaaattg	gaggccaaa	ccttaattct	gactgcagag	agtataacgc	agacaaggcc	900
atcgctggaca	gtggcaccac	gctgctgcgc	ctgccccaga	aggtgtttga	tgcgggtggtg	960
gaagctgttg	cccgcgcatc	tctgattcca	gaattctctg	atgggtttctg	gactgggtcc	1020
cagctggcgt	gctggacgaa	ttcgaaaca	ccttggtctt	acttccttaa	aatctccatc	1080
tacctgagag	atgagaactc	cagcaggtca	ttccgtatca	caatcctgcc	tcagctttac	1140
attcagccca	tgatgggggc	cggcctgaat	tatgaatgtt	accgattcgg	catttcccca	1200
tccacaaatg	cgctgggtgat	cggtgccacg	gtgatggagg	gcttctacgt	catcttcgac	1260

```
<210> 2
<211> 518
<212> PRT
<213> Homo sapiens
```

<400>	2														
Met	Gly	Ala	Leu	Ala	Arg	Ala	Leu	Leu	Leu	Pro	Leu	Leu	Ala	Gln	Trp
1				5					10					15	
Leu	Leu	Arg	Ala	Ala	Pro	Glu	Leu	Ala	Pro	Ala	Pro	Phe	Thr	Leu	Pro
			20					25					30		
Leu	Arg	Val	Ala	Ala	Ala	Thr	Asn	Arg	Val	Val	Ala	Pro	Thr	Pro	Gly
		35					40					45			
Pro	Gly	Thr	Pro	Ala	Glu	Arg	His	Ala	Asp	Gly	Leu	Ala	Leu	Ala	Leu
	50					55					60				
Glu	Pro	Ala	Leu	Ala	Ser	Pro	Ala	Gly	Ala	Ala	Asn	Phe	Leu	Ala	Met
65					70					75					80
Val	Asp	Asn	Leu	Gln	Gly	Asp	Ser	Gly	Arg	Gly	Tyr	Tyr	Leu	Glu	Met
				85					90					95	
Leu	Ile	Gly	Thr	Pro	Pro	Gln	Lys	Leu	Gln	Ile	Leu	Val	Asp	Thr	Gly
			100					105					110		
Ser	Ser	Asn	Phe	Ala	Val	Ala	Gly	Thr	Pro	His	Ser	Tyr	Ile	Asp	Thr
		115					120					125			
Tyr	Phe	Asp	Thr	Glu	Arg	Ser	Ser	Thr	Tyr	Arg	Ser	Lys	Gly	Phe	Asp
	130					135					140				
Val	Thr	Val	Lys	Tyr	Thr	Gln	Gly	Ser	Trp	Thr	Gly	Phe	Val	Gly	Glu
145					150					155					160
Asp	Leu	Val	Thr	Ile	Pro	Lys	Gly	Phe	Asn	Thr	Ser	Phe	Leu	Val	Asn
				165					170					175	
Ile	Ala	Thr	Ile	Phe	Glu	Ser	Glu	Asn	Phe	Phe	Leu	Pro	Gly	Ile	Lys
			180					185					190		
Trp	Asn	Gly	Ile	Leu	Gly	Leu	Ala	Tyr	Ala	Thr	Leu	Ala	Lys	Pro	Ser
		195					200					205			
Ser	Ser	Leu	Glu	Thr	Phe	Phe	Asp	Ser	Leu	Val	Thr	Gln	Ala	Asn	Ile
	210					215					220				
Pro	Asn	Val	Phe	Ser	Met	Gln	Met	Cys	Gly	Ala	Gly	Leu	Pro	Val	Ala
225					230					235					240

Gly Ser Gly Thr Asn Gly Gly Ser Leu Val Leu Gly Gly Ile Glu Pro
245 250 255

Ser Leu Tyr Lys Gly Asp Ile Trp Tyr Thr Pro Ile Lys Glu Glu Trp
260 265 270

Tyr Tyr Gln Ile Glu Ile Leu Lys Leu Glu Ile Gly Gly Gln Ser Leu
275 280 285

Asn Leu Asp Cys Arg Glu Tyr Asn Ala Asp Lys Ala Ile Val Asp Ser
290 295 300

Gly Thr Thr Leu Leu Arg Leu Pro Gln Lys Val Phe Asp Ala Val Val
305 310 315 320

Glu Ala Val Ala Arg Ala Ser Leu Ile Pro Glu Phe Ser Asp Gly Phe
325 330 335

Trp Thr Gly Ser Gln Leu Ala Cys Trp Thr Asn Ser Glu Thr Pro Trp
340 345 350

Ser Tyr Phe Pro Lys Ile Ser Ile Tyr Leu Arg Asp Glu Asn Ser Ser
355 360 365

Arg Ser Phe Arg Ile Thr Ile Leu Pro Gln Leu Tyr Ile Gln Pro Met
370 375 380

Met Gly Ala Gly Leu Asn Tyr Glu Cys Tyr Arg Phe Gly Ile Ser Pro
385 390 395 400

Ser Thr Asn Ala Leu Val Ile Gly Ala Thr Val Met Glu Gly Phe Tyr
405 410 415

Val Ile Phe Asp Arg Ala Gln Lys Arg Val Gly Phe Ala Ala Ser Pro
420 425 430

Cys Ala Glu Ile Ala Gly Ala Ala Val Ser Glu Ile Ser Gly Pro Phe
435 440 445

Ser Thr Glu Asp Val Ala Ser Asn Cys Val Pro Ala Gln Ser Leu Ser
450 455 460

Glu Pro Ile Leu Trp Ile Val Ser Tyr Ala Leu Met Ser Val Cys Gly
465 470 475 480

Ala Ile Leu Leu Val Leu Ile Val Leu Leu Leu Leu Pro Phe Arg Cys
485 490 495

Gln Arg Arg Pro Arg Asp Pro Glu Val Val Asn Asp Glu Ser Ser Leu
500 505 510

Val Arg His Arg Trp Lys
515

<210> 3

<211> 2070

<212> DNA

<213> Homo sapiens

<400> 3

atggcccaag ccctgccctg gctcctgctg tggatgggcg cgggagtgtc gcctgcccac 60

002224-0336

```

ggcaccacagc acggcatccg gctgccccctg cgcagcggcc tgggggggcgc ccccttgggg 120
ctgcggtctgc cccgggagac cgacgaagag cccgaggagc ccggccggag gggcagcttt 180
gtggagatgg tggacaacct gaggggcaag tccgggagag gctactacgt ggagatgacc 240
gtgggcagcc cccgcagac gctcaacatc ctggtggata caggcagcag taactttgca 300
gtgggtgctg ccccccaccc cttcctgcat cgctactacc agaggcagct gtccagcaca 360
taccgggacc tccggaagg gctgtatgtg ccctacaccc agggcaagt ggaaggggag 420
ctgggcaccg acctggtaa catcccccat ggccccaacg tcaactgtgcg tgccaacatt 480
gctgccatca ctgaatcaga caagtctctc atcaacggct ccaactggga aggcacctctg 540
gggctggcct atgctgagat tgccaggcct gacgactccc tggagccttt ctttgactct 600
ctggtaaagc agaccacgt tcccaacctc ttctccctgc accttgtgg tgctggcttc 660
cccccaacc agtctgaagt gctggcctct gtcggaggga gcatgatcat tggaggatc 720
gaccactcgc tgtacacagg cagtctctgg taccaccca tccggcggga gtggtattat 780
gaggatcatca ttgtgcgggt ggagatcaat ggacaggatc tgaaaatgga ctgcaaggag 840
tacaactatg acaagagcat tgtggacagt ggcaccacca accttcgttt gcccaagaaa 900
gtgtttgaag ctgcagtcaa atccatcaag gcagcctcct ccacggagaa gttccctgat 960
gggtttctggc taggagagca gctggtgtgc tggcaagcag gcaccacccc ttggaacatt 1020
ttcccagtc tctactcta cctaattggg gaggttacca accagtcctt ccgcatcacc 1080
atccttcgc agcaatacct gcggccagt gaaagtgtgg ccacgtccca agacgactgt 1140
tacaagtttg ccatctcaca gtcacccacg ggcactgtta tgggagctgt tatcatggag 1200
ggcttctacg ttgtctttga tccggcccga aaacgaattg gctttgctgt cagcgttgc 1260
catgtgcagc atgagttcag gacggcagcg gtggaaggcc cttttgtcac cttggacatg 1320
gaagactgtg gctacaacat tccacagaca gatgagtcaa cctcatgac catagcctat 1380
gtcatggctg ccatctgcgc cctcttcag ctgccactct gcctcatggt gtgtcagtgg 1440
cgctgcctcc gctgcctgcg ccagcagcat gatgactttg ctgatgacat ctccctgctg 1500
aagtgaggag gcccatgggc agaagataga gattcccctg gaccacacct ccgtggttca 1560
ctttggtcac aagtaggaga cacagatggc acctgtggcc agagcacctc aggaccctcc 1620
ccaccacca aatgcctctg ccttgatgga gaaggaaaag gctggcaagg tgggttccag 1680
ggactgtacc ttaggaaac agaaaagaga agaaagaagc actctgctgg cgggaatact 1740
cttggtcacc tcaaatttaa gtcgggaaat tctgctgctt gaaacttcag ccctgaacct 1800
ttgtccacca ttcttttaa ttctccacc caaagtattc ttcttttctt agtttcagaa 1860
gtactggcat cacacgcagg ttaccttggc gtgtgtccct gtggtaccct ggcagagaag 1920
agaccaagct tgttccctg ctggccaaag tcagtaggag aggatgcaca gtttgctatt 1980
tgcttttagag acagggactg tataaacaag cctaacattg gtgcaaagat tgcctcttga 2040
attaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2070

```

```

<210> 4
<211> 501
<212> PRT
<213> Homo sapiens

```

```

<400> 4
Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
  1             5             10             15

Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
      20             25             30

Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
      35             40             45

Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
      50             55             60

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
      65             70             75             80

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
      85             90             95

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
      100            105            110

```

002260-4-092960

Gln Thr Asp Glu Ser Thr Leu Met Thr Ile Ala Tyr Val Met Ala Ala
 450 455 460

Ile Cys Ala Leu Phe Met Leu Pro Leu Cys Leu Met Val Cys Gln Trp
 465 470 475 480

Arg Cys Leu Arg Cys Leu Arg Gln Gln His Asp Asp Phe Ala Asp Asp
 485 490 495

Ile Ser Leu Leu Lys
 500

<210> 5
 <211> 1977
 <212> DNA
 <213> Homo sapiens

<400> 5
 atggcccaag ccctgccctg gctcctgctg tggatgggcg cgggagtgtc gcctgcccac 60
 ggcacccagc acggcatccg gctgcccctg cgcagcggcc tggggggcgc cccctggggg 120
 ctgcggtctgc cccgggagac cgacgaagag cccgaggagc ccggccggag gggcagcttt 180
 gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240
 gtgggcagcc ccccgagac gctcaacatc ctgggtggata caggcagcag taactttgca 300
 gtgggtgtctg cccccaccc ctctctgcat cgctactacc agaggcagct gtccagcaca 360
 taccgggacc tccggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 420
 ctgggcaccg acctggtaag catcccccac ggccccaacg tcaactgtgcg tgccaacatt 480
 gctgccatca ctgaatcaga caagtcttc atcaacggct ccaactggga aggcattcctg 540
 gggctggcct atgctgagat tgccaggctt tgtggtgctg gcttccccct caaccagtct 600
 gaagtgtctg cctctgtcgg agggagcatg atcattggag gtatcgacca ctgctgtac 660
 acaggcagtc tctggtatac acccatccgg cgggagtggg attatgaggt gatcattgtg 720
 cgggtggaga tcaatggaca ggatctgaaa atggactgca aggagtacaa ctatgacaag 780
 agcattgtgg acagtggcac caccaacctt cgtttgccca agaaagtgtt tgaagctgca 840
 gtcaaatcca tcaaggcagc ctctccacg gagaagttcc ctgatggttt ctggctagga 900
 gagcagctgg tgtgctggca agcaggcacc accccttggga acattttccc agtcatctca 960
 ctctaccta tgggtgaggt taccaccag tccttccgca tcaccatcct tccgcagcaa 1020
 tacctgcggc cagtgggaaga tgtggccacg tcccaagacg actgttacaa gtttgccatc 1080
 tcacagtcac ccacgggcac tgttatggga gctgttatca tggagggctt ctacgttgtc 1140
 tttgatcggg cccgaaaacg aattggcttt gctgtcagcg cttgccatgt gcacgatgag 1200
 ttcaggacgg cagcgggtga aggcctttt gtcaccttgg gtcacattgg acatggaaga ctgtggctac 1260
 aacattccac agacagatga gtcaacctc atgaccatag cctatgtcat ggctgccatc 1320
 tgcgcccctc tcatgtgtcc actctgcctc atggtgtgtc agtggcgtg cctccgctgc 1380
 ctgcccagc agcatgatga ctctgtgat gacatctccc tgctgaagtg aggaggccca 1440
 tgggcagaag atagagattc ccctggacca cacctccgtg gttcactttg gtcacaagta 1500
 ggagacacag atggcacctg tggccagagc acctcaggac cctccccacc caccaaatgc 1560
 ctctgccttg atggagaagg aaaaggctgg caaggtgggt tccagggact gtacctgtag 1620
 gaaacagaaa agagaagaaa gaagcactct gctggcggga atactcttgg tcacctcaaa 1680
 ttttaagtcgg gaaattctgc tgcttgaaac ttcagccctg aacctttgtc caccattcct 1740
 ttaaattctc caaccctaaag tattcttctt ttcttagttt cagaagtact ggcacacac 1800
 gcaggttacc ttggcgtgtg tccctgtggt accctggcag agaagagacc aagcttgttt 1860
 cctgctggc caaagtcagt aggagaggat gcacagtttg ctatttgctt tagagacagg 1920
 gactgtataa acaagcctaa cattggtgca aagattgcct cttgaaaaaa aaaaaaa 1977

<210> 6
 <211> 476
 <212> PRT
 <213> Homo sapiens

<400> 6
 Met Ala Gln Ala Leu Pro Trp Leu Leu Trp Met Gly Ala Gly Val
 1 5 10 15

CCGCGGCTGC

Leu	Pro	Ala	His 20	Gly	Thr	Gln	His	Gly 25	Ile	Arg	Leu	Pro	Leu 30	Arg	Ser
Gly	Leu	Gly 35	Gly	Ala	Pro	Leu	Gly 40	Leu	Arg	Leu	Pro	Arg 45	Glu	Thr	Asp
Glu	Glu 50	Pro	Glu	Glu	Pro	Gly 55	Arg	Arg	Gly	Ser	Phe 60	Val	Glu	Met	Val
Asp 65	Asn	Leu	Arg	Gly	Lys 70	Ser	Gly	Gln	Gly	Tyr 75	Tyr	Val	Glu	Met	Thr 80
Val	Gly	Ser	Pro	Pro 85	Gln	Thr	Leu	Asn	Ile 90	Leu	Val	Asp	Thr	Gly 95	Ser
Ser	Asn	Phe	Ala 100	Val	Gly	Ala	Ala	Pro 105	His	Pro	Phe	Leu	His 110	Arg	Tyr
Tyr	Gln	Arg 115	Gln	Leu	Ser	Ser	Thr 120	Tyr	Arg	Asp	Leu	Arg 125	Lys	Gly	Val
Tyr	Val 130	Pro	Tyr	Thr	Gln	Gly 135	Lys	Trp	Glu	Gly	Glu 140	Leu	Gly	Thr	Asp
Leu 145	Val	Ser	Ile	Pro	His 150	Gly	Pro	Asn	Val	Thr 155	Val	Arg	Ala	Asn	Ile 160
Ala	Ala	Ile	Thr 165	Glu	Ser	Asp	Lys	Phe	Phe 170	Ile	Asn	Gly	Ser	Asn 175	Trp
Glu	Gly	Ile 180	Leu	Gly	Leu	Ala	Tyr	Ala 185	Glu	Ile	Ala	Arg	Leu	Cys	Gly
Ala	Gly 195	Phe	Pro	Leu	Asn	Gln	Ser 200	Glu	Val	Leu	Ala	Ser 205	Val	Gly	Gly
Ser	Met 210	Ile	Ile	Gly	Gly	Ile 215	Asp	His	Ser	Leu	Tyr 220	Thr	Gly	Ser	Leu
Trp 225	Tyr	Thr	Pro	Ile	Arg 230	Arg	Glu	Trp	Tyr	Tyr 235	Glu	Val	Ile	Ile	Val 240
Arg	Val	Glu	Ile	Asn 245	Gly	Gln	Asp	Leu	Lys 250	Met	Asp	Cys	Lys	Glu 255	Tyr
Asn	Tyr	Asp 260	Lys	Ser	Ile	Val	Asp 265	Ser	Gly	Thr	Thr	Asn	Leu 270	Arg	Leu
Pro	Lys 275	Lys	Val	Phe	Glu	Ala	Ala 280	Val	Lys	Ser	Ile	Lys 285	Ala	Ala	Ser
Ser	Thr 290	Glu	Lys	Phe	Pro	Asp 295	Gly	Phe	Trp	Leu	Gly 300	Glu	Gln	Leu	Val
Cys 305	Trp	Gln	Ala	Gly	Thr 310	Thr	Pro	Trp	Asn	Ile 315	Phe	Pro	Val	Ile	Ser 320
Leu	Tyr	Leu	Met	Gly 325	Glu	Val	Thr	Asn	Gln 330	Ser	Phe	Arg	Ile	Thr 335	Ile
Leu	Pro	Gln 340	Gln	Tyr	Leu	Arg	Pro	Val 345	Glu	Asp	Val	Ala	Thr 350	Ser	Gln


```
<210> 8
<211> 501
<212> PRT
<213> Mus musculus
```

Met Ala Pro Ala Leu His Trp Leu Leu Leu Trp Val Gly Ser Gly Met
1 5 10 15

Gly Leu Ala Gly Pro Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
35 40 45

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
65 70 75 80

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
100 105 110

Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
130 135 140

Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
165 170 175

Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln Thr His Ile Pro
195 200 205

Thr Glu Ala Leu Ala Ser Val Gly Gly Ser Met Ile Ile Gly Gly Ile
225 230 235 240

Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln
260 265 270

Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser Ile Val
275 280 285

Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val Phe Glu Ala
290 295 300

Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp
305 310 315 320

Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr
325 330 335

Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val
340 345 350

Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg
355 360 365

Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys Phe Ala
370 375 380

Val Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile Met Glu
385 390 395 400

Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala
405 410 415

Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu
420 425 430

Gly Pro Phe Val Thr Ala Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro
435 440 445

Gln Thr Asp Glu Ser Thr Leu Met Thr Ile Ala Tyr Val Met Ala Ala
450 455 460

Ile Cys Ala Leu Phe Met Leu Pro Leu Cys Leu Met Val Cys Gln Trp
465 470 475 480

Arg Cys Leu Arg Cys Leu Arg His Gln His Asp Asp Phe Ala Asp Asp
485 490 495

Ile Ser Leu Leu Lys
500

<210> 9

<211> 2088

<212> DNA

<213> Homo sapiens

<400> 9

atgctgcccg gtttggcact gtcctgctg gccgcctgga cggctcgggc gctggaggtg 60
cccactgatg gtaatgctgg cctgctggct gaacccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaa 180
acctgcattg ataccaagga aggcacctg cagtattgcc aagaagtcta ccctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtacca tccagaactg gtgcaagcgg 300
ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg cttagtgtgt 360
gagtttgtaa gtgatgcct tctcgttcct gacaagtgca aattcttaca ccaggagagg 420
atggatgttt gcgaaactca tcttcaactg cacaccgtcg ccaaagagac atgcagttag 480
aagagtacca acttgcatga ctacggcatg ttgctgccct gcggaattga caagttccga 540
ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgttga ttctgctgat 600

0966344-092200

```

gcggaggagg atgactcgga tgtctggtgg ggccggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgccca ccaccaccac caccaccaca 840
gagtcctgtg aagaggtggt tcgagttcct acaacagcag ccagtacccc tgatgccgtt 900
gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960
gagaggcttg aggccaagca ccgagagaga atgtcccagg tcatgagaga atgggaagag 1020
gcagaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080
caggagaaaag tgggaatcttt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140
acacacatgg ccagagtggg agccatgctc aatgaccgcc gccgcctggc cctgggagaac 1200
tacatcaccg ctctgcaggc tgttcctcct cggcctcgct acgtgttcaa tatgctaaag 1260
aagtatgtcc gcgcagaaca gaaggacaga cagcacacc taaagcattt cgagcatgtg 1320
cgcatggtgg atcccaagaa agccgctcag atccgggtccc aggttatgac acacctccgt 1380
gtgatttatg agcgcatgaa tcagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440
gaggagattc aggatgaagt tgatgagctg cttcagaaaag agcaaaacta ttcagatgac 1500
gtcttgccca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgccca 1560
tctttgaccg aaacgaaaac caccgtggag ctcttcccgt tgaatggaga gttcagcctg 1620
gacgatctcc agccgtggca ttcttttggg gctgactctg tgccagccaa cacagaaaac 1680
gaagttgagc ctggtgatgc ccgcctgct gccgaccgag gactgaccac tcgaccaggt 1740
tctgggttga caaatatcaa gacggaggag atctctgaag tgaagatgga tgcagaattc 1800
cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860
ggttcaaaca aaggtgcaat cattggactc atgggtgggc gtgttgtcat agcgacagtg 1920
atcgatcatc ccttggtgat gctgaagaag aaacagtaca catccattca tcatggtgtg 1980
gtggagggtg acgcgctgt caccacagag gagcgccacc tgtccaagat gcagcagaac 2040
ggctacgaaa atccaaccta caagttcttt gagcagatgc agaactag 2088

```

<210> 10
 <211> 695
 <212> PRT
 <213> Homo sapiens

<400> 10
 Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15
 Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30
 Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45
 Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60
 Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80
 Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95
 Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110
 Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125
 Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140
 Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160

002220" 4439350

Lys	Ser	Thr	Asn	Leu	His	Asp	Tyr	Gly	Met	Leu	Leu	Pro	Cys	Gly	Ile	
			165						170					175		
Asp	Lys	Phe	Arg	Gly	Val	Glu	Phe	Val	Cys	Cys	Pro	Leu	Ala	Glu	Glu	
			180					185					190			
Ser	Asp	Asn	Val	Asp	Ser	Ala	Asp	Ala	Glu	Glu	Asp	Asp	Ser	Asp	Val	
		195					200					205				
Trp	Trp	Gly	Gly	Ala	Asp	Thr	Asp	Tyr	Ala	Asp	Gly	Ser	Glu	Asp	Lys	
	210					215					220					
Val	Val	Glu	Val	Ala	Glu	Glu	Glu	Glu	Val	Ala	Glu	Val	Glu	Glu	Glu	
225					230					235					240	
Glu	Ala	Asp	Asp	Asp	Glu	Asp	Asp	Glu	Asp	Gly	Asp	Glu	Val	Glu	Glu	
				245					250					255		
Glu	Ala	Glu	Glu	Pro	Tyr	Glu	Glu	Ala	Thr	Glu	Arg	Thr	Thr	Ser	Ile	
			260					265					270			
Ala	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Glu	Ser	Val	Glu	Glu	Val	Val	Arg	
		275					280					285				
Val	Pro	Thr	Thr	Ala	Ala	Ser	Thr	Pro	Asp	Ala	Val	Asp	Lys	Tyr	Leu	
	290					295					300					
Glu	Thr	Pro	Gly	Asp	Glu	Asn	Glu	His	Ala	His	Phe	Gln	Lys	Ala	Lys	
305					310					315					320	
Glu	Arg	Leu	Glu	Ala	Lys	His	Arg	Glu	Arg	Met	Ser	Gln	Val	Met	Arg	
				325					330					335		
Glu	Trp	Glu	Glu	Ala	Glu	Arg	Gln	Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp	
			340					345					350			
Lys	Lys	Ala	Val	Ile	Gln	His	Phe	Gln	Glu	Lys	Val	Glu	Ser	Leu	Glu	
		355					360					365				
Gln	Glu	Ala	Ala	Asn	Glu	Arg	Gln	Gln	Leu	Val	Glu	Thr	His	Met	Ala	
	370					375					380					
Arg	Val	Glu	Ala	Met	Leu	Asn	Asp	Arg	Arg	Arg	Leu	Ala	Leu	Glu	Asn	
385					390					395					400	
Tyr	Ile	Thr	Ala	Leu	Gln	Ala	Val	Pro	Pro	Arg	Pro	Arg	His	Val	Phe	
			405						410					415		
Asn	Met	Leu	Lys	Lys	Tyr	Val	Arg	Ala	Glu	Gln	Lys	Asp	Arg	Gln	His	
			420					425					430			
Thr	Leu	Lys	His	Phe	Glu	His	Val	Arg	Met	Val	Asp	Pro	Lys	Lys	Ala	
		435					440					445				
Ala	Gln	Ile	Arg	Ser	Gln	Val	Met	Thr	His	Leu	Arg	Val	Ile	Tyr	Glu	
	450					455					460					
Arg	Met	Asn	Gln	Ser	Leu	Ser	Leu	Leu	Tyr	Asn	Val	Pro	Ala	Val	Ala	
465					470					475					480	
Glu	Glu	Ile	Gln	Asp	Glu	Val	Asp	Glu	Leu	Leu	Gln	Lys	Glu	Gln	Asn	
				485					490					495		

00226944096344096344

Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser
500 505 510

Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr
515 520 525

Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln
530 535 540

Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn
545 550 555 560

Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr
565 570 575

Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser
580 585 590

Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
595 600 605

His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
610 615 620

Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
625 630 635 640

Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
645 650 655

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
660 665 670

His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
675 680 685

Phe Phe Glu Gln Met Gln Asn
690 695

<210> 11
<211> 2088
<212> DNA
<213> Homo sapiens

<400> 11
atgctgcccc gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60
cccactgatg gtaatgctgg cctgctggct gaacccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaa 180
acctgcattg ataccaagga aggcacctcg cagtattgcc aagaagtcta ccctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtgaaca tccagaactg gtgcaagcgg 300
ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg cttagttagt 360
gagtttgtaa gtgatgccct tctcgttccg gacaagtgca aattcttaca ccaggagagg 420
atggatgttt gcgaaactca tcttccactgg cacaccgtcg ccaaagagac atgcagttag 480
aagagtacca acttgcatga ctacggcatg ttgctgccct gcggaattga caagttccga 540
ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
gcggaggagg atgactcgga tgtctggtgg ggccgagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgccca ccaccaccac caccaccaca 840
gagttctgtg aagaggtggg tgcagttcct acaacagcag ccagtacccc tgatgccgtt 900
gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960

002260"489960


```

gagaggcttg aggccaaagca ccgagagaga atgtcccagg tcatgagaga atgggaagag 1020
gcagaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080
caggagaaaag tgggaatcttt ggaacaggaa gcagccaacg agagacagca gctgggtggag 1140
acacacatgg ccagagtggg agccatgctc aatgaccgcc gccgcctggc cctggagaac 1200
tacatcaccg ctctgcaggc tgttcctcct cggcctcgtc acgtgttcaa tatgctaaag 1260
aagtatgtcc gcgcagaaca gaaggacaga cagcacacc taaagcattt cgagcatgtg 1320
cgcatgggtg atcccaagaa agccgctcag atccgggtccc aggttatgac acacctccgt 1380
gtgatttatg agcgcatgaa tcagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440
gaggagattc aggatgaagt tgatgagctg cttcagaaaag agcaaaacta ttcagatgac 1500
gtcttgggcca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560
tctttgaccg aaacgaaaac caccgtggag ctccctcccg tgaatggaga gttcagcctg 1620
gacgatctcc agccgtggca ttcttttggg gctgactctg tgccagccaa cacagaaaac 1680
gaagttgagc ctggtgatgc ccgcctgct gccgaccgag gactgaccac tcgaccaggt 1740
tctgggttga caaatatcaa gacggaggag atctctgaag tgaatctgga tgcagaattc 1800
cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860
ggttcaaaca aaggtgcaat cattggactc atggtgggcg gtgttgatc atgcacagtg 1920
atcgtcatca ccttggtgat gctgaagaag aaacagtaca catccattca tcatggtgtg 1980
tgaggaggtg acgcgctgt caccacagag gagcgccacc tgtccaagat gcagcagaac 2040
ggctacgaaa atccaaccta caagttcttt gagcagatgc agaactag 2088

```

<210> 12
 <211> 695
 <212> PRT
 <213> Homo sapiens

<400> 12
 Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15
 Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30
 Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45
 Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60
 Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80
 Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95
 Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110
 Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125
 Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140
 Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
 145 150 155 160
 Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
 165 170 175
 Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
 180 185 190

0966344-092200

Ser	Asp	Asn	Val	Asp	Ser	Ala	Asp	Ala	Glu	Glu	Asp	Asp	Ser	Asp	Val
		195					200					205			
Trp	Trp	Gly	Gly	Ala	Asp	Thr	Asp	Tyr	Ala	Asp	Gly	Ser	Glu	Asp	Lys
	210					215					220				
Val	Val	Glu	Val	Ala	Glu	Glu	Glu	Glu	Val	Ala	Glu	Val	Glu	Glu	Glu
	225				230					235					240
Glu	Ala	Asp	Asp	Asp	Glu	Asp	Asp	Glu	Asp	Gly	Asp	Glu	Val	Glu	Glu
				245					250					255	
Glu	Ala	Glu	Glu	Pro	Tyr	Glu	Glu	Ala	Thr	Glu	Arg	Thr	Thr	Ser	Ile
			260					265				270			
Ala	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Glu	Ser	Val	Glu	Glu	Val	Val	Arg
		275					280					285			
Val	Pro	Thr	Thr	Ala	Ala	Ser	Thr	Pro	Asp	Ala	Val	Asp	Lys	Tyr	Leu
	290					295					300				
Glu	Thr	Pro	Gly	Asp	Glu	Asn	Glu	His	Ala	His	Phe	Gln	Lys	Ala	Lys
	305				310					315					320
Glu	Arg	Leu	Glu	Ala	Lys	His	Arg	Glu	Arg	Met	Ser	Gln	Val	Met	Arg
				325					330					335	
Glu	Trp	Glu	Glu	Ala	Glu	Arg	Gln	Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp
			340					345					350		
Lys	Lys	Ala	Val	Ile	Gln	His	Phe	Gln	Glu	Lys	Val	Glu	Ser	Leu	Glu
		355					360					365			
Gln	Glu	Ala	Ala	Asn	Glu	Arg	Gln	Gln	Leu	Val	Glu	Thr	His	Met	Ala
	370					375					380				
Arg	Val	Glu	Ala	Met	Leu	Asn	Asp	Arg	Arg	Arg	Leu	Ala	Leu	Glu	Asn
	385				390					395					400
Tyr	Ile	Thr	Ala	Leu	Gln	Ala	Val	Pro	Pro	Arg	Pro	Arg	His	Val	Phe
			405						410				415		
Asn	Met	Leu	Lys	Lys	Tyr	Val	Arg	Ala	Glu	Gln	Lys	Asp	Arg	Gln	His
			420					425					430		
Thr	Leu	Lys	His	Phe	Glu	His	Val	Arg	Met	Val	Asp	Pro	Lys	Lys	Ala
		435					440					445			
Ala	Gln	Ile	Arg	Ser	Gln	Val	Met	Thr	His	Leu	Arg	Val	Ile	Tyr	Glu
	450					455					460				
Arg	Met	Asn	Gln	Ser	Leu	Ser	Leu	Leu	Tyr	Asn	Val	Pro	Ala	Val	Ala
	465				470					475					480
Glu	Glu	Ile	Gln	Asp	Glu	Val	Asp	Glu	Leu	Leu	Gln	Lys	Glu	Gln	Asn
				485					490					495	
Tyr	Ser	Asp	Asp	Val	Leu	Ala	Asn	Met	Ile	Ser	Glu	Pro	Arg	Ile	Ser
			500					505					510		


```

tacatcacccg ctctgcaggc tgttctctct cggcctcgtc acgtgttcaa tatgctaaag 1260
aagtatgtcc gcgcagaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320
cgcatgggtgg atcccaagaa agccgctcag atccgggtccc aggttatgac acacctccgt 1380
gtgatttatg agcgcataaa tcagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440
gaggagattc aggatgaagt tgatgagctg cttcagaaag agcaaaacta ttcagatgac 1500
gtcttggcca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560
tctttgaccg aaacgaaaac caccgtggag ctcttcccg tgaatggaga gttcagcctg 1620
gacgatctcc agccgtggca ttcttttggg gctgactctg tgccagccaa cacagaaaac 1680
gaagttgagc ctggtgatgc ccgccctgct gccgaccgag gactgaccac tgcaccaggt 1740
tctgggttga caaatatcaa gacggaggag atctctgaag tgaagatgga tgcagaattc 1800
cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860
ggttcaaaca aaggtgcaat cattggactc atggtgggcg gtgttgtcat agcgacagtg 1920
atcttcatca ccttgggtgat gctgaagaag aaacagtaca catccattca tcatgggtgtg 1980
gtggagggttg acgccgctgt caccacagag gagcgccacc tgtccaagat gcagcagaac 2040
ggctacgaaa atccaacctt caagttcttt gagcagatgc agaactag 2088

```

<210> 14
 <211> 695
 <212> PRT
 <213> Homo sapiens

<400> 14

Met	Leu	Pro	Gly	Leu	Ala	Leu	Leu	Leu	Leu	Ala	Ala	Trp	Thr	Ala	Arg
1				5					10					15	
Ala	Leu	Glu	Val	Pro	Thr	Asp	Gly	Asn	Ala	Gly	Leu	Leu	Ala	Glu	Pro
			20					25					30		
Gln	Ile	Ala	Met	Phe	Cys	Gly	Arg	Leu	Asn	Met	His	Met	Asn	Val	Gln
		35					40					45			
Asn	Gly	Lys	Trp	Asp	Ser	Asp	Pro	Ser	Gly	Thr	Lys	Thr	Cys	Ile	Asp
	50					55					60				
Thr	Lys	Glu	Gly	Ile	Leu	Gln	Tyr	Cys	Gln	Glu	Val	Tyr	Pro	Glu	Leu
	65				70					75					80
Gln	Ile	Thr	Asn	Val	Val	Glu	Ala	Asn	Gln	Pro	Val	Thr	Ile	Gln	Asn
			85						90					95	
Trp	Cys	Lys	Arg	Gly	Arg	Lys	Gln	Cys	Lys	Thr	His	Pro	His	Phe	Val
			100					105					110		
Ile	Pro	Tyr	Arg	Cys	Leu	Val	Gly	Glu	Phe	Val	Ser	Asp	Ala	Leu	Leu
		115					120					125			
Val	Pro	Asp	Lys	Cys	Lys	Phe	Leu	His	Gln	Glu	Arg	Met	Asp	Val	Cys
	130					135					140				
Glu	Thr	His	Leu	His	Trp	His	Thr	Val	Ala	Lys	Glu	Thr	Cys	Ser	Glu
145				150						155					160
Lys	Ser	Thr	Asn	Leu	His	Asp	Tyr	Gly	Met	Leu	Leu	Pro	Cys	Gly	Ile
			165					170						175	
Asp	Lys	Phe	Arg	Gly	Val	Glu	Phe	Val	Cys	Cys	Pro	Leu	Ala	Glu	Glu
		180					185						190		
Ser	Asp	Asn	Val	Asp	Ser	Ala	Asp	Ala	Glu	Glu	Asp	Asp	Ser	Asp	Val
	195					200					205				

006634-09600

Trp 210	Gly	Gly	Ala	Asp	Thr	Asp	Tyr	Ala	Asp	Gly	Ser	Glu	Asp	Lys	
Val 225	Val	Glu	Val	Ala	Glu	Glu	Glu	Glu	Val	Ala	Glu	Val	Glu	Glu	Glu
Glu	Ala	Asp	Asp	Asp	Glu	Asp	Asp	Glu	Asp	Gly	Asp	Glu	Val	Glu	Glu
Glu	Ala	Glu	Glu	Pro	Tyr	Glu	Glu	Ala	Thr	Glu	Arg	Thr	Thr	Ser	Ile
Ala	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Glu	Ser	Val	Glu	Glu	Val	Val	Arg
Val	Pro	Thr	Thr	Ala	Ala	Ser	Thr	Pro	Asp	Ala	Val	Asp	Lys	Tyr	Leu
Glu 305	Thr	Pro	Gly	Asp	Glu	Asn	Glu	His	Ala	His	Phe	Gln	Lys	Ala	Lys
Glu	Arg	Leu	Glu	Ala	Lys	His	Arg	Glu	Arg	Met	Ser	Gln	Val	Met	Arg
Glu	Trp	Glu	Glu	Ala	Glu	Arg	Gln	Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp
Lys	Lys	Ala	Val	Ile	Gln	His	Phe	Gln	Glu	Lys	Val	Glu	Ser	Leu	Glu
Gln	Glu	Ala	Ala	Asn	Glu	Arg	Gln	Gln	Leu	Val	Glu	Thr	His	Met	Ala
Arg 385	Val	Glu	Ala	Met	Leu	Asn	Asp	Arg	Arg	Arg	Leu	Ala	Leu	Glu	Asn
Tyr	Ile	Thr	Ala	Leu	Gln	Ala	Val	Pro	Pro	Arg	Pro	Arg	His	Val	Phe
Asn	Met	Leu	Lys	Lys	Tyr	Val	Arg	Ala	Glu	Gln	Lys	Asp	Arg	Gln	His
Thr	Leu	Lys	His	Phe	Glu	His	Val	Arg	Met	Val	Asp	Pro	Lys	Lys	Ala
Ala	Gln	Ile	Arg	Ser	Gln	Val	Met	Thr	His	Leu	Arg	Val	Ile	Tyr	Glu
Arg 465	Met	Asn	Gln	Ser	Leu	Ser	Leu	Leu	Tyr	Asn	Val	Pro	Ala	Val	Ala
Glu	Glu	Ile	Gln	Asp	Glu	Val	Asp	Glu	Leu	Leu	Gln	Lys	Glu	Gln	Asn
Tyr	Ser	Asp	Asp	Val	Leu	Ala	Asn	Met	Ile	Ser	Glu	Pro	Arg	Ile	Ser
Tyr	Gly	Asn	Asp	Ala	Leu	Met	Pro	Ser	Leu	Thr	Glu	Thr	Lys	Thr	Thr
Val	Glu	Leu	Leu	Pro	Val	Asn	Gly	Glu	Phe	Ser	Leu	Asp	Asp	Leu	Gln

Glu	Ala	Asp	Asp	Asp	Glu	Asp	Asp	Glu	Asp	Gly	Asp	Glu	Val	Glu	Glu	
				245					250					255		
Glu	Ala	Glu	Glu	Pro	Tyr	Glu	Glu	Ala	Thr	Glu	Arg	Thr	Thr	Ser	Ile	
		260						265					270			
Ala	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Glu	Ser	Val	Glu	Glu	Val	Val	Arg	
		275					280					285				
Val	Pro	Thr	Thr	Ala	Ala	Ser	Thr	Pro	Asp	Ala	Val	Asp	Lys	Tyr	Leu	
	290					295					300					
Glu	Thr	Pro	Gly	Asp	Glu	Asn	Glu	His	Ala	His	Phe	Gln	Lys	Ala	Lys	
305					310					315					320	
Glu	Arg	Leu	Glu	Ala	Lys	His	Arg	Glu	Arg	Met	Ser	Gln	Val	Met	Arg	
				325					330					335		
Glu	Trp	Glu	Glu	Ala	Glu	Arg	Gln	Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp	
		340						345					350			
Lys	Lys	Ala	Val	Ile	Gln	His	Phe	Gln	Glu	Lys	Val	Glu	Ser	Leu	Glu	
		355					360					365				
Gln	Glu	Ala	Ala	Asn	Glu	Arg	Gln	Gln	Leu	Val	Glu	Thr	His	Met	Ala	
	370					375					380					
Arg	Val	Glu	Ala	Met	Leu	Asn	Asp	Arg	Arg	Arg	Leu	Ala	Leu	Glu	Asn	
385					390					395					400	
Tyr	Ile	Thr	Ala	Leu	Gln	Ala	Val	Pro	Pro	Arg	Pro	Arg	His	Val	Phe	
				405					410					415		
Asn	Met	Leu	Lys	Lys	Tyr	Val	Arg	Ala	Glu	Gln	Lys	Asp	Arg	Gln	His	
			420					425					430			
Thr	Leu	Lys	His	Phe	Glu	His	Val	Arg	Met	Val	Asp	Pro	Lys	Lys	Ala	
		435					440					445				
Ala	Gln	Ile	Arg	Ser	Gln	Val	Met	Thr	His	Leu	Arg	Val	Ile	Tyr	Glu	
	450					455					460					
Arg	Met	Asn	Gln	Ser	Leu	Ser	Leu	Leu	Tyr	Asn	Val	Pro	Ala	Val	Ala	
465					470					475					480	
Glu	Glu	Ile	Gln	Asp	Glu	Val	Asp	Glu	Leu	Leu	Gln	Lys	Glu	Gln	Asn	
			485					490						495		
Tyr	Ser	Asp	Asp	Val	Leu	Ala	Asn	Met	Ile	Ser	Glu	Pro	Arg	Ile	Ser	
			500					505					510			
Tyr	Gly	Asn	Asp	Ala	Leu	Met	Pro	Ser	Leu	Thr	Glu	Thr	Lys	Thr	Thr	
		515					520					525				
Val	Glu	Leu	Leu	Pro	Val	Asn	Gly	Glu	Phe	Ser	Leu	Asp	Asp	Leu	Gln	
	530					535					540					
Pro	Trp	His	Ser	Phe	Gly	Ala	Asp	Ser	Val	Pro	Ala	Asn	Thr	Glu	Asn	
545					550					555					560	
Glu	Val	Glu	Pro	Val	Asp	Ala	Arg	Pro	Ala	Ala	Asp	Arg	Gly	Leu	Thr	
				565					570					575		

003334-05200

Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser
580 585 590

Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
595 600 605

His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
610 615 620

Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
625 630 635 640

Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
645 650 655

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
660 665 670

His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
675 680 685

Phe Phe Glu Gln Met Gln Asn Lys Lys
690 695

<210> 17
<211> 2094
<212> DNA
<213> Homo sapiens

<400> 17
atgctgcccc gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60
cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaa 180
acctgcattg ataccaagga aggcattcctg cagtattgcc aagaagtcta ccctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300
ggccgcaagc agtgcaagac ccatcccccac tttgtgatcc cctaccgctg cttagtgtgt 360
gagtttgtaa gtgatgccct tctcgttcct gacaagtgc aattcttaca ccaggagagg 420
atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagtga 480
aagagtacca acttgcattga ctacggcatg ttgctgccct gcggaattga caagttccga 540
ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
gcgaggagg atgactcgga tgtctggtgg ggcggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
gagtcgtgtg aagaggtgtg tcgagtccct acaacagcag ccagtacccc tgatgccgtt 900
gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960
gagaggcttg aggccaagca ccgagagaga atgtcccagg tcatgagaga atgggaagag 1020
gcagaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080
caggagaaa tggaatcttt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140
acacacatgg ccagagtggg agccatgctc aatgaaccgc gccgcctggc cctggagaac 1200
tacatcaccg ctctgcaggg tgttcctcct cggcctcgtc acgtgttcaa tatgctaaag 1260
aagtatgtcc gcgcagaaca gaaggacaga cagcacacc taaagcattt cgagcatgtg 1320
cgcatggtgg atcccaagaa agccgctcag atccggtccc aggttatgac acacctccgt 1380
gtgatttatg agcgcattga tcagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440
gaggagattc aggatgaagt tgatgagctg cttcagaaag agcaaaacta ttcagatgac 1500
gtcttgcca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560
tctttgaccg aaacgaaaac caccgtggag ctctctcccg tgaatggaga gttcagcctg 1620
gacgatctcc agccgtggca ttcttttggg gctgactctg tgccagccaa cacagaaaac 1680
gaagttgagc ctgttgatgc ccgcctgtc gccgaccgag gactgaccac tcgaccaggt 1740
tctgggttga caaatatcaa gacggaggag atctctgaag tgaatctgga tgcagaattc 1800
cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860

09563314-092600

ggttcaaaca aaggtgcaat cattggactc atggtgggcg gtgttgatcat agcgacagtg 1920
atcgatcatca ccttggtgat gctgaagaag aaacagtaca catccattca tcatggtgtg 1980
gtggaggttg acgccgtgt caccacagag gagcgccacc tgtccaagat gcagcagaac 2040
ggctacgaaa atccaacctt caagttcttt gagcagatgc agaacaagaa gtag 2094

<210> 18
<211> 697
<212> PRT
<213> Homo sapiens

<400> 18

Met	Leu	Pro	Gly	Leu	Ala	Leu	Leu	Leu	Leu	Ala	Ala	Trp	Thr	Ala	Arg	1	5	10	15
Ala	Leu	Glu	Val	Pro	Thr	Asp	Gly	Asn	Ala	Gly	Leu	Leu	Ala	Glu	Pro	20	25	30	
Gln	Ile	Ala	Met	Phe	Cys	Gly	Arg	Leu	Asn	Met	His	Met	Asn	Val	Gln	35	40	45	
Asn	Gly	Lys	Trp	Asp	Ser	Asp	Pro	Ser	Gly	Thr	Lys	Thr	Cys	Ile	Asp	50	55	60	
Thr	Lys	Glu	Gly	Ile	Leu	Gln	Tyr	Cys	Gln	Glu	Val	Tyr	Pro	Glu	Leu	65	70	75	80
Gln	Ile	Thr	Asn	Val	Val	Glu	Ala	Asn	Gln	Pro	Val	Thr	Ile	Gln	Asn	85	90	95	
Trp	Cys	Lys	Arg	Gly	Arg	Lys	Gln	Cys	Lys	Thr	His	Pro	His	Phe	Val	100	105	110	
Ile	Pro	Tyr	Arg	Cys	Leu	Val	Gly	Glu	Phe	Val	Ser	Asp	Ala	Leu	Leu	115	120	125	
Val	Pro	Asp	Lys	Cys	Lys	Phe	Leu	His	Gln	Glu	Arg	Met	Asp	Val	Cys	130	135	140	
Glu	Thr	His	Leu	His	Trp	His	Thr	Val	Ala	Lys	Glu	Thr	Cys	Ser	Glu	145	150	155	160
Lys	Ser	Thr	Asn	Leu	His	Asp	Tyr	Gly	Met	Leu	Leu	Pro	Cys	Gly	Ile	165	170	175	
Asp	Lys	Phe	Arg	Gly	Val	Glu	Phe	Val	Cys	Cys	Pro	Leu	Ala	Glu	Glu	180	185	190	
Ser	Asp	Asn	Val	Asp	Ser	Ala	Asp	Ala	Glu	Glu	Asp	Asp	Ser	Asp	Val	195	200	205	
Trp	Trp	Gly	Gly	Ala	Asp	Thr	Asp	Tyr	Ala	Asp	Gly	Ser	Glu	Asp	Lys	210	215	220	
Val	Val	Glu	Val	Ala	Glu	Glu	Glu	Glu	Val	Ala	Glu	Val	Glu	Glu	Glu	225	230	235	240
Glu	Ala	Asp	Asp	Asp	Glu	Asp	Asp	Glu	Asp	Gly	Asp	Glu	Val	Glu	Glu	245	250	255	
Glu	Ala	Glu	Glu	Pro	Tyr	Glu	Glu	Ala	Thr	Glu	Arg	Thr	Thr	Ser	Ile	260	265	270	

096634.092200

Ala	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Glu	Ser	Val	Glu	Glu	Val	Val	Arg
		275					280					285			
Val	Pro	Thr	Thr	Ala	Ala	Ser	Thr	Pro	Asp	Ala	Val	Asp	Lys	Tyr	Leu
	290					295					300				
Glu	Thr	Pro	Gly	Asp	Glu	Asn	Glu	His	Ala	His	Phe	Gln	Lys	Ala	Lys
305					310					315					320
Glu	Arg	Leu	Glu	Ala	Lys	His	Arg	Glu	Arg	Met	Ser	Gln	Val	Met	Arg
				325					330					335	
Glu	Trp	Glu	Glu	Ala	Glu	Arg	Gln	Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp
			340					345					350		
Lys	Lys	Ala	Val	Ile	Gln	His	Phe	Gln	Glu	Lys	Val	Glu	Ser	Leu	Glu
		355					360					365			
Gln	Glu	Ala	Ala	Asn	Glu	Arg	Gln	Gln	Leu	Val	Glu	Thr	His	Met	Ala
	370					375					380				
Arg	Val	Glu	Ala	Met	Leu	Asn	Asp	Arg	Arg	Arg	Leu	Ala	Leu	Glu	Asn
385					390					395					400
Tyr	Ile	Thr	Ala	Leu	Gln	Ala	Val	Pro	Pro	Arg	Pro	Arg	His	Val	Phe
				405					410					415	
Asn	Met	Leu	Lys	Lys	Tyr	Val	Arg	Ala	Glu	Gln	Lys	Asp	Arg	Gln	His
			420					425					430		
Thr	Leu	Lys	His	Phe	Glu	His	Val	Arg	Met	Val	Asp	Pro	Lys	Lys	Ala
		435					440					445			
Ala	Gln	Ile	Arg	Ser	Gln	Val	Met	Thr	His	Leu	Arg	Val	Ile	Tyr	Glu
	450					455					460				
Arg	Met	Asn	Gln	Ser	Leu	Ser	Leu	Leu	Tyr	Asn	Val	Pro	Ala	Val	Ala
465					470					475					480
Glu	Glu	Ile	Gln	Asp	Glu	Val	Asp	Glu	Leu	Leu	Gln	Lys	Glu	Gln	Asn
				485					490					495	
Tyr	Ser	Asp	Asp	Val	Leu	Ala	Asn	Met	Ile	Ser	Glu	Pro	Arg	Ile	Ser
			500					505					510		
Tyr	Gly	Asn	Asp	Ala	Leu	Met	Pro	Ser	Leu	Thr	Glu	Thr	Lys	Thr	Thr
		515					520					525			
Val	Glu	Leu	Leu	Pro	Val	Asn	Gly	Glu	Phe	Ser	Leu	Asp	Asp	Leu	Gln
	530					535					540				
Pro	Trp	His	Ser	Phe	Gly	Ala	Asp	Ser	Val	Pro	Ala	Asn	Thr	Glu	Asn
545					550					555					560
Glu	Val	Glu	Pro	Val	Asp	Ala	Arg	Pro	Ala	Ala	Asp	Arg	Gly	Leu	Thr
				565					570					575	
Thr	Arg	Pro	Gly	Ser	Gly	Leu	Thr	Asn	Ile	Lys	Thr	Glu	Glu	Ile	Ser
			580					585					590		
Glu	Val	Asn	Leu	Asp	Ala	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr	Glu	Val
		595					600					605			

His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
610 615 620

Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
625 630 635 640

Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
645 650 655

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
660 665 670

His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
675 680 685

Phe Phe Glu Gln Met Gln Asn Lys Lys
690 695

<210> 19
<211> 2094
<212> DNA
<213> Homo sapiens

<400> 19
atgctgcccc gtttggcact gtcctgctg gccgcctgga cggctcgggc gctggaggta 60
cccactgatg gtaatgctgg cctgctggct gaacccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaa 180
acctgcattg ataccaagga aggcacctcg cagtattgcc aagaagtcta ccctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtgaaca tccagaactg gtgcaagcgg 300
ggccgcaagc agtgcaagac ccaccccccac tttgtgattc cctaccgctg cttagtttgt 360
gagtttgtaa gtgatgccct tctcgctcct gacaagtgca aattcctaca ccaggagagg 420
atggatgttt gcgaaactca tcttcaactgg cacaccgtcg ccaaagagac atgcagtgag 480
aagagtacca acttgcatga ctacggcatg ttgctgccc cgggaattga caagttccga 540
ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
gcgaggagg atgactcgga tgtctggtgg ggcggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
gagtcctgtg aagaggtgtg tcgagttcct acaacagcag ccagtacccc tgatgccgtt 900
gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960
gagaggcttg aggccaagca ccgagagaga atgtcccagg tcatgagaga atgggaagag 1020
gcagaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080
caggagaaag tggaatcttt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140
acacacatgg ccagagtgga agccatgctc aatgaccgcc gccgcctggc cctggagaac 1200
tacatcaccg ctctgcaggc tgttcctcct cggcctcgtc acgtgttcaa tatgctaaag 1260
aagtatgtcc gcgcagaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320
cgcatggtgg atcccaagaa agccgctcag atccggtccc aggttatgac acacctccgt 1380
gtgatttatg agcgcatgaa tcagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440
gaggagattc aggatgaagt tgatgagctg cttcagaaaag agcaaaacta ttcagatgac 1500
gtcttgccca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560
tctttgaccg aaacgaaaac caccgtggag ctccctcccg tgaatggaga gttcagcctg 1620
gacgatctcc agccgtggca ttcttttggg gctgactctg tgccagccaa cacagaaaac 1680
gaagttgagc ctgttgatgc ccgccctgct gccgaccgag gactgaccac tcgaccaggt 1740
tctgggttga caaatatcaa gacggaggag atctctgaag tgaagatgga tgcagaattc 1800
cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860
ggttcaaaca aaggtgcaat cattggactc atggtggcg gtgtgtcat agcgacagtg 1920
atcttcatca ccttgggtgat gctgaagaag aaacagtaca catccattca tcatggtgtg 1980
gtggaggttg acgcccgtgt caccacagag gagcgccacc tgtccaagat gcagcagaac 2040
ggctacgaaa atccaaccta caagttcttt gagcagatgc agaacaagaa gtag 2094

<210> 20
<211> 697

00260-48960

<212> PRT

<213> Homo sapiens

<400> 20

```

Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1           5           10           15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
      20           25           30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
      35           40           45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
      50           55           60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
      65           70           75           80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
      85           90           95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
      100          105          110

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
      115          120          125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
      130          135          140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
      145          150          155          160

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
      165          170          175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
      180          185          190

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val
      195          200          205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys
      210          215          220

Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu
      225          230          235          240

Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu
      245          250          255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
      260          265          270

Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
      275          280          285

Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu
      290          295          300

```

002220"4T22250

Glu	Thr	Pro	Gly	Asp	Glu	Asn	Glu	His	Ala	His	Phe	Gln	Lys	Ala	Lys	
305					310					315					320	
Glu	Arg	Leu	Glu	Ala	Lys	His	Arg	Glu	Arg	Met	Ser	Gln	Val	Met	Arg	
				325					330					335		
Glu	Trp	Glu	Glu	Ala	Glu	Arg	Gln	Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp	
			340					345					350			
Lys	Lys	Ala	Val	Ile	Gln	His	Phe	Gln	Glu	Lys	Val	Glu	Ser	Leu	Glu	
		355					360					365				
Gln	Glu	Ala	Ala	Asn	Glu	Arg	Gln	Gln	Leu	Val	Glu	Thr	His	Met	Ala	
		370				375						380				
Arg	Val	Glu	Ala	Met	Leu	Asn	Asp	Arg	Arg	Arg	Leu	Ala	Leu	Glu	Asn	
385					390					395					400	
Tyr	Ile	Thr	Ala	Leu	Gln	Ala	Val	Pro	Pro	Arg	Pro	Arg	His	Val	Phe	
				405					410					415		
Asn	Met	Leu	Lys	Lys	Tyr	Val	Arg	Ala	Glu	Gln	Lys	Asp	Arg	Gln	His	
			420					425					430			
Thr	Leu	Lys	His	Phe	Glu	His	Val	Arg	Met	Val	Asp	Pro	Lys	Lys	Ala	
		435					440					445				
Ala	Gln	Ile	Arg	Ser	Gln	Val	Met	Thr	His	Leu	Arg	Val	Ile	Tyr	Glu	
		450				455					460					
Arg	Met	Asn	Gln	Ser	Leu	Ser	Leu	Leu	Tyr	Asn	Val	Pro	Ala	Val	Ala	
465					470					475					480	
Glu	Glu	Ile	Gln	Asp	Glu	Val	Asp	Glu	Leu	Leu	Gln	Lys	Glu	Gln	Asn	
			485						490					495		
Tyr	Ser	Asp	Asp	Val	Leu	Ala	Asn	Met	Ile	Ser	Glu	Pro	Arg	Ile	Ser	
			500					505					510			
Tyr	Gly	Asn	Asp	Ala	Leu	Met	Pro	Ser	Leu	Thr	Glu	Thr	Lys	Thr	Thr	
		515					520					525				
Val	Glu	Leu	Leu	Pro	Val	Asn	Gly	Glu	Phe	Ser	Leu	Asp	Asp	Leu	Gln	
		530				535					540					
Pro	Trp	His	Ser	Phe	Gly	Ala	Asp	Ser	Val	Pro	Ala	Asn	Thr	Glu	Asn	
545					550					555					560	
Glu	Val	Glu	Pro	Val	Asp	Ala	Arg	Pro	Ala	Ala	Asp	Arg	Gly	Leu	Thr	
				565					570					575		
Thr	Arg	Pro	Gly	Ser	Gly	Leu	Thr	Asn	Ile	Lys	Thr	Glu	Glu	Ile	Ser	
			580					585					590			
Glu	Val	Lys	Met	Asp	Ala	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr	Glu	Val	
		595					600					605				
His	His	Gln	Lys	Leu	Val	Phe	Phe	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	
		610				615					620					
Gly	Ala	Ile	Ile	Gly	Leu	Met	Val	Gly	Gly	Val	Val	Ile	Ala	Thr	Val	
625					630					635					640	

002220-092000

Gly	Gln	Gly	Tyr	Tyr	Val	Glu	Met	Thr	Val	Gly	Ser	Pro	Pro	Gln	Thr	65	70	75	80
Leu	Asn	Ile	Leu	Val	Asp	Thr	Gly	Ser	Ser	Asn	Phe	Ala	Val	Gly	Ala	85	90	95	
Ala	Pro	His	Pro	Phe	Leu	His	Arg	Tyr	Tyr	Gln	Arg	Gln	Leu	Ser	Ser	100	105	110	
Thr	Tyr	Arg	Asp	Leu	Arg	Lys	Gly	Val	Tyr	Val	Pro	Tyr	Thr	Gln	Gly	115	120	125	
Lys	Trp	Glu	Gly	Glu	Leu	Gly	Thr	Asp	Leu	Val	Ser	Ile	Pro	His	Gly	130	135	140	
Pro	Asn	Val	Thr	Val	Arg	Ala	Asn	Ile	Ala	Ala	Ile	Thr	Glu	Ser	Asp	145	150	155	160
Lys	Phe	Phe	Ile	Asn	Gly	Ser	Asn	Trp	Glu	Gly	Ile	Leu	Gly	Leu	Ala	165	170	175	
Tyr	Ala	Glu	Ile	Ala	Arg	Pro	Asp	Asp	Ser	Leu	Glu	Pro	Phe	Phe	Asp	180	185	190	
Ser	Leu	Val	Lys	Gln	Thr	His	Val	Pro	Asn	Leu	Phe	Ser	Leu	His	Leu	195	200	205	
Cys	Gly	Ala	Gly	Phe	Pro	Leu	Asn	Gln	Ser	Glu	Val	Leu	Ala	Ser	Val	210	215	220	
Gly	Gly	Ser	Met	Ile	Ile	Gly	Gly	Ile	Asp	His	Ser	Leu	Tyr	Thr	Gly	225	230	235	240
Ser	Leu	Trp	Tyr	Thr	Pro	Ile	Arg	Arg	Glu	Trp	Tyr	Tyr	Glu	Val	Ile	245	250	255	
Ile	Val	Arg	Val	Glu	Ile	Asn	Gly	Gln	Asp	Leu	Lys	Met	Asp	Cys	Lys	260	265	270	
Glu	Tyr	Asn	Tyr	Asp	Lys	Ser	Ile	Val	Asp	Ser	Gly	Thr	Thr	Asn	Leu	275	280	285	
Arg	Leu	Pro	Lys	Lys	Val	Phe	Glu	Ala	Ala	Val	Lys	Ser	Ile	Lys	Ala	290	295	300	
Ala	Ser	Ser	Thr	Glu	Lys	Phe	Pro	Asp	Gly	Phe	Trp	Leu	Gly	Glu	Gln	305	310	315	320
Leu	Val	Cys	Trp	Gln	Ala	Gly	Thr	Thr	Pro	Trp	Asn	Ile	Phe	Pro	Val	325	330	335	
Ile	Ser	Leu	Tyr	Leu	Met	Gly	Glu	Val	Thr	Asn	Gln	Ser	Phe	Arg	Ile	340	345	350	
Thr	Ile	Leu	Pro	Gln	Gln	Tyr	Leu	Arg	Pro	Val	Glu	Asp	Val	Ala	Thr	355	360	365	
Ser	Gln	Asp	Asp	Cys	Tyr	Lys	Phe	Ala	Ile	Ser	Gln	Ser	Ser	Thr	Gly	370	375	380	
Thr	Val	Met	Gly	Ala	Val	Ile	Met	Glu	Gly	Phe	Tyr	Val	Val	Phe	Asp	385	390	395	400

006634-09200


```

<400> 24
Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Gly Ser Met Thr
  1                    5                10              15
Ile Ser Asp Ser Pro Arg Glu Gln Asp Gly Ser Thr Gln His Gly Ile
                20                25              30
Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg
          35                40              45
Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly
  50                55              60
Ser Phe Val Glu Met Val Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly
  65                70              75              80
Tyr Tyr Val Glu Met Thr Val Gly Ser Pro Pro Gln Thr Leu Asn Ile
                85                90              95

```

Leu	Val	Asp	Thr	Gly	Ser	Ser	Asn	Phe	Ala	Val	Gly	Ala	Ala	Pro	His
			100				105					110			
Pro	Phe	Leu	His	Arg	Tyr	Tyr	Gln	Arg	Gln	Leu	Ser	Ser	Thr	Tyr	Arg
		115					120					125			
Asp	Leu	Arg	Lys	Gly	Val	Tyr	Val	Pro	Tyr	Thr	Gln	Gly	Lys	Trp	Glu
	130					135					140				
Gly	Glu	Leu	Gly	Thr	Asp	Leu	Val	Ser	Ile	Pro	His	Gly	Pro	Asn	Val
145					150					155					160
Thr	Val	Arg	Ala	Asn	Ile	Ala	Ala	Ile	Thr	Glu	Ser	Asp	Lys	Phe	Phe
				165					170					175	
Ile	Asn	Gly	Ser	Asn	Trp	Glu	Gly	Ile	Leu	Gly	Leu	Ala	Tyr	Ala	Glu
			180					185					190		
Ile	Ala	Arg	Pro	Asp	Asp	Ser	Leu	Glu	Pro	Phe	Phe	Asp	Ser	Leu	Val
		195					200					205			
Lys	Gln	Thr	His	Val	Pro	Asn	Leu	Phe	Ser	Leu	His	Leu	Cys	Gly	Ala
	210					215					220				
Gly	Phe	Pro	Leu	Asn	Gln	Ser	Glu	Val	Leu	Ala	Ser	Val	Gly	Gly	Ser
225				230					235						240
Met	Ile	Ile	Gly	Gly	Ile	Asp	His	Ser	Leu	Tyr	Thr	Gly	Ser	Leu	Trp
			245					250						255	
Tyr	Thr	Pro	Ile	Arg	Arg	Glu	Trp	Tyr	Tyr	Glu	Val	Ile	Ile	Val	Arg
			260					265					270		
Val	Glu	Ile	Asn	Gly	Gln	Asp	Leu	Lys	Met	Asp	Cys	Lys	Glu	Tyr	Asn
		275					280					285			
Tyr	Asp	Lys	Ser	Ile	Val	Asp	Ser	Gly	Thr	Thr	Asn	Leu	Arg	Leu	Pro
	290					295					300				
Lys	Lys	Val	Phe	Glu	Ala	Ala	Val	Lys	Ser	Ile	Lys	Ala	Ala	Ser	Ser
305					310					315					320
Thr	Glu	Lys	Phe	Pro	Asp	Gly	Phe	Trp	Leu	Gly	Glu	Gln	Leu	Val	Cys
				325					330					335	
Trp	Gln	Ala	Gly	Thr	Thr	Pro	Trp	Asn	Ile	Phe	Pro	Val	Ile	Ser	Leu
			340					345					350		
Tyr	Leu	Met	Gly	Glu	Val	Thr	Asn	Gln	Ser	Phe	Arg	Ile	Thr	Ile	Leu
		355					360					365			
Pro	Gln	Gln	Tyr	Leu	Arg	Pro	Val	Glu	Asp	Val	Ala	Thr	Ser	Gln	Asp
	370					375					380				
Asp	Cys	Tyr	Lys	Phe	Ala	Ile	Ser	Gln	Ser	Ser	Thr	Gly	Thr	Val	Met
385					390					395					400
Gly	Ala	Val	Ile	Met	Glu	Gly	Phe	Tyr	Val	Val	Phe	Asp	Arg	Ala	Arg
				405					410					415	
Lys	Arg	Ile	Gly	Phe	Ala	Val	Ser	Ala	Cys	His	Val	His	Asp	Glu	Phe
			420					425					430		

Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu Asp
435 440 445

Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser
450 455

<210> 25
<211> 1302
<212> DNA
<213> Homo sapiens

<400> 25
atgactcagc atggtattcg tctgccactg cgtagcggtc tgggtgggtgc tccactgggt 60
ctgcgtctgc cccgggagac cgacgaagag cccgaggagc ccggccggag gggcagcttt 120
gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 180
gtgggcagcc cccgcagac gctcaacatc ctgggtggata caggcagcag taactttgca 240
gtgggtgctg cccccaccc ctctctgcat cgctactacc agaggcagct gtccagcaca 300
taccgggacc tccggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 360
ctgggcaccg acctggtaag catcccccat ggccccaacg tcaactgtgcg tgccaacatt 420
gctgccatca ctgaatcaga caagttcttc atcaacggct ccaactggga aggcacctcg 480
gggctggcct atgctgagat tgccaggcct gacgactccc tggagccttt ctttgactct 540
ctggtaaagc agaccacgt tcccaacctc ttctccctgc acctttgtgg tgctggcttc 600
ccctcaacc agtctgaagt gctggcctct gtcggaggga gcatgatcat tggaggatc 660
gaccactcgc tgtacacagg cagtctctgg tatacaccca tccggcggga gtggtattat 720
gaggtcatca ttgtgcgggt ggagatcaat ggacaggatc tgaaaatgga ctgcaaggag 780
tacaactatg acaagagcat tgtggacagt ggcaccacca accttcgttt gcccaagaaa 840
gtgtttgaag ctgcagtcaa atccatcaag gcagcctcct ccacggagaa gttccctgat 900
ggtttctggc taggagagca gctgggtgtg tggcaagcag gcaccacccc ttggaacatt 960
ttccagtc a tctcactcta cctaattgggt gaggttacca accagtcctt ccgcatcacc 1020
atccttccgc agcaatacct gcggccagtg gaagatgtgg ccacgtccca agacgactgt 1080
tacaagtttg ccatctcaca gtcatccacg ggcactgtta tgggagctgt tatcatggag 1140
ggcttctacg ttgtctttga tcggggcccg aaacgaattg gctttgctgt cagcgcttgc 1200
catgtgcacg atgagttcag gacggcagcg gtggaaggcc cttttgtcac cttggacatg 1260
gaagactgtg gctacaacat tccacagaca gatgagtcat ga 1302

<210> 26
<211> 433
<212> PRT
<213> Homo sapiens

<400> 26
Met Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly
1 5 10 15
Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu
20 25 30
Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val Asp Asn Leu Arg
35 40 45
Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr Val Gly Ser Pro
50 55 60
Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser Ser Asn Phe Ala
65 70 75 80
Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr Tyr Gln Arg Gln
85 90 95
Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val Tyr Val Pro Tyr
100 105 110

002250"4449960

Ser

<210> 27
<211> 1278
<212> DNA
<213> Homo sapiens

<400> 27
atggctagca tgactggtgg acagcaaatg ggtcgcggat cgatgactat ctctgactct 60
ccgctggact ctggtatcga aaccgacgga tcctttgtgg agatggtgga caacctgagg 120
ggcaagtcgg ggcagggcta ctacgtggag atgaccgtgg gcagccccc gcagacgctc 180
aacatcctgg tggatacagg cagcagtaac tttgcagtgg gtgctgcccc ccaccccttc 240
ctgcatcgct actaccagag gcagctgtcc agcacatacc gggacctccg gaaggggtgtg 300
tatgtgccct acaccaggg caagtgggaa ggggagctgg gcaccgacct ggtaagcatc 360
ccccatggcc ccaacgtcac tgtgcgtgcc aacattgctg ccatcactga atcagacaag 420
ttcttcatca acggctccaa ctgggaaggc atcctggggc tggcctatgc tgagattgcc 480
aggcctgacg actccctgga gcctttcttt gactctctgg taaagcagac ccacgttccc 540
aacctcttct ccttcgacct ttgtggtgct ggcttcccc tcaaccagtc tgaagtgtgt 600
gcctctgtcg gaggagcat gatcattgga ggtatcgacc actcgtgtga cacaggcagt 660
ctctggtata caccatccg gcgggagtgg tattatgagg tcatcattgt gcgggtggag 720
atcaatggac aggatctgaa aatggactgc aaggagtaca actatgacaa gagcattgtg 780
gacagtggca ccaccaacct tcgtttgccc aagaaagtgt ttgaagctgc agtcaaatac 840
atcaaggcag cctcctccac ggagaagttc cctgatggtt tctggctagg agagcagctg 900
gtgtgctggc aagcaggcac cacccttgg aacattttcc cagtcactc actctacct 960
atgggtgagg ttaccaacca gtcttccgc atcaccatcc ttccgcagca atacctgcgg 1020
ccagtggaa atgtggccac gtcccaagac gactgttaca agtttgccat ctcacagtca 1080
tccacgggca ctgttatggg agctgttatc atggagggt tctacgttgt ctttgatcgg 1140
gcccgaatac gaattggctt tgctgtcagc gcttgccatg tgcacgatga gttcaggacg 1200
gcagcgggtg aaggcccttt tgtcaccttg gacatggaag actgtggcta caacattcca 1260
cagacagatg agtcatga 1278

<210> 28
<211> 425
<212> PRT
<213> Homo sapiens

<400> 28
Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Gly Ser Met Thr
1 5 10 15
Ile Ser Asp Ser Pro Leu Asp Ser Gly Ile Glu Thr Asp Gly Ser Phe
20 25 30
Val Glu Met Val Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr
35 40 45
Val Glu Met Thr Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val
50 55 60
Asp Thr Gly Ser Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe
65 70 75 80
Leu His Arg Tyr Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu
85 90 95
Arg Lys Gly Val Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu
100 105 110
Leu Gly Thr Asp Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val
115 120 125
Arg Ala Asn Ile Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn
130 135 140

002260"4"TES960


```

ctgccggtgc cccgggagac cgacgaagag cccgaggagc cccggccggag gggcagcttt 180
gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240
gtgggcagcc ccccgagac gctcaacatc ctgggtggata caggcagcag taacttttgc 300
gtgggtgctg cccccaccc cttcctgcat cgctactacc agaggcagct gtccagcaca 360
taccgggacc tccggaaggg tgtgtatgtg ccctacacc agggaagtg ggaaggggag 420
ctgggcaccg acctggtaag catcccccat ggcccacacg tcactgtgcg tgccaacatt 480
gctgccatca ctgaatcaga caagtctctt atcaacggct ccaactggga aggcacctg 540
gggctggcct atgctgagat tgccaggcct gacgactccc tggagccttt ctttgactct 600
ctggtaaagc agaccacgt tcccacctc ttctccctgc acctttgtgg tgctggcttc 660
cccccaacc agtctgaagt gctggcctct gtcggaggga gcatgatcat tggaggatc 720
gaccactcgc tgtacacagg cagtctctgg tatacaccca tccggcggga gtggtattat 780
gaggtcatca ttgtgcgggt ggagatcaat ggacaggatc tgaaaatgga ctgcaaggag 840
tacaactatg acaagagcat tgtggacagt ggcaccacca accttcgttt gcccaagaaa 900
gtgtttgaag ctgcagtcaa atccatcaag gcagcctcct ccacggagaa gtccctgat 960
ggtttctggc taggagagca gctgggtgtg tggcaagcag gcaccacccc ttggaacatt 1020
ttcccagtc tctcactcta cctaattggg gaggttacca accagtcctt ccgcatcacc 1080
atccttcgc agcaatacct gcggccagt gaagatgtgg ccacgtccca agacgactgt 1140
tacaagtttg ccatctcaca gtcattccag ggcactgtta tgggagctgt tatcatggag 1200
ggcttctacg ttgtctttga tcgggcccga aaacgaattg gctttgctgt cagcgcttgc 1260
catgtgcacg atgagttcag gacggcagcg gtggaaggcc cttttgtcac cttggacatg 1320
gaagactgtg gctacaacat tccacagaca gatgagtcac ga 1362

```

<210> 30
 <211> 453
 <212> PRT
 <213> Homo sapiens

<400> 30
 Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
 1 5 10 15
 Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
 20 25 30
 Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
 35 40 45
 Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
 50 55 60
 Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
 65 70 75 80
 Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
 85 90 95
 Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
 100 105 110
 Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
 115 120 125
 Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
 130 135 140
 Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
 145 150 155 160
 Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
 165 170 175

002250 "453660"

```
<210> 31
<211> 1380
<212> DNA
<213> Homo sapiens

<400> 31
atggcccaag ccttgccctg gctcctgctg tggatgggag cgggagtgct gectgcccac 60
```



```

ggcaccacgac acggcatccg gctgccccctg cgcagcgggcc tgggggggcgc ccccttgggg 120
ctgcgggctgc cccgggagac cgacgaagag cccgaggagc ccggccggag gggcagcttt 180
gtggagatgg tggacaacct gaggggcaag tccggggcagg gctactacgt ggagatgacc 240
gtgggcagcc ccccgagac gctcaacatc ctgggtggata caggcagcag taactttgca 300
gtgggtgctg ccccccaccc cttcctgcat cgctactacc agaggcagct gtccagcaca 360
taccgggacc tccggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 420
ctgggcaccg acctggtaag catcccccat ggcccccaacg tcaactgtgcg tgccaacatt 480
gctgccatca ctgaatcaga caagttcttc atcaacggct ccaactggga aggcattctg 540
gggctggcct atgctgagat tgccaggcct gacgactccc tggagccttt ctttgactct 600
ctggtaaagc agaccacgt tcccaacctc ttctccctgc acctttgtgg tgctggcttc 660
ccctcaacc agtctgaagt gctggcctct gtcggaggga gcatgatcat tggaggtatc 720
gaccactcgc tgtacacagg cagtctcttg tatacaccca tccggcggga gtggtattat 780
gaggtcatca ttgtgcgggt ggagatcaat ggacaggatc tgaaaatgga ctgcaaggag 840
tacaactatg acaagagcat tgtggacagt ggcaccacca accttcgttt gcccagaaa 900
gtgtttgaag ctgcagtcaa atccatcaag gcagcctcct ccacggagaa gttccctgat 960
ggttttctggc taggagagca gctgggtgtgc tggcaagcag gcaccacccc ttggaacatt 1020
ttcccagtca tctcactcta cctaattggg gaggttacc accagtcctt ccgcatcacc 1080
atccttccgc agcaatacct gcgccagtg gaagatgtgg ccacgtccca agacgactgt 1140
tacaagtttg ccatttcaca gtcattccac ggcactgtta tgggagctgt tatcatggag 1200
ggctttctacg ttgtctttga tccggcccg aaacgaattg gctttgctgt cagcgcttgc 1260
catgtgcacg atgagttcag gacggcagcg gtggaaggcc cttttgtcac cttggacatg 1320
gaagactgtg gctacaacat tccacagaca gatgagtcac agcagcagca gcagcagtga 1380

```

<210> 32
 <211> 459
 <212> PRT
 <213> Homo sapiens

```

<400> 32
Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
  1              5              10              15
Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
          20              25              30
Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
          35              40              45
Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
          50              55              60
Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
          65              70              75              80
Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
          85              90              95
Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
          100             105             110
Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
          115             120             125
Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
          130             135             140
Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
          145             150             155             160
Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
          165             170             175

```

002200"4E8960

<400> 33

```
<400> 39
cggcaccggt ctgccctgc gtagcgggtt ggggtggtgt cactgggtc tgcgtctgcc 60
ccgggagacc gacgaag                                     77
```


<220>
<223> Description of Artificial Sequence: 6-His tag

```
<210> 47
<211> 22
<212> DNA
<213> Artificial Sequence
```

<400> 47
gactgaccac tcgaccaggt tc 22

```
<210> 48
<211> 51
<212> DNA
<213> Artificial Sequence
```

<400> 48
cgaattaaat tccagcacac tggctacttc ttgtttctgca tctcaaagaa c 51

```
<210> 49
<211> 26
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: primer

<400> 49
cgaattaaat tccagcacac tggcta 26

```
<210> 50
<211> 1287
<212> DNA
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence: Hu-Asp2(b)
      delta TM
```

<400>	50						
atggcccaag	cctgccctg	gctcctgctg	tggatgggcg	cgggagtgct	gcctgccac	60	
ggcaccagc	acggcatccg	gctgcccctg	cgcagcggcc	tggggggcgc	ccccctgggg	120	
ctgcggtctg	ccggggagac	cgacgaagag	ccgaggagc	ccggccggag	gggcagcttt	180	
gtggagatgg	tggacaacct	gaggggcaag	tcggggcagg	gctactacgt	ggagatgacc	240	
gtgggcagcc	ccccgcagac	gctcaacatc	ctggtggata	caggcagcag	taactttgca	300	
gtgggtgctg	ccccccacc	cttcctgcat	cgctactacc	agaggcagct	gtccagcaca	360	
taccgggacc	tccggaagg	tgtgtatgtg	ccctacacc	agggcaagt	ggaaggggag	420	
ctgggcaccg	acctggtaag	catcccccat	ggcccaacg	tcactgtgcg	tgccaacatt	480	
gctgccatca	ctgaatcaga	caagtctctc	atcaacggct	ccaactggga	aqqcatcctg	540	

```

gggctggcct atgctgagat tgccaggcct tgtgggtgctg gcttccccct caaccagtct 600
gaagtgctgg cctctgtcgg agggagcatg atcattggag gtatcgacca ctcgctgtac 660
acaggcagtc tctggtatac acccatccgg cgggagtggt attatgaggt catcattgtg 720
cgggtggaga tcaatggaca ggatctgaaa atggactgca aggagtacaa ctatgacaag 780
agcattgtgg acagtggcac caccaacctt cgtttgccca agaaagtgtt tgaagctgca 840
gtcaaatcca tcaaggcagc ctctccacg gagaagtccc ctgatgggtt ctggctagga 900
gagcagctgg tgtgctggca agcaggcacc accccttgga acattttccc agtcattctca 960
ctctacctaa tgggtgaggt taccaaccag tccttccgca tcaccatcct tccgcagcaa 1020
tacctgcggc cagtgggaaga tgtggccacg tcccaagacg actgttataa gtttgccatc 1080
tcacagtcac ccacgggcac tggtatggga gctgttatca tggagggcct ctacgttgct 1140
tttgatcggg cccgaaaacg aattggcttt gctgtcagcg cttgccatgt gcacgatgag 1200
ttcaggacgg cagcgggtgga aggcctttt gtcaccttgg acatggaaga ctgtggctac 1260
aacattccac agacagatga gtcatga 1287

```

<210> 51

<211> 428

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Hu-Asp2(b)
delta TM

<400> 51

```

Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
  1              5              10              15

Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
          20              25              30

Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
          35              40              45

Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
          50              55              60

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
          65              70              75              80

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
          85              90              95

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
          100             105             110

Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
          115             120             125

Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
          130             135             140

Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
          145             150             155             160

Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
          165             170             175

Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Leu Cys Gly
          180             185             190

Ala Gly Phe Pro Leu Asn Gln Ser Glu Val Leu Ala Ser Val Gly Gly
          195             200             205

```

002260"47E8950

Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu
210 215 220

Trp Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val
225 230 235 240

Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr
245 250 255

Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu
260 265 270

Pro Lys Lys Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser
275 280 285

Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val
290 295 300

Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser
305 310 315 320

Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile
325 330 335

Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln
340 345 350

Asp Asp Cys Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val
355 360 365

Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala
370 375 380

Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu
385 390 395 400

Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu
405 410 415

Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser
420 425

<210> 52

<211> 1305

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Hu-Asp2(b)
delta TM

<400> 52

atggcccaag cctgcccctg gctcctgctg tggatgggcg cgggagtgct gcctgcccac 60
ggcaccacagc acggcatccg gctgcccctg cgcagcggcc tggggggcgc cccctgagg 120
ctgcggctgc cccgggagac cgacgaagag cccgaggagc ccggccggag gggcagcttt 180
gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240
gtgggcagcc ccccgagac gctcaacatc ctggtggata caggcagcag taactttgca 300
gtgggtgctg ccccccaccc ctctctgcat cgctactacc agaggcagct gtccagcaca 360
taccgggacc tccggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 420
ctgggcaccg acctggtgaag catcccccat ggcccccaacg tcaactgtgcg tgccaacatt 480
gctgccatca ctgaatcaga caagttcttc atcaacggct ccaactggga aggcacacct 540
gggctggcct atgctgagat tgccaggctt tgtggtgctg gcttccccct caaccagtct 600

095634-09990

```

gaagtgtctgg cctctgtcgg agggagcatg atcattggag gtatcgacca ctctgtgtac 660
acaggcagtc tctggtatac acccatccgg cgggagtggt attatgaggt catcattgtg 720
cgggtggaga tcaatggaca ggatctgaaa atggactgca aggagtacaa ctatgacaag 780
agcattgttg acagtggcac caccaacctt cgtttgccca agaaagtgtt tgaagctgca 840
gtcaaatacca tcaaggcagc ctctccacg gagaagttcc ctgatggttt ctggctagga 900
gagcagctgg tgtgtcggca agcaggcacc accccttggg acattttccc agtcatctca 960
ctctacctaa tgggtgaggt taccaaccag tccttcgcga tcaccatcct tccgcagcaa 1020
tacctgcggc cagtgggaaga tgtggccacg tcccaagacg actgttataa gtttgccatc 1080
tcacagtcac ccacgggcac tgttatggga gctgttatca tggagggctt ctacgttgtc 1140
tttgatcggg cccgaaaacg aattggcttt gctgtcagcg cttgccatgt gcacgatgag 1200
ttcaggacgg cagcgggtga aggccctttt gtcaccttgg acatggaaga ctgtggctac 1260
aacattccac agacagatga gtcacagcag cagcagcagc agtga 1305

```

<210> 53
 <211> 434
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Hu-Asp2(b)
 delta TM

<400> 53

Met	Ala	Gln	Ala	Leu	Pro	Trp	Leu	Leu	Leu	Trp	Met	Gly	Ala	Gly	Val
1				5					10					15	
Leu	Pro	Ala	His	Gly	Thr	Gln	His	Gly	Ile	Arg	Leu	Pro	Leu	Arg	Ser
			20					25					30		
Gly	Leu	Gly	Gly	Ala	Pro	Leu	Gly	Leu	Arg	Leu	Pro	Arg	Glu	Thr	Asp
		35					40					45			
Glu	Glu	Pro	Glu	Glu	Pro	Gly	Arg	Arg	Gly	Ser	Phe	Val	Glu	Met	Val
		50				55					60				
Asp	Asn	Leu	Arg	Gly	Lys	Ser	Gly	Gln	Gly	Tyr	Tyr	Val	Glu	Met	Thr
65					70					75					80
Val	Gly	Ser	Pro	Pro	Gln	Thr	Leu	Asn	Ile	Leu	Val	Asp	Thr	Gly	Ser
				85					90					95	
Ser	Asn	Phe	Ala	Val	Gly	Ala	Ala	Pro	His	Pro	Phe	Leu	His	Arg	Tyr
			100					105					110		
Tyr	Gln	Arg	Gln	Leu	Ser	Ser	Thr	Tyr	Arg	Asp	Leu	Arg	Lys	Gly	Val
		115					120					125			
Tyr	Val	Pro	Tyr	Thr	Gln	Gly	Lys	Trp	Glu	Gly	Glu	Leu	Gly	Thr	Asp
		130				135					140				
Leu	Val	Ser	Ile	Pro	His	Gly	Pro	Asn	Val	Thr	Val	Arg	Ala	Asn	Ile
145					150					155					160
Ala	Ala	Ile	Thr	Glu	Ser	Asp	Lys	Phe	Phe	Ile	Asn	Gly	Ser	Asn	Trp
				165					170					175	
Glu	Gly	Ile	Leu	Gly	Leu	Ala	Tyr	Ala	Glu	Ile	Ala	Arg	Leu	Cys	Gly
			180					185						190	
Ala	Gly	Phe	Pro	Leu	Asn	Gln	Ser	Glu	Val	Leu	Ala	Ser	Val	Gly	Gly
		195				200						205			

002260-4-11-1990


```

gcgaggagg atgactcgga tgtctggtgg ggcggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgccca ccaccaccac caccaccaca 840
gagtctgtgg aagaggtggg tgcgaggggt tgctctgaac aagccgagac ggggcccgtgc 900
cgagcaatga tctcccgctg gtactttgat gtgactgaag ggaagtgtgc cccattcttt 960
tacggcggat gtggcggcaa ccggaacaac tttgacacag aagagtactg catggccgtg 1020
tgtggcagcg ccatgtccca aagtttactc aagactaccg aggaacctct tggccgagat 1080
cctgttaaac ttcctacaac agcagccagt acccctgatg ccgttgacaa gtatctcgag 1140
acacctgggg atgagaatga acatgcccac ttccagaaag ccaaagagag gcttgaggcc 1200
aagcaccgag agagaatgtc ccaggtcatg agagaatggg aagaggcaga acgtcaagca 1260
aagaacttgc ctaaagctga taagaaggca gttatccagc atttccagga gaaagtggaa 1320
tctttggaac aggaagcagc caacgagaga cagcagctgg tggagacaca catggccaga 1380
gtggaagcca tgctcaatga ccgccgccgc ctggccctgg agaactacat caccgctctg 1440
caggetgttc ctccctcgcc tcgtcacgtg ttcaatatgc taaagaagta tgtccgcgca 1500
gaacagaagg acagacagca caccctaaag catttcgagc atgtgcgcat ggtggatccc 1560
aagaaagccg ctcagatccg gtccaggtt atgacacacc tccgtgtgat ttatgagcg 1620
atgaatcagt ctctctccct gctctacaac gtgcctgcag tggccgagga gattcaggat 1680
gaagttgatg agctgcttca gaaagagcaa aactattcag atgacgtctt ggccaacatg 1740
attagtgaac caaggatcag ttacggaaac gatgctctca tgccatcttt gaccgaaacg 1800
aaaaccaccg tggagctcct tcccgtgaat ggagagttca gcctggacga tctccagccg 1860
tggcattctt ttggggctga ctctgtgcca gccaacacag aaaacgaagt tgagcctgtt 1920
gatgcccgcc ctgctgccga ccgaggactg accactcgac caggttcttg gttgacaaat 1980
atcaagacgg aggagatctc tgaagtgaag atggatgcag aattccgaca tgactcagga 2040
tatgaagttc atcatcaaaa attggtgttc tttgcagaag atgtgggttc aaacaaaggt 2100
gcaatcattg gactcatggt gggcggtgtt gtcatagcga cagtgatcgt catcaccttg 2160
gtgatgctga agaagaaaca gtacacatcc attcatcatg gtgtgggtgga gggttgacgcc 2220
gctgtcaccg cagaggagcg ccacctgtcc aagatgcagc agaacggcta cgaaaatcca 2280
acctacaagt tctttgagca gatgcagaac 2310

```

<210> 55
 <211> 770
 <212> PRT
 <213> Homo sapiens

<400> 55
 Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15
 Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30
 Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45
 Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
 50 55 60
 Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
 65 70 75 80
 Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
 85 90 95
 Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
 100 105 110
 Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
 115 120 125
 Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
 130 135 140

002260"4731550

Glu 145	Thr	His	Leu	His	Trp 150	His	Asp	Thr	Val	Ala	Lys 155	Glu	Thr	Cys	Ser	Glu 160
Lys	Ser	Thr	Asn	Leu 165	His	Asp	Tyr	Gly	Met 170	Leu	Leu	Pro	Cys	Gly 175	Ile	
Asp	Lys	Phe	Arg 180	Gly	Val	Glu	Phe	Val 185	Cys	Cys	Pro	Leu	Ala 190	Glu	Glu	
Ser	Asp	Asn 195	Val	Asp	Ser	Ala	Asp 200	Ala	Glu	Glu	Asp 205	Asp	Ser	Asp	Val	
Trp	Trp 210	Gly	Gly	Ala	Asp 215	Thr	Asp	Tyr	Ala	Asp 220	Gly	Ser	Glu	Asp	Lys	
Val 225	Val	Glu	Val	Ala	Glu 230	Glu	Glu	Glu	Val	Ala 235	Glu	Val	Glu	Glu	Glu 240	
Glu	Ala	Asp	Asp	Asp 245	Glu	Asp	Asp	Glu	Asp 250	Gly	Asp	Glu	Val	Glu 255	Glu	
Glu	Ala	Glu	Glu 260	Pro	Tyr	Glu	Glu	Ala 265	Thr	Glu	Arg	Thr	Thr 270	Ser	Ile	
Ala	Thr	Thr 275	Thr	Thr	Thr	Thr	Thr 280	Glu	Ser	Val	Glu 285	Glu	Val	Val	Arg	
Glu 290	Val	Cys	Ser	Glu	Gln 295	Ala	Glu	Thr	Gly	Pro 300	Cys	Arg	Ala	Met	Ile	
Ser 305	Arg	Trp	Tyr	Phe	Asp 310	Val	Thr	Glu	Gly	Lys 315	Cys	Ala	Pro	Phe	Phe 320	
Tyr	Gly	Gly	Cys	Gly 325	Gly	Asn	Arg	Asn 330	Asn	Phe	Asp	Thr	Glu 335	Glu	Tyr	
Cys	Met	Ala	Val 340	Cys	Gly	Ser	Ala	Met 345	Ser	Gln	Ser	Leu 350	Leu	Lys	Thr	
Thr	Gln	Glu 355	Pro	Leu	Ala	Arg	Asp 360	Pro	Val	Lys	Leu 365	Pro	Thr	Thr	Ala	
Ala	Ser 370	Thr	Pro	Asp	Ala	Val 375	Asp	Lys	Tyr	Leu 380	Glu	Thr	Pro	Gly	Asp	
Glu 385	Asn	Glu	His	Ala	His 390	Phe	Gln	Lys	Ala	Lys 395	Glu	Arg	Leu	Glu	Ala 400	
Lys	His	Arg	Glu	Arg 405	Met	Ser	Gln	Val	Met 410	Arg	Glu	Trp	Glu 415	Glu	Ala	
Glu	Arg	Gln	Ala 420	Lys	Asn	Leu	Pro	Lys 425	Ala	Asp	Lys	Lys	Ala 430	Val	Ile	
Gln	His 435	Phe	Gln	Glu	Lys	Val	Glu 440	Ser	Leu	Glu	Gln 445	Glu	Ala	Ala	Asn	
Glu 450	Arg	Gln	Gln	Leu	Val	Glu 455	Thr	His	Met	Ala 460	Arg	Val	Glu	Ala	Met	
Leu 465	Asn	Asp	Arg	Arg 470	Arg	Leu	Ala	Leu	Glu	Asn 475	Tyr	Ile	Thr	Ala	Leu 480	

Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys
485 490 495

Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe
500 505 510

Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser
515 520 525

Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser
530 535 540

Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp
545 550 555 560

Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val
565 570 575

Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala
580 585 590

Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro
595 600 605

Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe
610 615 620

Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val
625 630 635 640

Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
645 650 655

Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp
660 665 670

Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu
675 680 685

Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly
690 695 700

Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu
705 710 715 720

Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val
725 730 735

Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met
740 745 750

Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met
755 760 765

Gln Asn
770

<210> 56
<211> 2253
<212> DNA
<213> Homo sapiens

00224403300

```

<400> 56
atgctgcccc gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60
cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatggt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggacaaa 180
acctgcattg ataccaagga aggcacctct cagtattgcc aagaagtcta cctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtgaacca tccagaactg gtgcaagcgg 300
ggccgcaagc agtgcaagac ccacccccac tttgtgattc cctaccgctg cttagttggg 360
gagttttgtaa gtgatgccct tctcgttcct gacaagtgca aattcttaca ccaggagagg 420
atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagttag 480
aagagtacca acttgcatga ctacggcatg ttgctgccct gcggaattga caagttccga 540
ggggttagag ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
gcggaggagg atgactcgga tgtctgggtg ggccggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
gagtcctgtg aagagggtgt tgcagaggtg tgctctgaac aagccgagac ggggcccgtg 900
cgagcaatga tctcccgctg gtactttgat gtgactgaag ggaagtgtgc cccattcttt 960
tacggcggat gtggcggcaa ccggaacaac tttgacacag aagagtactg catggccgtg 1020
tgtggcagcg ccattcctac aacagcagcc agtaccctg atgccgttga caagtatctc 1080
gagacacctg gggatgagaa tgaacatgcc catttccaga aagccaaaga gaggcttgag 1140
gccaagcacc gagagagaat gtcccagggt atgagagaat ggggaaggagc agaacgtcaa 1200
gcaaagaact tgcctaaagc tgataagaag gcagttatcc agcatttcca ggagaaagtg 1260
gaatcttttg aacaggaagc agccaacgag agacagcagc tgggtggagac acacatggcc 1320
agagtggaa gcatgctcaa tgaccgccgc cgctggccc tggagaacta catcacgct 1380
ctgcaggctg tctcctctcg gcctcgtcac gtgttcaata tgctaaagaa gtatgtccgc 1440
gcagaacaga aggacagaca gcacacccta aagcatttct agcatgtgcg catggtggat 1500
cccaagaaag ccgctcagat ccggtcccag gttatgacac acctccgtgt gatttatgag 1560
cgcatgaatc agtctctctc cctgctctac aacgtgcctg cagtggccga ggagattcag 1620
gatgaagttg atgagctgct tcagaaagag caaaactatt cagatgacgt cttggccaac 1680
atgattagtg aaccaaggat cagttacgga aacgatgctc tcatgccatc tttgaccgaa 1740
acgaaaacca ccgtggagct ccttcccgtg aatggagagt tcagcctgga cgatctccag 1800
ccgtggcatt cttttggggc tgactctgtg ccagccaaca cagaaaacga agttgagcct 1860
gttgatgccc gccctgctgc cgaccgagga ctgaccactc gaccagggtc tgggttgaca 1920
aatatcaaga cggaggagat ctctgaagtg aagatggatg cagaattccg acatgactca 1980
ggatatgaag ttcattcatc aaaattgggt tcttttgag aagatgtggg ttcaaacaaa 2040
ggtgcaatca ttggactcat ggtgggcggg gttgtcatag cgacagtgat cgtcatcacc 2100
ttggtgatgc tgaagaagaa acagtacaca tccattcatc atggtgtggg ggaggttgac 2160
gccgctgtca cccagagga gcgccacctg tccaagatgc agcagaacgg ctacgaaaat 2220
ccaacctaca agttctttga gcagatgcag aac 2253

```

```

<210> 57
<211> 751
<212> PRT
<213> Homo sapiens

```

```

<400> 57
Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
  1             5             10             15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
      20             25             30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
      35             40             45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
      50             55             60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
      65             70             75             80

```

096314-09200

Gln	Ile	Thr	Asn	Val	Val	Glu	Ala	Asn	Gln	Pro	Val	Thr	Ile	Gln	Asn		
				85					90					95			
Trp	Cys	Lys	Arg	Gly	Arg	Lys	Gln	Cys	Lys	Thr	His	Pro	His	Phe	Val		
			100					105						110			
Ile	Pro	Tyr	Arg	Cys	Leu	Val	Gly	Glu	Phe	Val	Ser	Asp	Ala	Leu	Leu		
		115					120					125					
Val	Pro	Asp	Lys	Cys	Lys	Phe	Leu	His	Gln	Glu	Arg	Met	Asp	Val	Cys		
	130					135					140						
Glu	Thr	His	Leu	His	Trp	His	Thr	Val	Ala	Lys	Glu	Thr	Cys	Ser	Glu		
145					150					155					160		
Lys	Ser	Thr	Asn	Leu	His	Asp	Tyr	Gly	Met	Leu	Leu	Pro	Cys	Gly	Ile		
			165						170					175			
Asp	Lys	Phe	Arg	Gly	Val	Glu	Phe	Val	Cys	Cys	Pro	Leu	Ala	Glu	Glu		
			180					185					190				
Ser	Asp	Asn	Val	Asp	Ser	Ala	Asp	Ala	Glu	Glu	Asp	Asp	Ser	Asp	Val		
		195					200					205					
Trp	Trp	Gly	Gly	Ala	Asp	Thr	Asp	Tyr	Ala	Asp	Gly	Ser	Glu	Asp	Lys		
	210					215					220						
Val	Val	Glu	Val	Ala	Glu	Glu	Glu	Glu	Val	Ala	Glu	Val	Glu	Glu	Glu		
225					230					235					240		
Glu	Ala	Asp	Asp	Asp	Glu	Asp	Asp	Glu	Asp	Gly	Asp	Glu	Val	Glu	Glu		
			245						250					255			
Glu	Ala	Glu	Glu	Pro	Tyr	Glu	Glu	Ala	Thr	Glu	Arg	Thr	Thr	Ser	Ile		
			260					265					270				
Ala	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Glu	Ser	Val	Glu	Glu	Val	Val	Arg		
		275					280					285					
Glu	Val	Cys	Ser	Glu	Gln	Ala	Glu	Thr	Gly	Pro	Cys	Arg	Ala	Met	Ile		
	290					295					300						
Ser	Arg	Trp	Tyr	Phe	Asp	Val	Thr	Glu	Gly	Lys	Cys	Ala	Pro	Phe	Phe		
305					310					315					320		
Tyr	Gly	Gly	Cys	Gly	Gly	Asn	Arg	Asn	Asn	Phe	Asp	Thr	Glu	Glu	Tyr		
				325					330					335			
Cys	Met	Ala	Val	Cys	Gly	Ser	Ala	Ile	Pro	Thr	Thr	Ala	Ala	Ser	Thr		
			340					345					350				
Pro	Asp	Ala	Val	Asp	Lys	Tyr	Leu	Glu	Thr	Pro	Gly	Asp	Glu	Asn	Glu		
		355					360					365					
His	Ala	His	Phe	Gln	Lys	Ala	Lys	Glu	Arg	Leu	Glu	Ala	Lys	His	Arg		
	370					375					380						
Glu	Arg	Met	Ser	Gln	Val	Met	Arg	Glu	Trp	Glu	Glu	Ala	Glu	Arg	Gln		
385					390					395					400		
Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp	Lys	Lys	Ala	Val	Ile	Gln	His	Phe		
				405					410					415			

096634-092200

Gln	Glu	Lys	Val	Glu	Ser	Leu	Glu	Gln	Glu	Ala	Ala	Asn	Glu	Arg	Gln	
			420						425						430	
Gln	Leu	Val	Glu	Thr	His	Met	Ala	Arg	Val	Glu	Ala	Met	Leu	Asn	Asp	
			435						440						445	
Arg	Arg	Arg	Leu	Ala	Leu	Glu	Asn	Tyr	Ile	Thr	Ala	Leu	Gln	Ala	Val	
			450						455						460	
Pro	Pro	Arg	Pro	Arg	His	Val	Phe	Asn	Met	Leu	Lys	Lys	Tyr	Val	Arg	
			465						470						475	
Ala	Glu	Gln	Lys	Asp	Arg	Gln	His	Thr	Leu	Lys	His	Phe	Glu	His	Val	
			485						490						495	
Arg	Met	Val	Asp	Pro	Lys	Lys	Ala	Ala	Gln	Ile	Arg	Ser	Gln	Val	Met	
			500						505						510	
Thr	His	Leu	Arg	Val	Ile	Tyr	Glu	Arg	Met	Asn	Gln	Ser	Leu	Ser	Leu	
			515						520						525	
Leu	Tyr	Asn	Val	Pro	Ala	Val	Ala	Glu	Glu	Ile	Gln	Asp	Glu	Val	Asp	
			530						535						540	
Glu	Leu	Leu	Gln	Lys	Glu	Gln	Asn	Tyr	Ser	Asp	Asp	Val	Leu	Ala	Asn	
			545						550						555	
Met	Ile	Ser	Glu	Pro	Arg	Ile	Ser	Tyr	Gly	Asn	Asp	Ala	Leu	Met	Pro	
			565						570						575	
Ser	Leu	Thr	Glu	Thr	Lys	Thr	Thr	Val	Glu	Leu	Leu	Pro	Val	Asn	Gly	
			580						585						590	
Glu	Phe	Ser	Leu	Asp	Asp	Leu	Gln	Pro	Trp	His	Ser	Phe	Gly	Ala	Asp	
			595						600						605	
Ser	Val	Pro	Ala	Asn	Thr	Glu	Asn	Glu	Val	Glu	Pro	Val	Asp	Ala	Arg	
			610						615						620	
Pro	Ala	Ala	Asp	Arg	Gly	Leu	Thr	Thr	Arg	Pro	Gly	Ser	Gly	Leu	Thr	
			625						630						635	
Asn	Ile	Lys	Thr	Glu	Glu	Ile	Ser	Glu	Val	Lys	Met	Asp	Ala	Glu	Phe	
			645						650						655	
Arg	His	Asp	Ser	Gly	Tyr	Glu	Val	His	His	Gln	Lys	Leu	Val	Phe	Phe	
			660						665						670	
Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	Gly	Ala	Ile	Ile	Gly	Leu	Met	Val	
			675						680						685	
Gly	Gly	Val	Val	Ile	Ala	Thr	Val	Ile	Val	Ile	Thr	Leu	Val	Met	Leu	
			690						695						700	
Lys	Lys	Lys	Gln	Tyr	Thr	Ser	Ile	His	His	Gly	Val	Val	Glu	Val	Asp	
			705						710						715	
Ala	Ala	Val	Thr	Pro	Glu	Glu	Arg	His	Leu	Ser	Lys	Met	Gln	Gln	Asn	
			725						730						735	
Gly	Tyr	Glu	Asn	Pro	Thr	Tyr	Lys	Phe	Phe	Glu	Gln	Met	Gln	Asn		
			740						745						750	

<210> 58
 <211> 2316
 <212> DNA
 <213> Homo sapiens

<400> 58
 atgctgcccc gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60
 cccactgatg gtaatgctgg cctgctggct gaacccacaga ttgccatggt ctgtggcaga 120
 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaa 180
 acctgcattg ataccaagga aggcacccct cagtattgcc aagaagtcta cctgaactg 240
 cagatcacca atgtggtaga agccaacca ccagtgacca tccagaactg gtgcaagcgg 300
 ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg cttagttggg 360
 gagttttgtaa gtgatgccct tctcgttcct gacaagtgca aattcttaca ccaggagagg 420
 atggatgttt gcgaaactca tcttactctg cacaccgtcg ccaaagagac atgcagttag 480
 aagagtacca acttgcata ctacggcatg ttgctgccct gcggaattga caagttccga 540
 ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
 gcggaggagg atgactcgga tgtctggtgg ggccggagcag acacagacta tgcagatggg 660
 agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
 gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
 ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
 gagtctgtgg aagaggtggt tcgagaggtg tgctctgaac aagccgagac ggggcccgtg 900
 cgagcaatga tctcccgtg gtactttgat gtgactgaag ggaagtgtgc cccattcttt 960
 tacggcggat gtggcggcaa ccggaacaac tttgacacag aagagtactg catggccgtg 1020
 tgtggcagcg ccatgtccca aagtttactc aagactacc aggaacctct tggccgagat 1080
 cctgttaaac ttcctacaac agcagccagt acccctgatg ccgttgacaa gtatctcgag 1140
 acacctgggg atgagaatga acatgcccat ttccagaaag ccaaagagag gcttgaggcc 1200
 aagcaccgag agagaatgtc ccaggtcagt agagaatggg aagaggcaga acgtcaagca 1260
 aagaacttgc ctaaagctga taagaaggca gttatccagc atttccagga gaaagtggaa 1320
 tctttggaac aggaagcagc caacgagaga cagcagctgg tggagacaca catggccaga 1380
 gtggaagcca tgctcaatga ccgcccgcgc ctggccctgg agaactacat caccgctctg 1440
 caggctgttc ctctcggcc tcgtcacgtg ttcaatatgc taaagaagta tgtccgcgca 1500
 gaacagaagg acagacagca caccctaaag catttcgagc atgtgcgcat ggtggatccc 1560
 aagaaagccg ctccagatccg gtcccagggt atgacacacc tccgtgtgat ttatgagcgc 1620
 atgaatcagt ctctctccct gctctacaac gtgcctgcag tggccgagga gattcaggat 1680
 gaagttgatg agctgcttca gaaagagcaa aactattcag atgacgtctt ggccaacatg 1740
 attagtgaac caaggatcag ttacggaaac gatgctctca tgccatcttt gaccgaaacg 1800
 aaaaccaccg tggagctcct tcccgtgaat ggagagttca gcctggacga tctccagccg 1860
 tggcattctt ttggggctga ctctgtgcca gccaacacag aaaacgaagt tgagcctgtt 1920
 gatgcccgcc ctgctgccga ccgaggactg accactcgac caggttctgg gttgacaaat 1980
 atcaagacgg aggagatctc tgaagtgaag atggatgcag aattccgaca tgactcagga 2040
 tatgaagttc atcatcaaaa attggtgttc tttgcagaag atgtgggttc aaacaaaggt 2100
 gcaatcattg gactcatggt gggcgggtgt gtcatagcga cagtgatcgt catcaccttg 2160
 gtgatgctga agaagaaaca gtacacatcc attcatcatg gtgtggtgga ggttgacgcc 2220
 gctgtcaccg cagaggagcg ccacctgtcc aagatgcagc agaacggcta cgaaaatcca 2280
 acctacaagt tctttgagca gatgcagaac aagaag 2316

<210> 59
 <211> 772
 <212> PRT
 <213> Homo sapiens

<400> 59
 Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15
 Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
 20 25 30
 Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45

002260"4"096344"092000

Asn	Gly	Lys	Trp	Asp	Ser	Asp	Pro	Ser	Gly	Thr	Lys	Thr	Cys	Ile	Asp
50						55					60				
Thr	Lys	Glu	Gly	Ile	Leu	Gln	Tyr	Cys	Gln	Glu	Val	Tyr	Pro	Glu	Leu
65					70					75					80
Gln	Ile	Thr	Asn	Val	Val	Glu	Ala	Asn	Gln	Pro	Val	Thr	Ile	Gln	Asn
				85					90					95	
Trp	Cys	Lys	Arg	Gly	Arg	Lys	Gln	Cys	Lys	Thr	His	Pro	His	Phe	Val
			100					105					110		
Ile	Pro	Tyr	Arg	Cys	Leu	Val	Gly	Glu	Phe	Val	Ser	Asp	Ala	Leu	Leu
		115					120					125			
Val	Pro	Asp	Lys	Cys	Lys	Phe	Leu	His	Gln	Glu	Arg	Met	Asp	Val	Cys
	130					135					140				
Glu	Thr	His	Leu	His	Trp	His	Thr	Val	Ala	Lys	Glu	Thr	Cys	Ser	Glu
145					150					155					160
Lys	Ser	Thr	Asn	Leu	His	Asp	Tyr	Gly	Met	Leu	Leu	Pro	Cys	Gly	Ile
				165					170					175	
Asp	Lys	Phe	Arg	Gly	Val	Glu	Phe	Val	Cys	Cys	Pro	Leu	Ala	Glu	Glu
			180					185					190		
Ser	Asp	Asn	Val	Asp	Ser	Ala	Asp	Ala	Glu	Glu	Asp	Asp	Ser	Asp	Val
		195					200					205			
Trp	Trp	Gly	Gly	Ala	Asp	Thr	Asp	Tyr	Ala	Asp	Gly	Ser	Glu	Asp	Lys
	210					215					220				
Val	Val	Glu	Val	Ala	Glu	Glu	Glu	Glu	Val	Ala	Glu	Val	Glu	Glu	Glu
225					230					235					240
Glu	Ala	Asp	Asp	Asp	Glu	Asp	Asp	Glu	Asp	Gly	Asp	Glu	Val	Glu	Glu
				245					250					255	
Glu	Ala	Glu	Glu	Pro	Tyr	Glu	Glu	Ala	Thr	Glu	Arg	Thr	Thr	Ser	Ile
			260					265					270		
Ala	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Glu	Ser	Val	Glu	Glu	Val	Val	Arg
		275					280					285			
Glu	Val	Cys	Ser	Glu	Gln	Ala	Glu	Thr	Gly	Pro	Cys	Arg	Ala	Met	Ile
	290					295					300				
Ser	Arg	Trp	Tyr	Phe	Asp	Val	Thr	Glu	Gly	Lys	Cys	Ala	Pro	Phe	Phe
305					310					315					320
Tyr	Gly	Gly	Cys	Gly	Gly	Asn	Arg	Asn	Asn	Phe	Asp	Thr	Glu	Glu	Tyr
				325					330					335	
Cys	Met	Ala	Val	Cys	Gly	Ser	Ala	Met	Ser	Gln	Ser	Leu	Leu	Lys	Thr
			340					345					350		
Thr	Gln	Glu	Pro	Leu	Ala	Arg	Asp	Pro	Val	Lys	Leu	Pro	Thr	Thr	Ala
		355					360					365			
Ala	Ser	Thr	Pro	Asp	Ala	Val	Asp	Lys	Tyr	Leu	Glu	Thr	Pro	Gly	Asp
	370					375					380				

002260" 4778950


```
<210> 61
<211> 753
<212> PRT
<213> Homo sapiens
```

<400> 61

Met	Leu	Pro	Gly	Leu	Ala	Leu	Leu	Leu	Leu	Ala	Ala	Trp	Thr	Ala	Arg	1	5	10	15
Ala	Leu	Glu	Val	Pro	Thr	Asp	Gly	Asn	Ala	Gly	Leu	Leu	Ala	Glu	Pro	20	25	30	
Gln	Ile	Ala	Met	Phe	Cys	Gly	Arg	Leu	Asn	Met	His	Met	Asn	Val	Gln	35	40	45	
Asn	Gly	Lys	Trp	Asp	Ser	Asp	Pro	Ser	Gly	Thr	Lys	Thr	Cys	Ile	Asp	50	55	60	
Thr	Lys	Glu	Gly	Ile	Leu	Gln	Tyr	Cys	Gln	Glu	Val	Tyr	Pro	Glu	Leu	65	70	75	80
Gln	Ile	Thr	Asn	Val	Val	Glu	Ala	Asn	Gln	Pro	Val	Thr	Ile	Gln	Asn	85	90	95	
Trp	Cys	Lys	Arg	Gly	Arg	Lys	Gln	Cys	Lys	Thr	His	Pro	His	Phe	Val	100	105	110	
Ile	Pro	Tyr	Arg	Cys	Leu	Val	Gly	Glu	Phe	Val	Ser	Asp	Ala	Leu	Leu	115	120	125	
Val	Pro	Asp	Lys	Cys	Lys	Phe	Leu	His	Gln	Glu	Arg	Met	Asp	Val	Cys	130	135	140	
Glu	Thr	His	Leu	His	Trp	His	Thr	Val	Ala	Lys	Glu	Thr	Cys	Ser	Glu	145	150	155	160
Lys	Ser	Thr	Asn	Leu	His	Asp	Tyr	Gly	Met	Leu	Leu	Pro	Cys	Gly	Ile	165	170	175	
Asp	Lys	Phe	Arg	Gly	Val	Glu	Phe	Val	Cys	Cys	Pro	Leu	Ala	Glu	Glu	180	185	190	
Ser	Asp	Asn	Val	Asp	Ser	Ala	Asp	Ala	Glu	Glu	Asp	Asp	Ser	Asp	Val	195	200	205	
Trp	Trp	Gly	Gly	Ala	Asp	Thr	Asp	Tyr	Ala	Asp	Gly	Ser	Glu	Asp	Lys	210	215	220	
Val	Val	Glu	Val	Ala	Glu	Glu	Glu	Glu	Val	Ala	Glu	Val	Glu	Glu	Glu	225	230	235	240
Glu	Ala	Asp	Asp	Asp	Glu	Asp	Asp	Glu	Asp	Gly	Asp	Glu	Val	Glu	Glu	245	250	255	
Glu	Ala	Glu	Glu	Pro	Tyr	Glu	Glu	Ala	Thr	Glu	Arg	Thr	Thr	Ser	Ile	260	265	270	
Ala	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Glu	Ser	Val	Glu	Glu	Val	Val	Arg	275	280	285	
Glu	Val	Cys	Ser	Glu	Gln	Ala	Glu	Thr	Gly	Pro	Cys	Arg	Ala	Met	Ile	290	295	300	
Ser	Arg	Trp	Tyr	Phe	Asp	Val	Thr	Glu	Gly	Lys	Cys	Ala	Pro	Phe	Phe	305	310	315	320

00334409300

Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr
 325 330 335
 Cys Met Ala Val Cys Gly Ser Ala Ile Pro Thr Thr Ala Ala Ser Thr
 340 345 350
 Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp Glu Asn Glu
 355 360 365
 His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala Lys His Arg
 370 375 380
 Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala Glu Arg Gln
 385 390 395 400
 Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile Gln His Phe
 405 410 415
 Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn Glu Arg Gln
 420 425 430
 Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met Leu Asn Asp
 435 440 445
 Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu Gln Ala Val
 450 455 460
 Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys Tyr Val Arg
 465 470 475 480
 Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe Glu His Val
 485 490 495
 Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser Gln Val Met
 500 505 510
 Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser Leu Ser Leu
 515 520 525
 Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp Glu Val Asp
 530 535 540
 Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val Leu Ala Asn
 545 550 555 560
 Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala Leu Met Pro
 565 570 575
 Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro Val Asn Gly
 580 585 590
 Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe Gly Ala Asp
 595 600 605
 Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val Asp Ala Arg
 610 615 620
 Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr
 625 630 635 640
 Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp Ala Glu Phe
 645 650 655

00663344-002200

Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe
660 665 670

Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val
675 680 685

Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu Val Met Leu
690 695 700

Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val Glu Val Asp
705 710 715 720

Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met Gln Gln Asn
725 730 735

Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met Gln Asn Lys
740 745 750

Lys

<210> 62
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic

<400> 62
Leu Glu Val Leu Phe Gln Gly Pro
1 5

<210> 63
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic

<400> 63
Ser Glu Val Asn Leu Asp Ala Glu Phe Arg
1 5 10

<210> 64
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic

<400> 64
Ser Glu Val Lys Met Asp Ala Glu Phe Arg
1 5 10

<210> 65
<211> 15

002260-47E9960

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 65

Arg Arg Gly Gly Val Val Ile Ala Thr Val Ile Val Gly Glu Arg
1 5 10 15

<210> 66

<211> 518

<212> PRT

<213> Homo sapiens

<400> 66

Met Gly Ala Leu Ala Arg Ala Leu Leu Leu Pro Leu Leu Ala Gln Trp
1 5 10 15

Leu Leu Arg Ala Ala Pro Glu Leu Ala Pro Ala Pro Phe Thr Leu Pro
20 25 30

Leu Arg Val Ala Ala Ala Thr Asn Arg Val Val Ala Pro Thr Pro Gly
35 40 45

Pro Gly Thr Pro Ala Glu Arg His Ala Asp Gly Leu Ala Leu Ala Leu
50 55 60

Glu Pro Ala Leu Ala Ser Pro Ala Gly Ala Ala Asn Phe Leu Ala Met
65 70 75 80

Val Asp Asn Leu Gln Gly Asp Ser Gly Arg Gly Tyr Tyr Leu Glu Met
85 90 95

Leu Ile Gly Thr Pro Pro Gln Lys Leu Gln Ile Leu Val Asp Thr Gly
100 105 110

Ser Ser Asn Phe Ala Val Ala Gly Thr Pro His Ser Tyr Ile Asp Thr
115 120 125

Tyr Phe Asp Thr Glu Arg Ser Ser Thr Tyr Arg Ser Lys Gly Phe Asp
130 135 140

Val Thr Val Lys Tyr Thr Gln Gly Ser Trp Thr Gly Phe Val Gly Glu
145 150 155 160

Asp Leu Val Thr Ile Pro Lys Gly Phe Asn Thr Ser Phe Leu Val Asn
165 170 175

Ile Ala Thr Ile Phe Glu Ser Glu Asn Phe Phe Leu Pro Gly Ile Lys
180 185 190

Trp Asn Gly Ile Leu Gly Leu Ala Tyr Ala Thr Leu Ala Lys Pro Ser
195 200 205

Ser Ser Leu Glu Thr Phe Phe Asp Ser Leu Val Thr Gln Ala Asn Ile
210 215 220

Pro Asn Val Phe Ser Met Gln Met Cys Gly Ala Gly Leu Pro Val Ala
225 230 235 240

002260"002260

```
<210> 67
<211> 475
<212> PRT
<213> Homo sapiens
```

<400> 67
Met Gly Ala Leu Ala Arg Ala Leu Leu Leu Pro Leu Leu Ala Gln Trp
1 5 10 15

Leu Leu Arg Ala Ala Pro Glu Leu Ala Pro Ala Pro Phe Thr Leu Pro
 20 25 30
 Leu Arg Val Ala Ala Ala Thr Asn Arg Val Val Ala Pro Thr Pro Gly
 35 40 45
 Pro Gly Thr Pro Ala Glu Arg His Ala Asp Gly Leu Ala Leu Ala Leu
 50 55 60
 Glu Pro Ala Leu Ala Ser Pro Ala Gly Ala Ala Asn Phe Leu Ala Met
 65 70 75 80
 Val Asp Asn Leu Gln Gly Asp Ser Gly Arg Gly Tyr Tyr Leu Glu Met
 85 90 95
 Leu Ile Gly Thr Pro Pro Gln Lys Leu Gln Ile Leu Val Asp Thr Gly
 100 105 110
 Ser Ser Asn Phe Ala Val Ala Gly Thr Pro His Ser Tyr Ile Asp Thr
 115 120 125
 Tyr Phe Asp Thr Glu Arg Ser Ser Thr Tyr Arg Ser Lys Gly Phe Asp
 130 135 140
 Val Thr Val Lys Tyr Thr Gln Gly Ser Trp Thr Gly Phe Val Gly Glu
 145 150 155 160
 Asp Leu Val Thr Ile Pro Lys Gly Phe Asn Thr Ser Phe Leu Val Asn
 165 170 175
 Ile Ala Thr Ile Phe Glu Ser Glu Asn Phe Phe Leu Pro Gly Ile Lys
 180 185 190
 Trp Asn Gly Ile Leu Gly Leu Ala Tyr Ala Thr Leu Ala Lys Pro Ser
 195 200 205
 Ser Ser Leu Glu Thr Phe Phe Asp Ser Leu Val Thr Gln Ala Asn Ile
 210 215 220
 Pro Asn Val Phe Ser Met Gln Met Cys Gly Ala Gly Leu Pro Val Ala
 225 230 235 240
 Gly Ser Gly Thr Asn Gly Gly Ser Leu Val Leu Gly Gly Ile Glu Pro
 245 250 255
 Ser Leu Tyr Lys Gly Asp Ile Trp Tyr Thr Pro Ile Lys Glu Glu Trp
 260 265 270
 Tyr Tyr Gln Ile Glu Ile Leu Lys Leu Glu Ile Gly Gly Gln Ser Leu
 275 280 285
 Asn Leu Asp Cys Arg Glu Tyr Asn Ala Asp Lys Ala Ile Val Asp Ser
 290 295 300
 Gly Thr Thr Leu Leu Arg Leu Pro Gln Lys Val Phe Asp Ala Val Val
 305 310 315 320
 Glu Ala Val Ala Arg Ala Ser Leu Ile Pro Glu Phe Ser Asp Gly Phe
 325 330 335
 Trp Thr Gly Ser Gln Leu Ala Cys Trp Thr Asn Ser Glu Thr Pro Trp
 340 345 350

006634-000000

<220>
<223> Description of Artificial Sequence: Peptide

<400> 70
Glu Val Lys Met Asp Ala Glu Phe
1 5

<210> 71
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 71
Glu Val Asn Leu Asp Ala Glu Phe
1 5

<210> 72
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 72
Leu Val Phe Phe Ala Glu Asp Val
1 5

<210> 73
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 73
Lys Leu Val Phe Phe Ala Glu Asp
1 5

<210> 74
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 74
cgctttaagc ttgccaccat gggcgcaactg gcccgggcg

<210> 75
<211> 57
<212> DNA
<213> Artificial Sequence

<220>

002260"4E3950

<223> Description of Artificial Sequence: Primer

<400> 75

cgctttctcg agctaattggt gatggtgatg gtgccacaaa atgggctcgc tcaaaga 57

<210> 76

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide

<400> 76

Arg	Arg	Gly	Gly	Val	Val	Ile	Ala	Thr	Val	Ile	Val	Gly	Glu	Arg
1				5				10					15	

003350"4433960